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Abstract 
 
Introduction: Expression of neurochemical markers in dorsal root ganglion (DRG) has been 
shown to underlie nerve injury induced neuropathic pain and are usually examined once post injury 
in rodent models. Here I hypothesize that neurochemical markers are expressed differentially at 
various time points post nerve injury and that expression of these markers differ between traumatic 
and non-traumatic models of neuropathic pain, thus reflecting variations in pathophysiology.   
In two different rat models of neuropathic pain, namely, the tibial nerve transection (TNT) and 
the d4T (HIV antiretroviral drug) associated toxic neuropathy; immunohistochemical labelling was 
used to determine the expression of various neurochemical markers across time. Double labelling 
with peripherin or NF-200 (labels small and large neurons respectively) and a cell size analysis 
were conducted to validate cellular phenotype. Pain behaviour was measured in vivo using 
mechanical and thermal hypersensitivity assays.  
To confirm tibial nerve distribution in the DRGs, Fluorogold retrograde labelling was 
performed. I also explored the effect of the omega-3 polyunsaturated fatty acid dicosahexonoic acid 
(DHA) on TNT associated mechanical hypersensitivity and inflammation, as previous studies have 
shown DHA to be both anti-inflammatory and neuroprotective in animal models of spinal cord 
injury and stroke, and therefore could be relevant in peripheral nerve injury. 
 
Results: 
% expression in TNT injured rats (± standard error of mean) 
Markers   Day1 Day 7 Day 14 Day 28 Day 43 
Activating 
transcription factor -3        
Peripherin 
NF-200 
 
11.9 ± 5.6 
71.1 ± 7.2 
 
 
19.0 ± 4.9 
25.7 ± 7.7 
 
 
18.9 ± 6.6 
30.4 ± 8.7 
 
 
15.2 ± 1.4 
18.7 ± 6.0 
 
 
25.4 ± 8.3 
11.5 ± 4.2 
Gap associated 
protein-43        
Peripherin 
NF-200 
 
 
3.8 ± 1.4 
3.2 ± 2.1 
 
 
7.2 ± 0.7 
0.3 ± 0.3 
 
 
15.7 ± 1.8 
15.9 ± 4.8 
 
 
11.6 ± 2.5 
10.0 ± 1.9 
 
 
10.0 ± 6.4 
8.3 ± 1.0 
Neuropeptide Y            
Peripherin                       
NF-200 
 
0 
0 
 
2.1 ± 0.6 
51.3 ± 4.8 
 
3.4 ± 1.4 
51.7 ± 8.3 
 
6.5 ± 0.8 
27.3 ± 3.4 
 
5.0 ± 0.8 
14.5 ± 2.9 
Galanin       
Peripherin 
NF-200 
 
0 
0.7 ± 0.7 
 
15.7 ± 2.7 
11.8 ± 1.2 
 
19.3 ± 4.9 
25.8 ± 4.2 
 
5.7 ± 1.3 
5.8 ± 1.6 
 
7.7 ± 1.7 
7.8 ± 2.0 
 
From day 7, TNT rats developed mechanical hypersensitivity (↓62% from baseline at peak, day 
28). Rats injected with d4T exhibited bilateral hind paw mechanical hypersensitivity (↓~47% from 
baseline at peak, day 22), but failed to exhibit any neurochemical changes in the DRG such as that 
observed in TNT injury. Seven days following Fluorogold injection into the tibial nerve of naive 
rats, labelling was identified in the L4 (38.5%) and L5 (27.5%) DRGs. Since DHA did not alter 
TNT induced mechanical hypersensitivity, key neurochemical markers were not evaluated.  
Investigations examined the potential of DHA to modulate the DRG macrophage response, and 
revealed no differences compared to saline controls at day 28 post TNT injury.   
 
Conclusion: The results of the study demonstrate completely different expression patterns of 
neurochemical markers following TNT injury and treatment with d4T, and highlight the 
mechanistic difference between nerve trauma and antiretroviral associated neuropathic pain. 
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PLA2 Phospholipase A2 
PNS Peripheral nervous system 
PPAR Peroxisome proliferator-activated receptors 
PSNL Partial sciatic nerve ligation 
PSNT Partial sciatic nerve transection 
PUFAs Poly unsaturated fatty acids 
PWL Paw withdrawal latency 
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PWT Paw withdrawal threshold 
Quin-2 Fluorescent calcium indicator 
Reg-2 Regenerating gene protein-2 (also known as pancreatitis 
associated protein 1 (PAP1)) 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RVM Rostral ventramedial medulla  
RXR Retinoic-x-receptor 
SCI Spinal cord injury 
SCNA Synuclein, alpha 
SEM Standard error of the mean 
SK Small conductance potassium ion channel 
SNI  Spared nerve injury 
SNL Spinal nerve ligation 
SNT Spinal nerve transection 
SOD-2 Superoxide dismutase-2 
SPRR1A Small Proline Rich Protein 1A 
Tc T cytotoxic 
TDF Tenofovir 
Th T helper 
TLR3 Toll like receptor 3 
TMB-8 8-(N, N-diethylamino)-octyl-3, 4, 5-trimethoxybenzoate 
TNFR1 Tumor necrosis factor α receptor 1 
TNFα Tumor necrosis factor α  
TNT Tibial nerve transection 
tPA Tissue pasminogen activator  
TRAAK Two pore-forming potassium ion channel 
TREK-1 Two pore-forming potassium ion channel also known as 
KCNQ2 
TrkA Tyrosine kinase receptor for NGF 
TRPV1 Transient receptor potential vanilloid 1 
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TTX Tetrodotoxin 
TTXr Tetrodotoxin resistant 
TUNEL  Terminal deoxynucleotidyl transferase dUTP nick end 
labelling  
UK United Kingdom 
VGCC Voltage gated calcium ion channel 
VGKC Voltage gated potassium ion channels 
VGSC Voltage gated sodium channel 
VIP Vasoactive intestinal peptide 
VZV Varicella zoster virus 
WDR Wide dynamic range 
WIN 55,212-2 (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo 
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Hypothesis 
 
Peripheral nerve damage initiates neurochemical changes in the dorsal root ganglion, and 
the development pain-like behaviours, which can be modulated via the administration of ω-
3 polyunsaturated fatty acids. 
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Chapter 1 
 
1 General Introduction 
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1.1 Pain 
 
Pain is defined by the International Association for the Study of Pain (IASP) as ‘An 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage’ (Merskey and Bogduk, 1994). Pain is an 
intrinsic warning system that allows the body to withdraw and be protected from harm or 
trauma, and also helps deters future similar situations. Pain is also a multidimensional 
experience that is highly subjective and essential for the maintenance and preservation of 
bodily tissues. In addition to the physiological effects of pain, there are also psychological 
implications such as anxiety, stress, anticipation and empathy to pain (Brooks and Tracey, 
2005).  
 
1.1.1 Nociception 
 
The concept of a distinct class of peripheral nerve pain signal transduction mechanism was 
first proposed by Sir Charles Sherrington (Sherrington, 1906). The consensus now is that 
the transmission of pain (nociception) involves activation of specialized sensory receptors 
called the nociceptors (Brooks and Tracey, 2005). There are two types of nociceptive nerve 
fibres; the Aδ fibres and the nociceptive C-fibres. C-fibers are considered polymodal since 
they react to various stimuli such as hypoxia and hypoglycemia (Craig, 2003), and some C-
fibers are exquisitely sensitive to non-noxious light touch (Vallbo et al., 1999). C-fibres can 
be further subdivided into the peptidergic and non-peptidergic populations (Snider and 
McMahon, 1998). The Aδ fibre is thinly myelinated, and has medium conduction velocities 
(6-25 m s
-1
) whereas the nociceptive C-fibres are non-myelinated and have slow 
conduction velocities (1 m s
-1
). The Aδ and nociceptive C-fibres normally mediate 'first' 
and 'second' pain respectively, namely the rapid, acute, sharp pain and the delayed, more 
diffuse, dull type of pain (Julius and Basbaum, 2001).  When peripheral Aδ and nociceptive 
C-fibres are activated by noxious stimuli they generate action potentials that travel to their 
cell bodies, i.e. dorsal root ganglion (DRG) neurons, and then to the spinal cord and 
ultimately synapse at the superficial dorsal horn. These messages are eventually sent to the 
midbrain, limbic, and cortical areas of the brain where pain sensation is registered (Snider 
and McMahon, 1998). 
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1.1.2 Gate control theory of pain 
 
The gate control theory of pain was first proposed in 1965 (Melzack and Wall, 1965). In 
this paper the authors summarized two schools of thought regarding the perception and 
central control of pain, before then explaining the gate control theory. The first theory 
suggests that pain is a specific modality like vision, or hearing, which requires a specialized 
set of receptors. The second is the pattern theory, which suggests that nerve impulse 
patterns for pain are produced via intense simulation of non-specific receptors. While both 
theories are plausible they do not attempt to explain other factors such as the physiological 
influence on pain behaviour. In the newly proposed gate control theory the authors 
proposed that both small and large diameter neurons transmit information from the 
periphery to ‘inhibitory’ and ‘transmission’ cells in the spinal cord. When this input 
surpasses a certain threshold (e.g. noxious stimulation of skin), pain is then transmitted to 
the spinal cord and the gate is ‘open’. During noxious stimulation, the activation of large 
diameter fibres also activates inhibitory cells in the substantia gelatinosa which acts to shut 
the ‘gate’ thus reducing transmission of sensory information. Activation of small fibres 
during noxious stimulation reduces activation of the inhibitory cells thus causing the gate 
to ‘open’. In addition, a connection from the periphery straight to central control was also 
described, which by-passes the inhibitory and transmission cells, which can then go on to 
influence the mechanistics of the ‘gate’. The advantage of the new concept of the gate 
control was that it could account for the hyperalgesia, spontaneous pain, and long delays 
after stimulation characteristic of pathological pain syndromes which could not be easily 
explained in the earlier two theories. The gate control theory allowed a benchmark for 
further studies to investigate and test the mechanisms of neuropathic pain, however the gate 
control theory is now considered to be an incomplete hypothesis since the theory does not 
incorporate long term changes in the central nervous system (CNS), plasticity of neurons, 
and inflammatory factors which influence nociceptor sensitivity (Loeser and Melzack, 
1999). 
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1.2 Pain classifications 
 
Pain can be categorized according to whether the pain is acute or chronic in nature; both 
have different approaches in terms of their mechanisms, management, and treatment.    
 
1.2.1 Acute pain 
 
Pain that is characterized by a rapid onset of symptoms is termed acute pain, and persists 
for a short period of time, ranging from a few days to weeks.  Acute pain may range from 
mild to severe depending on the nature of the tissue injury and the emotional state; some of 
the common causes are surgery, disease, childbirth, broken bones, burns, and cuts. The 
acute inflammation caused by tissue injury acts to sensitize nociceptors, which leads to an 
increase in discharge rate and a lowered threshold for stimulus activation (Carr and 
Goudas, 1999). Acute pain usually remits when the injured tissue has healed and may not 
require medical intervention (Loeser and Melzack, 1999). To aid the healing process and 
reduce symptoms, acute pain can be managed by the effective use of opioids, non steroidal 
anti-inflammatory drugs (NSAIDS), paracetamol, and local anaesthetics (Carr and Goudas, 
1999).  
 
1.2.2 Chronic pain 
 
Chronic pain can be divided into two main broad subtypes; (1) inflammatory pain e.g. 
rheumatoid osteoarthritis, and (2) neuropathic pain e.g. diabetic polyneuropathy (DPN) 
(Baron, 2006).  
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1.3 Inflammatory pain 
 
Tissue injury results in the local release of numerous chemicals (such as substance P and 
bradykinin) that mediate or facilitate inflammatory processes which leads to the 
sensitisation of primary afferent nociceptive terminals.  This sensitisation initiates an 
increase in nociceptive activity that is ultimately responsible for the primary hyperalgesia. 
Inflammatory processes in neurons along with corresponding ectopic nerve activity may 
represent a source for central sensitisation which may contribute to chronic persistent pain. 
Chronic pain may encompass features such as allodynia which is pain caused by a stimulus 
that does not normally provoke pain (mechanical or thermal generated) or hyperalgesia; an 
increased pain sensation in response to a normally painful stimulus; symptoms that both 
feature in neuropathic pain. 
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1.4 Neuropathic pain  
 
Neuropathic pain has always been prevalent throughout documented history, but it was not 
until the IASP was founded in 1973 that attention was focused on the causes and treatment 
of neuropathic pain. The presence of neuropathic pain whether it is peripherally or centrally 
mediated continues to be a significant health burden which reduces the quality of life for 
the individual, and has wide scale impacts on healthcare resources. IASP originally defined 
neuropathic pain as ‘pain arising from a primary lesion or dysfunction of the nervous 
system’ (Merskey and Bogduk, 1994). While this current definition has been useful in 
diagnosing neuropathic pain, it lacks the specificity that would differentiate it from other 
types of pain where there is a ‘dysfunction’ in sensory processing, which may not be 
neuropathic in origin such as musculoskeletal and inflammatory pain. A revised definition 
of neuropathic pain has been proposed as ‘pain arising as a direct consequence of a lesion 
or disease affecting the somatosensory system’ (Treede et al., 2008). ISAP have now 
adopted the new version omitting the word ‘direct’ (Jensen et al., 2011). This new 
definition replaces the word ‘dysfunction’ with disease as it is somewhat misleading and 
could be interpreted to include the normal plasticity that occurs within the nociceptive 
system.  The word ‘disease’ implies that there is a known pathology such as postherpetic 
neuralgia (PHN) or diabetes, while the word ‘lesion’ refers to macro or microscopically 
identifiable
 
damage. A lesion or disease affecting the nervous system may cause other 
types of pain that should be differentiated from neuropathic, such as pain associated with 
spasticity and rigidity that is initiated by nociceptive afferents from muscles. Consequently, 
the replacement of the wording ‘nervous system’ with ‘somatosensory system’ is 
anatomically precise and recognizes that in neuropathic pain it is somatosensory processing 
that is perturbed beyond the normal plasticity of undamaged neurons. The intrinsic 
‘nociceptive pain system’ is important because it forms a natural human defense 
mechanism and serves a useful biological function which is the avoidance of potentially 
harmful situations. However neuropathic pain serves no useful biological purpose and is 
regarded as a symptom of a disease process. Neuropathic pain may also represent aborrent 
attempts of the nervous system to regenerate after an insult.  
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1.4.1 Neuropathic pain disorders  
 
There is no international consensus to the characterization of neuropathic pain disorders; 
however the traditional approach is via the anatomical location of nerve injury and 
aetiology (see Table 1.1) (Asbury and Fields, 1984). Unlike the CNS, the PNS is not 
protected by bone and skull and therefore it is more exposed to the risks of mechanical, 
thermal, or chemical injury. Since cutaneous tissues are the most exposed organ innervated 
by the PNS these tissues are often the subject of nerve damage. Neuropathic pain may be 
idiopathic in nature; however the most widespread causes arise from a number of different 
aetiologies including: diabetes, herpes zoster, human immunodeficiency virus (HIV) 
infection, amputation, surgery, and certain cancer chemotherapy agents (Jensen et al., 
2001). The lesion or disease affecting the somatosensory system may result in damage to 
peripheral nerves in cutaneous regions of the body, the DRG or the dorsal root neurons, as 
well as the CNS. Central related pain is distinct to that of peripheral origin, and can be 
differentiated by injury to the spinal cord or brain (Finnerup, 2008).  
 
Peripheral Central 
Postherpetic neuralgia Stroke 
Diabetic polyneuropathy Multiple sclerosis 
Trigeminal neuralgia Spinal cord injury 
HIV related (including antiretroviral 
associated) 
HIV related (including antiretroviral 
associated) 
Phantom limb Cancer and chemotherapy agents 
Radiculopathies  Parkinson’s disease 
Cancer and chemotherapy agents Epilepsy  
Complex regional pain syndrome (type 2)  
Nerve trauma injury   
Alcoholic polyneuropathy  
 
Table 1.1 List of different examples of neuropathic pain conditions according to 
disease/trauma and anatomical site. Table adapted from Dworkin et al (2003). 
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The specific mechanisms that elicit neuropathic pain are not completely clear and at 
present is the subject of ongoing research. Although classifying neuropathic pain in terms 
of the aetiology is useful in terms of identifying the root cause of the pain, the diagnosis 
does not attempt to explain the underlying mechanisms which may give a functional 
framework for the clinical management of the pain.  The pain that manifests in response to 
a specific lesion or disease in patients may operate through different mechanisms while 
different aetiologies may share common pain mechanisms. Additionally, more than one 
mechanism may be operating within a single patient; this may lead to different symptoms, 
further complicating treatment. A different approach has been proposed that classifies 
neuropathic pain according to the presumed mechanisms (Baron, 2006;Sindrup and Jensen, 
1999;Woolf and Mannion, 1999). This focus on the actual mechanisms is important 
because, for example, HIV antiretroviral associated neuropathy has a clear mitochondrial 
toxicity brought on by NRTI treatments (Bacellar et al., 1994), and this toxicity could be 
specifically targeted. Conversely, mitochondrial toxicity does not appear to have a major 
role in traumatic neruopathies and may involve dysregulation of proteins/ion channels that 
is associated with ectopic activity of peripheral nerves (Lai et al., 2004). By identifying and 
targeting the nerve damage mechanisms specifically with therapeutic interventions, there is 
a possibility to limit the effects of nerve damage which could develop into neuropthatic 
pain, thus leading to better treatment outcomes (Finnerup et al., 2010b;Finnerup et al., 
2010a).  
 
Diagnosis of neuropathic pain 
 
There is no standard diagnostic procedure for neuropathic pain and diagnosis is based upon 
clinical judgment that involves two steps both of which are essential: (1) demonstration of 
lesion or disease and (2) demonstration that the pain is neuropathic. This can involve 
physical and neurological examinations, questionnaires, magnetic resonance imaging, and 
electrophysiological studies. Nerve and skin biopsies may also be taken to examine 
abnormal nerve fibres. In most cases the pain can be explained via a demonstrable lesion, 
previous traumatic injury or disease process e.g. herpes zoster, diabetes. However when no 
lesion can be demonstrated the array of diagnostic tools mentioned cannot always exclude 
the likelihood that the pain is of neuropathic origin. 
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1.4.2 Clinical aspects of neuropathic pain 
 
Clinically, neuropathic pain is characterized by the presence of spontaneous (stimulus 
independent) or stimulus-evoked type pain (stimulus dependent) (Dworkin, 2002).  
 
1.4.2.1 Stimulus independent 
 
Spontaneous pain is present in the absence of any stimulation and it can be either 
continuous or intermittent (Jensen et al., 2001). The pain may demonstrate different 
qualities, for example the pain can be described as aching, stabbing, and burning in nature. 
Spontaneous pain can present shooting, electric shock-like paroxysms lasting a few 
seconds. Often patients will experience continuous pain which may vary in its intensity.  
Shooting type pains often occur in instances where there is nerve compression e.g. sipped 
disc. Spontaneous activity in small (nociceptive) unmyelinated C-fibres is thought to be 
responsible for mediating burning type pains and the sensitisation of dorsal horn neurons 
(Jensen et al., 2001). Equally, spontaneous activity in the large (non nociceptive) 
myelinated fibres is related to abnormal stimulus-independent sensations such as 
paraesthesie (which are not unpleasant) and, after central sensitisation, to dysaesthesie 
(unpleasant) (Woolf and Mannion, 1999).  
 
1.4.2.2 Stimulus dependent pain 
 
The stimulus evoked type pain is a common feature of neuropathic pain and can be 
initiated via mechanical, thermal, and chemical stimulation (Jensen et al., 2001). Several 
types of evoked pain may co-exist within a patient, in others only one may be present. The 
evoked pains are usually brief, lasting for the duration of the stimulation, but at times they 
can persist in the aftermath of stimulation lasting from a few minutes to hours or even days 
(Jensen et al., 2001). Such evoked stimulation produces allodynia (pain caused by 
innocuous stimuli) and hyperalgesia (increased pain response to a normally noxious 
stimulus). Allodynia is mediated via Aβ fibres, and human studies has demonstred that the 
blockade of Aβ fibres can abolish allodynia (Torebjork et al., 1992). Hyperalgesia can be 
evoked via pinprick (e.g. von Frey hair) and is mediated via sensitised Aδ fibres or C-fibres 
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(Ziegler et al., 1999). It is important to recognise other phenomena such as hypoalgesia 
(sensory loss) which can reside in areas of pain, representing a paradoxical type of pain. 
Hypoalgesia appears to affect all sensory modalities, and has been observed with respect to 
thermal in PHN patients (Besson et al., 2005;Rowbotham and Fields, 1996). This response 
may reflect a loss of afferent fibres in affected areas with the addition of sensitized 
peripheral neurons. A loss of spinothalamic function has been hypothesized since they 
propagate information regarding temperature, touch, and pain (Jensen and Lenz, 1995). 
Although some patients will use descriptors such as burning, shooting, and electric to 
describe their pain, Rasmussen and colleagues (2004) reported some difficulties in using 
these descriptors to differentiate between pain of neuropathic origin and non-neuropathic 
pain, given that these words can be used to describe non neuropathic types of pain 
(Rasmussen et al., 2004).  
 
1.4.3 Heterogeniety of neuropathic pain symptoms   
 
The past few years has seen an increasing realization of the heterogeneity of neuropathic 
pain symptoms, even in patients with the same aetiology (Baron et al., 2009;Maier et al., 
2010). Screening tools including quantitative sensory testing (QST) and pain 
questionnaires have been used to evaluate symptoms of pain that maybe neuropathic in 
origin (Haanpaa et al., 2011).  
 
The use of QST has allowed the quantification of sensory function in patients that either 
have or might be at risk of developing neuropathic pain, and is useful in identifying 
abnormalities of both small and large fibre function (Cruccu et al., 2010). QST typically 
involves measuring the detection thresholds to a range of stimuli including; mechanical, 
pressure, vibration, coolness, warmth, cold, and heat (Rolke et al., 2006b;Rolke et al., 
2006a). Various QST protocols exist and therefore a standard protocol has been proposed 
by the German research network on neuropathic pain (GRNP) that can provide an 
assessment of a patient within a 30 minute time frame (Rolke et al., 2006a). A previous 
study using the GRNP-QST protocol demonstrated notable differences in the 
somatosensory profiles of patients with PHN, complex regional pain syndrome (CRPS; 
type I and II), and trigeminal neuralgia (Maier et al., 2010). For example, thermal and 
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mechanical hyperalgesias were most frequent in complex regional pain syndrome patients 
and peripheral nerve injury patients, and allodynia in postherpetic neuralgia patients.  
 
The use of pain questionnaires, which broadly focuses on sensory descriptors of pain, 
provides useful information to the clinician regarding quality and intensity of pain which 
can aid diagnosis or the monitoring of pain. In a previous study, using the painDETECT 
questionnaire, 498 patients with PHN and 1623 patients with PDN were analyzed, and the 
results revealed that patients broadly fitted into 5 symptomatic characteristic subgroups 
(Baron et al., 2009). This again demonstrates the diverse range of symptoms that can exist 
within one neuropathic pain aetiology and it may be more appropriate to treat patients 
according to specific symptoms rather on the basis of ateiology.  
 
Taken together, the clinical data from the QST and questionnaire studies suggest that a 
diverse range of mechanisms is likely to be operating for the manifestation of a particular 
symptom within any given ateiology.  It is important to recognise such phenomena in 
preclinical studies which can be addressed by investigating a variety of peripheral nerve 
injury models to account for the diverse mechanisms.  
 
1.4.4 Peripheral mechanisms of neuropathic pain 
 
To date, the understanding of neuropathic pain mechanisms has derived from basic science 
research involving both traditional in vivo and in vitro as well as novel cell-molecular 
approaches. In addition to pre-clinical research, there has been a steady focus on 
experimental human pain models which have provided further insight into human pain 
pathology.  Following peripheral nerve injury there are biochemical changes at the site of 
injury as well as the affected nerve which may set to drive the symptoms of neuropathic 
pain. 
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1.4.4.1 Dysregulation of ion channels and ectopic activity of neurons  
 
Ectopic activity from injured primary afferents neurons in the peripheral nervous system is 
related to the dysregulation of the synthesis and function of sodium ion channels. Voltage 
gated sodium channels (VGSCs) play a fundamental role in regulating neuronal 
excitability, which is important to the physiology of neurons. There are different isoforms 
of VGSC (named Nav1.1 to Nav1.9) and they all differ in terms of their kinetic and 
pharmacological properties and some have distinct distribution patterns (Wood et al., 
2004). The Nav1.8 and Nav1.9 ion channels are all exclusively expressed in small 
unmyelinated C-fibres. Other channels such as Nav1.4 and Nav1.5 are located in the muscle 
and heart respectively and are important in determining the functional specialization of 
those tissues. Following peripheral nerve injury the Nav1.3 channel (which is expressed at 
low levels in the adult DRG and at high levels during neuronal development) is upregulated 
in the DRG (Lai et al., 2004). This upregulation is associated with ectopic activity which 
correlates with the development of neuropathic pain like behaviour in rodents (Lai et al., 
2004). Additionally, Nav1.3 is upregulated in the dorsal horn of animals with experimental 
spinal cord injury (SCI) and anti sense knockdown of Nav1.3 attenuates dorsal horn 
excitability and pain like behaviours (Hains et al., 2003), although this result is in regards 
to the CNS, it provides evidence for Nav1.3 role in pain. Despite this compelling evidence, 
the global knockout of Nav1.3 in mice still results in pain related behaviours (Nassar et al., 
2006). Furthermore, the use of conditional knockouts via cre-recombinase systems to 
exercise out the Nav1.3 gene which can bypass any genetic possible compensatory 
mechanisms additionally resulted in the development of pain related behaviours. Other 
channels such as the Nav1.8 and Nav1.9 isoforms are down-regulated in injured DRG 
neurons following axotomy in both humans and animal pain models, while uninjured 
afferent expression levels are unchanged (Decosterd et al., 2002;Dib-Hajj et al., 1998). A 
direct involvement of Nav1.8 in neuropathic pain was observed in a study where a 
knockdown of Nav1.8 in the spinal nerve ligation model (SNL) of nerve injury reversed 
both the mechanical and thermal hypersensitivity associated with this injury (Gold et al., 
2003;Lai et al., 2002). Since Nav1.8 is down-regulated in the DRG, it is unlikely to 
contribute to the phenotype described. Interestingly an upregulation of Nav1.8 is observed 
at sites along uninjured nerve afferents (Novakovic et al., 1998); this upregulation may 
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result in the development neuropathic pain-like behaviours. This dynamic shift in 
expression suggests that uninjured or spared neurons play a role in neuropathic pain; 
furthermore, redistribution of Nav1.8 channels in injured sciatic nerve neurons has been 
described in the chronic constriction injury (CCI) model (Novakovic et al., 1998) and 
neuropathic pain patients (Coward et al., 2000). 
 
Ectopic activity can be reduced by sodium channel blockers such as lidocaine and 
tetrodotoxin (TTX) (Matzner and Devor, 1994). Clinical trials have shown the lidocaine 
(5% patch) to be effective in the treatment of PHN and is considered a first-line treatment 
for neuropathic pain states due to its tolerability and safety (Markman and Dworkin, 
2006).This provides direct evidence of sodium ion channel involvement in neuropathic 
pain. Other human data linking VGSC to pain derives from patients with erythromelalgia 
and paroxysmal extreme pain disorder. These hereditary disorders are caused by ‘gain in 
function’ missense mutation in the SCNA gene that encodes the Nav1.7 VGSC (Yang et al., 
2004). Electrophysiological recordings have indicated that the mutation lowers the 
threshold for channel activation and slows down the rate of deactivation thus leading to 
increased excitability and ectopic activity in neurons (Cummins et al., 2004;Dib-Hajj et al., 
2005).  Differing mutations in the SCNA can result the inability to experience pain, which 
is linked to a loss of channel function (Cox et al., 2006). The discovery of this has raised 
the possibility of Nav1.7 VGSC can become an attractive drug target if selectively targeted.  
 
Voltage gated potassium ion channels (VGKC) play a role in modulating excitability in 
neurons by acting as a break and repolarising neurons to restore baseline membrane 
potentials. The major potassium currents arising in neurons are regulated by the VGKC and 
the calcium activating potassium channels (KCa) (Wickenden, 2002). Other potassium 
currents are regulated by the inward rectifying (Kir) and two pore ion channels (K2P) 
(Wickenden, 2002). Experimental peripheral nerve injury leads to the reduction in VGKCs 
in the DRG such as Kv1.4 (which is expressed on small size cells), thus suggesting a 
potential mechanism for ectopic activity in injured neurons (Rasband et al., 2001). One 
VGKC that can regulate the excitability of neurons is the KM channel (KCNQ). The KM 
channel operates at low thresholds in the CNS and is responsible for the inhibitory M 
current in DRG neurons (Marrion, 1997). Retigabine, a drug that can facilitate the M 
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current, can reverse the associated mechanical hypersensitivity in experimental nerve 
injury models (Blackburn-Munro and Jensen, 2003). VGKCs may be a potential target that 
can be exploited for the treatment of neuropathic pain. The small conductance potassium 
ion channel (SK) may play a role in modulating sensory transmission form the periphery to 
the spinal cord. In vivo electrophysiological recordings reveal that neuronal responses to 
nociceptive stimulation increase after application of a selective SK channel blocker, thus 
demonstrating that SK channels can modulate afferent input (Bahia et al., 2005). 
Furthermore, these SK channels are present on peripherin immunoreactive neurons which 
represent the C-fibre (nociceptive) class of sensory neurons, which suggest the SK 
channels maybe involved in processing nociceptive input.  
 
Permeable to both potassium and sodium ions are the hyperpolarization activated cyclic 
nucleotide modulated channels (HCN). These ion channels are also known as pacemaker 
channels and are critical to the production of rhythmic activity in cardiac cells (Biel et al., 
2009). However, the HCN channels are also located on primary afferent neurons, and 
therefore likely to play a role in regulating resting membrane potentials in sensory neurons. 
SNL injury can increase pacemaker currents in large diameter DRG neurons which results 
in pacemaker driven spontaneous action potentials in the ligated nerve. Blockade of the 
HCN channels can reverse hypersensitivity produced by light touch and decreases the 
firing frequency of ectopic discharges originating in Aβ and Aδ , in a dose dependent 
manor (Chaplan et al., 2003). This result suggests that HCN cannels may be, at least in 
part, an underlying factor in ectopic discharge in nerve injury.  
 
A specific role of voltage gated calcium ion channels (VGCC) has been recognised in 
neuropathic pain. There are several different types of VGCC found within the body, all 
distinct via their electrophysiology or response to particular toxins/channel blockers. L-
type channels are key determinants of membrane excitability whereas N and P/Q channels 
are involved with neurotransmitter release. Pharmacological evidence suggests that the N-
type VGCC plays a role in neuropathic pain since intrathecal delivery of N-type 
antagonists reduces the mechanical hypersensitivity associated with SNL injury (Calcutt 
and Chaplan, 1997;Chaplan et al., 1994). The L-type Ca
2+
 channels may also play a role in 
neuropathic pain given that its knockdown in the dorsal horn reverses the mechanical 
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hypersensitivity (Fossat et al., 2010). The auxiliary α2δ subunit of the calcium ion channel 
could act to maintain excitability of neurons. Following spinal nerve injury the α2δ subunit 
is upregulated in the DRG and sciatic nerve axons this also correlates with neuropathic pain 
like behaviours (Bauer et al., 2010;Luo et al., 2001). In addition, transgenic animals which 
over express the α2δ1 subunit in neuronal tissues demonstrate exaggerated dorsal horn 
neuronal responses to both mechanical and thermal stimulation in the hind paws in both 
uninjured and nerve injured neurons (Li et al., 2006). Gabapentin, which is used in the 
treatment of clinical neuropathic pain, binds to the α2δ of the VGCC and this is associated 
with reduced Ca
2+
 currents in excitable neurons and ectopic discharges (Pan et al., 
1999;Stefani et al., 1998). The exact mechanism of pregabalin induced analgesia is not 
fully understood, however a recent study has suggested that the in vivo application of 
pregabalin is associated with impaired trafficking of α2δ subunit on presynaptic terminals, 
which results in reduced neurotransmitter release and neuronal hyperexcitability (Bauer et 
al., 2010).  
 
Transient receptor potential (TRP) receptors are ligand gated, non-selective cation channels 
involved in the biological transduction of thermal mediated nociceptor responses (Veronesi 
and Oortgiesen, 2006). The TRP channels allow the influx of Na
+
 and Ca
2+
 ions resulting in 
depolarization of neurons, which may lead to the generation of action potentials. The 
TRPV1 channel was the first recognized pain transducer and was originally characterized 
by its activation by capsaicin; the pungent chemical found in chilli peppers (Immke and 
Gavva, 2006). The TRPV1 channel is present on both Aδ and C-fibres. It was found that 
TRPV1 channels could be activated by temperatures above 43
o
C, low pH conditions, and 
pharmacologically via anandamide (Ramsey et al., 2006). Other heat sensing channels 
include TRPV2 which actvates at temperatures >50
o
C (Tominaga and Caterina, 2004) and 
TRPM3 which exhibits robust responses to heat in vitro (Vriens et al., 2011).  Conversely, 
the TRPA1 channel responds to noxious cold temperatures (<17
o
C) and other substances 
such as mustard, cinnamon, and ginger oils. The TRPV1 receptor is of immense interest 
given their role in nociception, and their activation can result in burning-like pain 
sensations; a frequently reported symptom of neuropathic pain. The exact role of TRPV1 
channels in nerve injury is not well established however changes in TRPV1 expression 
have been reported in nerve injury models. TRPV1 messenger ribonucleic acid (mRNA) 
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and protein is down-regulated in the spinal cord and somata of damaged sensory neurons 
following sciatic nerve axotomy (Ma et al., 2005;Michael and Priestley, 1999). A further 
study had demonstrated in addition to the down-regulation of TRPV1 in the damaged 
sensory neurons, an upregulation of TRPV1 in the undamaged population (determined by 
tract tracing) – this may be crucial to the development or maintenance of neuropathic pain 
(Hudson et al., 2001). In addition, an increase of TRPV1 is observed in Aβ fibres which 
indicates a likely phenotypic switch since TRPV1 is normally expressed on Aδ and C-
fibres (Immke and Gavva, 2006). Evidence from transgenic studies reveal that mice with a 
knockout in the gene coding the TRPV1 channel exhibit normal responses to noxious 
mechanical and thermal stimuli, however in the context of inflammation this response is 
impaired (Caterina et al., 2000). This indicates a role of TRPV1 in mediating mechanical 
and thermal hypersensitivity in conditions of tissue injury.  
 
The TRPA1 channel has also been shown to be dysregulated following nerve injury, given 
the increased expression in small diameter cells (Obata et al., 2003). It may be that this 
dysregulation is linked to the development of cold hypersensitivity that is evident in 
neuropathic pain models. Indeed a mutation of the gene coding for TRPA1 is responsible 
for a heritable episodic human pain syndrome termed familial episodic pain syndrome 
(FEPS), that can be triggered when exposed to cold (Kremeyer et al., 2010). 
 
1.4.4.2 Sensitization of nociceptors by inflammatory mediators 
 
Injury to a peripheral nerve is usually associated with neuroinflammation with the release 
of proinflammatory cytokines and chemokines from different cell types. Such phenomena 
can occur in Wallerian degeneration whereby the axon becomes separated from the cell 
soma and degenerates distal to the injury (Gaudet et al., 2011). The release of 
proinflammatory mediators can act to sensitize neurons by lowering action potential 
thresholds, which is associated with ectopic discharges, thus leading to an increase in 
neuronal excitability (McMahon et al., 2005). Such proinflammatory mediators include 
tumor necrosis factor α (TNFα), interlukin (IL) 1β, IL-6, adenosine triphosphate (ATP), 
and bradykinin (Ji and Strichartz, 2004). Proinflammatory mediators can be released from 
damaged axons or Schwann cells, Langerhan cells, infiltrating leukocytes and 
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macrophages, and are likely to contribute to allodynia and hyperalgesia observed in human 
neuropathic pain conditions. Intraplantar or intrathecal injections of both TNFα and IL-1β 
cytokines are associated with pain-like behaviour in rodents (Cunha et al., 1992;Safieh-
Garabedian et al., 1995;Youn et al., 2008); and similarly the use of neutralizing antibodies 
can attenuate neuropathic pain related behaviours (Schafers et al., 2001;Sommer et al., 
1999). The administration of TNFα to sensory neurons in vivo is known to affect the firing 
properties of injured and uninjured DRG neurons (Schafers et al., 2003b); this may occur 
through an interaction with VGSCs  and VGCCs (Wilkinson et al., 1996). A consequence 
of IL-1β is the genesis of signaling cascade that leads to the release of pronociceptive 
molecules (e.g. nitric oxide; certain prostaglandins such as PGE2) from immune cells or 
Schwann cells.  The cytokines IL-6 and leukemia inhibitory factor (LIF) can elicit the 
release of neuropeptides (e.g. galanin and SP) and BDNF, all of which can modulate 
nociceptive processing (McMahon et al., 2005). Further evidence for a role of interleukins 
stem from transgenic studies whereby a knockout of IL-6 markedly delays the onset of 
thermal induced hypersensitivity in mice following nerve injury (Ramer et al., 1998). 
Recently, there has been increasing interest in the role of CCL2, which has been linked to 
the pathogenesis of pain in the PNS (Sun et al., 2006). CCL2 is upregulated in the cell 
soma of DRG neurons after trauma nerve injury (White et al., 2005b) and is transported 
and released in an activity dependent manner in the central terminals of these fibres in the 
dorsal horn of the spinal cord (Thacker et al., 2009).   
 
Aside from the direct action of cytokines on nociceptors, there are other circumstances that 
can result in the activation of nociceptors. Firstly, the chemokine fractalkine (CX3CL1)  is 
normally expressed in sensory neurons in the DRG, and its receptor (CX3CR1) is located 
in satellite cells (as well as microglia in the cord) (Verge et al., 2004). However in response 
to neuronal activity,  fractalkine can be cleaved by matrix metalloproteinase (MMPs), 
which can act on its receptors where its activation have been shown to be involved in the 
initiation of neuropathic pain-like behaviour in rats (Milligan et al., 2004). Secondly, the 
viral protein gp120, which is a cell surface protein found on HIV, when applied to the 
sciatic nerve can interact with CCR5 and CXCR4 expressed on sensory neurons (and 
Schwann cells), which initiates a macrophage infiltration at application site and has been 
associated with mechanical hypersensitivity in rats (Wallace et al., 2007a). Upregulation of 
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satellite cell marker GFAP is additionally observed in the DRG which may also release 
proinflammatory cytokines (Wallace et al., 2007a).  
 
In addition to cytokines and chemokines, peptides have a role in regulating nociceptive 
responses. Bradykinin, a small peptide of the kinin family which regulates contraction of 
blood vessels can additionally mediate acute and chronic inflammatory responses (White et 
al., 2005a). Traumatic peripheral nerve injury initiates the release of bradykinin from non 
neuronal cells, which binds to the two bradykinin receptors (BK1 and BK2), therefore 
leading to the activation of the secondary messenger protein kinase C which promotes 
nociceptor sensitivity (Julius and Basbaum, 2001;White et al., 2005a) most likely through 
the TRPV1 receptor (Vellani et al., 2004). The B1 receptor appears to be of relevance since 
this receptor is significantly upregulated on sensory neurons following tissue injury (Fox et 
al., 2003) and is located in small diameter neurons in the DRG (Ma, 2001;Wotherspoon 
and Winter, 2000). B1 receptor activation additionally evokes the release of 
proinflammatory cytokines including PGE2 and PGI2, reactive oxygen species (ROS), and 
nitric oxide from endothelial cells (Walker et al., 1995). Pharmacological studies have 
revealed that the intraplantar administration of bradykinin B1 agonists does not affect paw 
withdrawal thresholds (PWT) to mechanical stimuli (Fox et al., 2003), however it can 
argument nociceptive behaviours following traumatic nerve injury through similarly 
administration routes (Werner et al., 2007). Antagonists of B1 receptor when administered 
systemically (i.v) to rats can reduce the mechanical and thermal hypersensitivity associated 
with traumatic peripheral nerve injury (Ferreira et al., 2005;Levy and Zochodne, 
2000;Yamaguchi-Sase et al., 2003). Furthermore, ablation of the gene for the B1 receptor 
results in a significant reduction in early stages of mechanical and thermal hypersensitivity 
(Ferreira et al., 2005).  
 
Neuropeptides such as calcitonin gene related peptide (CGRP) and Substance P are 
involved in what is defined as neurogenic inflammation – the inflammation arising from 
neurons which is characterized by plasma extravasation and vasodilation in the affected 
region. Sensitization of unmyelinated nociceptive afferents has been hypothesised to play a 
pivotal role in neuropathic pain conditions such as CRPS (Holzer, 1998). Studies in 
patients have demonstrated an increase in systemic CGRP, Substance P, and bradykinin in 
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the acute stages of CRPS (Birklein et al., 2001). Moreover, neurogenic inflammation was 
elicited by directly activating the skin by transcutaneous electrical stimulation via 
intradermal microdialysis capillaries. Animal experiments involving neurogenic 
inflammation have observed similar findings in regards to increases in neuropeptides, and 
pharmacological blockaded of the neurokinin-1 (NK-1) receptor results in a reversal of 
plasma extravsation in rodents (Holzer, 1998;Xu et al., 1992). The neurogenic 
inflammation was associated with alteration in thermal coding and decreases in mechanical 
withdrawal thresholds.  
 
Angiotensin-converting enzyme (ACE) is a key kinase involved in the degradation of 
substance P and bradykinin. A clinical study have indicated an association between the the 
use of ACE inhibitors and the risk of developing CRPS (de Mos et al., 2009), which 
suggests a role for substance P and bradykinin in the underlying pathogenic process. 
 
1.4.4.3 Apoptosis in the DRG  
   
Apoptosis is a distinct form of cell death that can be triggered by a variety of physiological 
and pathological stimuli (Earnshaw et al., 1999). Nerve damage and pain related 
behaviours demonstrated in nerve injury models are accompanied by apoptotic signaling 
cascades in sensory neurons of the DRG (Joseph and Levine, 2004;Sekiguchi et al., 2009). 
Activated caspase-3 (the critical executioner of cell death) is induced in the L5 DRG 
following crush injury to the ipsilateral L5 spinal nerve (Sekiguchi et al., 2009). Recent 
findings by Schaeffer et al., 2010, using the terminal deoxynucleotidyl transferase nick end 
labelling (TUNEL) technique as a marker of apoptosis, demonstrated immunolabeling of 
satellite cells in the DRG of CCI animals 30 days after injury. Previous investigations using 
traumatic, ddC (Zalcitabine) antretroviral, and vincristine-induced models of nerve damage 
have demonstrated that the administration of caspases inhibitors can attenuate pain-related 
behaviours, and therefore caspases signaling pathways may contribute towards neuropathic 
pain  in humans (Joseph and Levine, 2004;Scholz et al., 2005;Sekiguchi et al., 2009). 
Apoptotic pathways may be activated via ROS, ceraminde, and nitric oxide (Benn and 
Woolf, 2004) or stimulation of death receptors such as tumor necrosis factor receptor 1 
(TNFR1) which can act via the c-Jun N-terminal kinase (JNK) pathway to activate effector 
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capsases (Earnshaw et al., 1999). Activation of the TNFR1 occurs by binding with TNFα 
which is released by immune cells such as macrophages in the aftermath of nerve injury 
(Scholz and Woolf, 2007) and is found in the DRG (Schafers et al., 2003a) where it co-
localises with caspases-3 (Kim et al., 2011). This suggests TNFα could potentially play a 
role in initiating apoptosis. Apoptotic signaling may be of particular relevance in ‘die back’ 
neuropathies where the terminal of sensory neurons are diminished while the cell body 
remains, and has the potential to regenerate a new terminal. Although it is assumed that 
once the apoptosis process passes critical checkpoints, cell death ensues, evidence from a 
recent study using a variety of cells including brain cells indicates that late stage apoptosis 
can be reversed (Tang et al., 2012). 
 
1.4.4.4 Altered gene expression and functional genomics  
 
When peripheral sensory neurons undergo damage such as nerve transection, 
transcriptional changes lead to alterations in neuronal physiology which may influence the 
metabolic state, capacity to regenerate and neuronal plasticity, all of which bear relevance 
in neuropathic pain conditions. Since the pathophysiology of neuropathic pain is complex 
and may involve several mechanisms, a more rational approach has been considered taking 
into context changes in gene expression. Recent advances in molecular biology have led to 
the development of deoxyribonucleic acid (DNA) microarray based technologies, which 
have the capacity to measure changes in gene expression by analyzing the entire genome 
(Reilly et al., 2004). This technique has led to the identification of many potential targets 
which maybe relevant to the development or maintenance and symptoms of neuropathic 
pain. There are now several published studies documenting altered expression of 
neuropeptides, ion channels, neuroinflammatory markers and transcription factors, in the 
DRGs of traumatic models of nerve injury (Costigan et al., 2002;Valder et al., 2003;Wang 
et al., 2002). In an attempt to identify dysregulated genes in a model of peripheral nerve 
damage representing a clinically relevant aetiology, DRG gene expression in the gp120 + 
ddC (zalcitabine) was investigated and compared to the spinal nerve transection (SNT) 
model (Maratou et al., 2009). These models were associated with distinct sets of gene 
expression changes, with 5140 dysregulated genes in the SNT model and 656 in the gp120 
+ ddC model compared to sham control, interestingly, only 39 genes were found to be 
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commonly dysregulated (in the same direction) between the two models, some of which 
had not been previously implicated in mechanical hypersensitivity. Several of the genes 
identified such as pancreatitis associated protein-1/regenerating gene protein-2 
(PaP1/Reg2) and neuropeptide Y (NPY) have previously been reported to be implicated in 
the onset of nerve injury related paw hypersensitivity in rodents (Maratou et al., 2009). 
However, other genes which have been previously unidentified such as VGF which is 
significantly upregulated in the g120 + ddC and SNT model has not been examined fully, 
and consequently warrants further investigation. Microarray technology therefore provides 
a basis to which novel targets can be identified and then specifically investigated. 
 
1.4.4.5 Summary 
 
In summary, research over the past 20 years has resulted in an increased understanding of 
neuropathic pain mechanisms. The notion that there is a single underlying hypothesis for 
the development and perhaps maintenance of neuropathic pain is not likely given the array 
of literature encompassing many potential targets and mechanisms (Bridges et al., 2001b). 
In addition, psychological and cognitive factors are increasingly recognized in their ability 
to profoundly influence the overall pain experience, which adds another level of 
complexity (Daniel et al., 2008;Nicholson and Verma, 2004). Research is still ongoing and 
advances in technology such as next generation sequencing technologies may afford the 
possibility of identifying novel targets which may lead to the development of new 
treatments.  
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Figure 1.1 Diagram to summarise the various peripheral mechanisms of neurpathic pain 
following partial nerve injury. Such mechanisms involve dysregulation of ion channels and 
ectopic activity of neurons, sensitization of nociceptors by inflammatory mediators, 
apoptosis in the DRG, and altered gene expression.  
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1.4.5 Central mechanisms of neuropathic pain 
 
1.4.5.1 Central sensitization – wind up 
 
Central sensitization involves changes to the plasticity of neurons at the spinal level, 
whereby afferent inputs such as those arising from low threshold mechanical neurons 
which do not signal pain then begin to do so (D'Mello and Dickenson, 2008). Additionally, 
responsiveness to normally painful stimuli are now interpreted as more painful. Peripheral 
sensitization on the other hand is usually restricted to the site of tissue injury and results in 
the lowered threshold to a particular stimulus.  The phenomenon of central sensitization 
was first demonstrated in a study where thermal cutaneous nerve injury produced long 
lasting changes to the receptive field properties of flexor motor neurons, which was used as 
a measure of functional plasticity in the spinal cord (Woolf, 1983). Since this time, the 
neuronal substrate for the activation of central sensitization has largely focused on 
glutamate. Glutamate is the major excitatory neurotransmitter of the nervous system and 
therefore essential to pain signaling. The vast majority of primary afferents synapsing at the 
dorsal horn utilize glutamate as a neurotransmitter, which then acts on a number of post 
synaptic receptors including the metabotropic glutamate receptors, and the ionotropic 2-
amino-3-(5-methyl-3-oxo-1,2 oxazol-4yl) propanoic acid (AMPA) & N-Methyl-D-aspartic 
acid (NMDA) receptors (Bleakman et al., 2006). The release of glutamate and the 
activation of the AMPA receptors are usually in response to noxious and non-noxious 
stimuli, which represents the constitutive baseline response of dorsal horn neurons 
(D'Mello and Dickenson, 2008). However in the context of nerve injury where repetitive 
high frequency stimulation of C-fibres occurs, there is an increased release of glutamate 
from synapses in the spinal cord which acts on the NMDA receptor (Kawamata and 
Omote, 1996), leading to a non-proportional amplification in the response of dorsal horn 
neurons, also known as wind up (Dickenson and Sullivan, 1987). This high frequency 
stimulation as well as phosphorylation of the NMDA receptor is necessary for the removal 
of the Mg
2+
 block at the NMDA receptor and the opening of the receptor pore. This results 
in the influx of Ca
2+
 and the activation of downstream cellular kinases calcium-calmodulin 
(CAMKI/II) and extracellular signal regulated mitogen activated protein kinase (ERK) (Ji 
et al., 1999;Matsumura et al., 2010), both of which can promote the plasticity of neurons. 
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Wind up can be ablated through the use of NMDA antagonists such as mematine, MK-801, 
and the clinically used ketamine; all of which have been shown to be antinoicceptive in 
SNL induced peripheral nerve injury (Suzuki et al., 2001). Similar antinociceptive 
responses can be observed with the more specific NR2B subunit NMDA antagognist 
(Boyce et al., 1999). Taken together, the evidence supports the role of NMDA contributing 
towards neuropathic pain.   
 
1.4.5.2 Loss of inhibitory systems in spinal cord 
 
The neurotransmitter γ-aminobutyric acid (GABA) is primarily responsible for some of the 
key inhibitory processes that occur within the CNS. GABA acts through the fast acting 
inotropic GABAA receptor and the slow acting metabotropic GABAB receptor to initiate 
hyperpolarization in the mature nervous system. Evidence of GABA role in pain 
processing derives from pharmacological studies, which have demonstrated reduced 
mechanical hypersensitivity in SNL injured rats following intrathecal administration of 
GABAA and GABAB receptor agonists (Hwang and Yaksh, 1997). Furthermore, partial 
nerve injury results in decreases in the dorsal horn levels of GABA and its synthesizing
 
enzyme glutamic acid decarboxylase (GAD) 65 kDa ipsilateral to
 
the injury (Moore et al., 
2002). GABA-mediated inhibitory currents and extracellular concentrations are 
additionally decreased. Interestingly, apoptosis can also be observed in the dorsal horn in 
nerve injured animals as demonstrated by TUNEL labelling, which may be attributed to 
excitotoxicity caused by excessive nerve discharge
 
 (Moore et al., 2002;Sugimoto et al., 
1990). This apoptosis may reflect a selective degeneration of GABAergic interneurons 
which may give rise to the reduced GABA and GAD65 concentration that occurs following 
nerve injury.  
 
Peripheral nerve injury results in the loss of opioids receptors in the DRG (Zhang et al., 
1998) and spinal cord (Besse et al., 1991;Besse et al., 1992b) which most likely reflects the 
loss of primary afferents. These opioids receptors are localised predominately on pre 
synaptic terminals of primary afferents in the superficial lamina of the dorsal horn, and 
there is greater loss of mu opioid receptors than the delta isoform following peripheral 
nerve injury (Besse et al., 1992a). In addition to opioid receptor loss, there is a concurrent 
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increase in spinal mRNA cholecystokinin (CCK, an endogenous antagonist of the opioid 
receptor) and its receptor (CCKB) (Kovelowski et al., 2000). This happening may act to 
lessen the potency of systemic or intrathecal delivered opioids in neuropathic pain and may 
explain the reduced effectiveness of opioids over time (Rashid et al., 2004).  
 
1.4.5.3 Anatomical reorganization 
 
A particular feature of neuropathic pain in humans is the development of allodynia, which 
is thought to mediate from Aβ fibres; however the mechanism by which this happens is 
unclear. One proposed mechanism is anatomical reorganization within the spinal cord. 
Evidence taken from labelling studies suggest that following peripheral nerve injury Aβ 
fibres sprout from their normal termination sites in the deeper lamina of the cord up to the 
superficial dorsal horn, which is normally innervated by C-fibres (Woolf et al., 1992).  This 
reorganization could lead to situation whereby innocuous stimulation is now coded as 
nociceptive. The Aβ fibre sprouting is prevented by treatment with NGF or glial derived 
neurotrophic factor (GDNF), thereby indicating that trophic support during nerve injury is 
integral to nerve plasticity, however the degree to which this relates to pain-like behaviour 
is less clear (Bennett et al., 1996a). Interestingly, there are some studies that have raised 
concerns regarding whether Aβ fibre sprouting is a true phenomenon or is indeed artefact. 
There is evidence to suggest that uptake of the label cholera toxin β subunit (CTB)  is 
altered following nerve injury, such that the label is taken up by C-fibres rather than 
sprouting Aβ fibres (Hughes et al., 2003;Tong et al., 1999). In addition, optimal sprouting 
does not occur until 2 weeks after injury, which would suggest other mechanisms are in 
place regarding hyper-reflexive  responses (Woolf et al., 1992). Despite conflicting 
information in the literature, electrophysiological evidence supports the sprouting theory 
since stimulation of Aβ fibres after nerve injury can activate neurons in the superficial 
lamina II of the spinal cord (Okamoto et al., 2001). It has become clear that further studies 
are warranted in order to clarify contradictory reports in the literature regarding Aβ fibre 
sprouting and the extent to which this may contribute to hind paw hypersensitivity 
following peripheral nerve injury. 
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1.4.5.4 Descending modulation of primary afferents in the spinal cord 
 
Supraspinal modulation of the spinal cord is thought to play an important role in 
neuropathic pain (D'Mello and Dickenson, 2008). This descending modulation 
encompasses both facilitatory and inhibitory controls (Zhuo and Gebhart, 1997); the 
balance of the two ultimately determines the excitability of neurons in the spinal cord. The 
descending projection pathways originate directly or indirectly from several brain stem 
nuclei which include the rostral ventromedial medulla (RVM) - which represents one of the 
main output nuclei for descending control, the parabrachial area (PB), and periaqueductal 
grey (PAG) (Millan, 2002). Within the RVM those facilitatory cells have been defined as 
‘ON cells’ and the inhibitory cells, ‘OFF cells’ (Fields et al., 1995). Following peripheral 
nerve injury, there is enhanced descending excitatory drive from the RVM to the spinal 
cord, which has been described to contribute to the rather than induction of neuropathic 
pain-like behaviours in rodents (Burgess et al., 2002;Vera-Portocarrero et al., 2006) and 
persistent pain in humans (Gebhart, 2004). This excitatory drive may represent a method 
by which the CNS attempts to counteract the loss of sensory input caused by damaged 
neurons. Investigations have indicated that activation of spinal descending serotonin 
pathways play a pivotal role since the pharmacological blockade of 5-hydroxytryptamine-3 
(5-HT3) receptors using ondansetron suppresses spinal responses to punctate mechanical 
stimuli after SNL (Suzuki et al., 2004). In addition, depletion of serotonin in the spinal cord 
attenuates behavioural hypersensitivity after spinal nerve ligation injury (Rahman et al., 
2006). Nociceptive information arrives on superficial regions of the dorsal horn where they 
terminate on NK-1 (substance p receptor) neurons (Todd, 2002).  
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Figure 1.2 Pain pathways from periphery to brain. Primary afferent fibres  transmit 
impulses from the periphery, through the dorsal root ganglion (DRG) and into the dorsal 
horn of the spinal cord. Nociceptive specific (NS) cells are mainly found in the superficial 
dorsal horn (laminae I–II), whereas most wide dynamic ranges (WDRs) are located deeper 
(lamina V). Projection neurones from lamina I innervate areas such as the parabrachial area 
(PB) and periaqueductal grey (PAG) and such pathways. From here descending pathways 
(yellow arrows) from brainstem nuclei such as the rostral ventromedial medulla (RVM) are 
activated and modulate spinal processing. Lamina V neurones mainly project to the 
thalamus (spinothalamic tract), and from here the various cortical regions. Figure adapted 
from D’Mello and Dickenson, 2008. 
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This nociceptive information is then conveyed to higher centers within the brain - such as 
the thalamus, where sensations are perceived thus representing the sensory-discriminative 
aspect of pain. NK-1R expressing neurons represent a small part of the neuronal population 
in superficial lamina, however they represent approximately 77% of the nociceptive cells 
that project supraspinally (Cheunsuang and Morris, 2000). A large proportion of these NK-
1 cells make connections with the RVM, PAG, PB, thalamus, and hypothalamus (Braz et 
al., 2005). The ablation of NK-1 positive neurons using substance p-saporin results in 
reduced excitability of deep dorsal horn wide dynamic range (WDR) neurons which 
suggests that the descending connections are mainly facilitatory (Suzuki et al., 2002). 
Additionally, this ablation can reduce the receptor field sizes in the hind paw and their 
ability to accurately code both mechanical and thermal stimuli (in an animal model of 
peripheral neuropathy) compared to saporin controls (Suzuki et al., 2005). Further 
connections are made from the PB to the amygdala with similarly descending projections. 
Consequently, the amygdala has the ability to modulate the PB and accounts for the 
affective aspect of pain. Other transmitters in addition to serotonin have been implicated in 
descending facilitation – the peptide CCK when microinjected into the RVM of naive rats 
produces a robust mechanical hypersensitivity (Kovelowski et al., 2000), that is associated 
with the activation of OFF cells, and additionally prevents the antinociceptive actions of 
systemic morphine (Heinricher et al., 2001). Over 80% of RVM cells co-express the mu 
opioid receptor (MOR) and CCKB receptor, and ablation of these cells using CCK-saporin 
or dermorphin-saporin respectively does not alter basal sensory thresholds but abolishes the 
tactile hypersensitivity induced by microinjection of CCK into the RVM (Zhang et al., 
2009). Finally, the neuropathic pain drug pregabalin has been proposed to require 
exacerbated descending facilitations as seen in nerve injury to exert its mechanistic action 
(Bee and Dickenson, 2008), most likely by restoring the normal responses to nociceptive 
inputs. 
 
Descending noradrenergic pathways can exert inhibitory influences onto the spinal cord, 
acting primarily via spinal α2-adrenoceptors. These pathways originate from regions such 
as the locus coeruleus (LC) and RVM. This descending inhibition is observed following 
peripheral nerve injury. It is possible that this is a mechanism to restore increased 
excitatory drive in the spinal cord. In fact clonidine – a partial α2-adrenoceptor agonist is 
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used clinically for the alleviation of some neuropathic pain states, and is effective in cancer 
pain (Eisenach et al., 1996). Upregulation of α2-adrenoceptor in the cord may explain the 
added effect of α2-adrenoceptor agonist in reducing pain-like behaviour following 
peripheral nerve injury.  The release of noradrenaline at the spinal cord level could 
additionally provide inhibition by activating inhibitory interneurons (e.g. GABA or 
glycine) in the superficial lamina. Other neurotransmitters may account for the descending 
inhibition as spinal projections of RVM contain GABA, glycine, serotonin somatastatin, 
and enkephalins (Millan, 2002). The cannabinoid system may also have a role to play; the 
cannabinoid receptor 1 (CB1) is particularly abundant in the PAG, the dorsolateral 
funiculus, and the superficial lamina of the dorsal horn (Farquhar-Smith et al., 
2000;Herkenham, 1991). Microinjection of CB1 agonists into the PAG or RVM of naïve 
rats results in antinociceptive in regards to the plantar test (Lichtman et al., 1996;Maione et 
al., 2006), however pronociceptive effects have been observed with low doses (Maione et 
al., 2006). These paradoxical effects have been associated enhanced or reduced activity of 
RVM OFF cells (Maione et al., 2006), suggesting that these actions occur via stimulation 
or inhibition of excitatory PAG projection neurons. The endocannabinoids additionally 
appear important in manipulating descending pain pathways (Petrosino et al., 2007), and 
CB1 agonists are being perused clinically as novel analgesics, though they are yet to be 
fully evaluated and there are concerns regarding their psychoactive associations and 
potential for abuse (Rice, 2008).  
 
1.4.5.5 Immune cell mediated sensitivity of the spinal cord 
 
It was previously thought that only neurons were involved in regulating pain responses, but 
there is an increasing body of evidence from animal studies indicating the role of glial cells 
in maintaining both acute and chronic pain states (Watkins et al., 2001b). Several types of 
glial cells exist in the CNS, namely, microglia, astrocytes, and ogliodendrocytes which 
differ in their associative functions but collectively act to support neuronal function and 
maintain homeostasis. Glia which outnumbers neurons 10 to 1 in the CNS, provides an 
additional important function which is to provide protection from pathogens such as viruses 
and bacteria that can cause their activation. However peripheral nerve injury can result in 
the activation of glia and cascade of immune responses in the spinal cord, of which, 
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microglia and astrocytes have been particularly implicated (Tsuda et al., 2005). There is 
also evidence to suggest immune cells other than astrocytes and microglia such as T cells 
are involved in neuropathic pain mechanisms (Zenonos and Kim, 2010). 
 
Microglia 
 
Microglia constitutes 5-10% of the glial population in the adult CNS, and are considered to 
be of macrophage lineage (Gehrmann et al., 1995). Microglia under normal conditions are 
not actively implicated in nociceptive processing and often considered to be in a ‘resting’ 
state, but they are constantly surveying the environment for potential foreign antigens. In 
the context of peripheral nerve injury, spinal microglia aggregate in affected regions of the 
spinal cord where they become activated and interact with sensory neurons. When 
activated, microglia experience morphological changes where they become hypertrophic 
and adopt an amoeboid shape in contrast to their normal dentritic shape (Kreutzberg, 
1996). Several proinflammatory cytokines are synthesized and released including IL-β, 
TNFα, PGE2, cytotoxic mediators such as ROS, proteases, and excitatory amino acids, 
which act to sensitise nociceptors and are associated with pain hypersensitivity (Ji and 
Strichartz, 2004). An important driver in the production of proinflammatory cytokines in 
microglia following nerve injury is the activation of p38 mitogen activated protein kinase 
(MAPK) and the resulting signaling cascade. Inhibitors of p38 can reverse mechanical 
hypersensitivity in a range of nerve injury models (Ji and Woolf, 2001). Ectopic 
dischargers from primary afferents following nerve injury can result in the release of 
neurotransmitters such as ATP, substance P, and glutamate in the dorsal horn of the spinal 
cord. The receptors for these neurotransmitters are expressed on microglia; therefore they 
are likely to activate p38 as well as other MAPKs such as ERK (Ji and Strichartz, 2004). 
The activation of microglia has been suggested to be associated with large A fibre activity 
since the blockade of TRPV1 fibres (putative C-fibres) using resiniferatoxin in the sciatic 
nerve could not prevent peripheral nerve injury induced microglial activation (Suter et al., 
2009). The pharmacological blockade of spinal P2X4 receptors (receptor for ATP) results 
in attenuation of tactile mechanical hypersensitivity following nerve injury (Tsuda et al., 
2003). There is also involvement of the chemokine CCL2 and its CCR2 (which is 
expressed on microglia) since intrathecal CCL2 in naive animals leads to activation of 
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microglia and the induction of neuropathic pain-like behaviours (Dansereau et al., 
2008;Thacker et al., 2009), correspondingly a knockdown of the CCL2 (Abbadie et al., 
2003) or the use of CCL2 antagonists (Dansereau et al., 2008) leads to the reduction of 
neuropathic pain-related behaviours. Minocycline, an antibiotic that can inhibit the 
activation of microglia can prevent the initiation of mechanical hypersensitivity following 
SNT and gp120-associated nerve damage (Ledeboer et al., 2005;Raghavendra et al., 2003). 
Although no effects were observed on establish nerve damage induced mechanical 
hypersensitivity despite the attenuation in inflammatory mediators in the L5 spinal cord, 
thus indicating that microgliosis is important for the initiation rather than maintenance of 
neuropathic pain. Coull and collages (2005) investigations proposed a further mechanism 
where microglia activation indirectly alters GABAA currents so that its activation causes 
depolarization rather than hyperpolarisation and hence the sensitization of spinal neurons. 
The release of BDNF from activated microglia leads to the reduction in the potassium-
chloride co-transporter (KCC) transporter in lamina I of the spinal cord, thus leading to an 
increased intracellular chloride concentration. This shift in GABAA currents can be 
mimicked by administration of BDNF (Coull et al., 2005). Furthermore, inhibiting the 
release of BDNF from microglia via treatment with interfering RNA prevents the alteration 
in chloride currents, and the associated behavioural hypersensitivity (Coull et al., 2005). 
Additionally, the eventual depolarization by GABAA currents may lead to the removal of 
the voltage dependent Mg
2+
 block of the NMDA receptor, which is required for the 
receptor activation.  
 
Several immunophenotypical changes occur to microglia following nerve injury whereby 
microglia upregulates cell surface markers. These include major histocompatibility 
complex (MHC) class 1 & II (Streit et al., 1989), complement receptor-3 (CR-3 or 
CD11b/18) (Graeber et al., 1988), co-stimulatory  molecules B7-1 & B7-2 (Williams et al., 
1994), TLR3 & TLR4 (Obata et al., 2008;Tanga et al., 2005), and CXCR1 (Lindia et al., 
2005). The upregulation of cell surface markers can further activate microglia and enable 
them to interact with other immune cells such as T cells (Hickey et al., 1991). The 
identification of activated microglia is often performed using the antibody OX42 which 
labels CD11b and the morphological status regarding their amoeboid shape can be 
observed (Graeber et al., 1994). The purinergic receptor, P2Y12, which binds adenosine 
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diphosphate (ADP) has been reported to be upregulated (Tozaki-Saitoh et al., 2008), but 
the consequences of its expression is yet to be elucidated. Finally, the cannabinoid  (CB) 2 
receptor which demonstrates limited expression in healthy CNS tissue, (Graeber and 
Christie, 2012) is upregulated in microglia. Moreover, the activation of the CB2 receptor 
has been shown to attenuate hypersensitivity associated with inflammation and nerve 
damage (Ibrahim et al., 2003;Quartilho et al., 2003) and therefore this activation may be 
related to reducing microglial activity or the inflammatory burden on neurons in the spinal 
cord. Spinal microgliosis appears to be a consequence of traumatic rather than non-
traumatic nerve injury. Previous studies have demonstrated via immunohistochemical 
analysis or flow cytometry, increased numbers of cells expressing CD11b (microglial 
marker) in SNT or CCI models and to a lesser extent in the HIV drug induced neuropathy 
models but not the varicella zoster virus (VZV) or cancer chemotherapy drug induced 
models (Blackbeard et al., 2012;Zheng et al., 2011a). 
 
Astrocytes 
 
The astrocytes are the most abundant glial cells, representing 40-50% of the total glial 
population in the CNS and are in close proximity to neurons (Aldskogius and Kozlova, 
1998). Although both microglia and astrocytes are activated following peripheral nerve 
injury, the microglial response precedes that of astrocytes. An increase in microglial 
markers occurs within a few hours of nerve injury whereas the increase in the astrocyte 
marker – glial fibrillary acidic protein (GFAP) is not detected until at least 4 days (DeLeo 
et al., 2004). In addition, ERK activation shifts from microglia to astrocytes 2-3 weeks after 
nerve injury therefore astrocytes may play a role in the maintenance of neuropathic pain 
(Zhuang et al., 2005). Astrocytes are thought to be activated in response to 
neurotransmitters/neuromodulators (e.g. glutamate, ATP, TNFα) following nerve injury 
resulting in the activation of JNK and ERK signaling pathways (Dominguez et al., 
2008;Tsuda et al., 2011). There is an increasing list of signaling molecules/events released 
from astrocytes that can contribute directly or indirectly to the sensitization of nociceptors. 
Astrocytes release proinflammatory cytokines (e.g. IL-1β and TNFα); chemokines (e.g. 
CCL2) (Gao and Ji, 2010);  and proteases, such as  tissue-type plasminogen activator (tPA) 
and matrix metalloproteinase (MMP)-2 and 9, which are involved in the cleavage and 
release of signalling molecules (Kozai et al., 2007). The glutamate transporter-1 is 
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abundantly expressed on astrocytes (Beart and O'Shea, 2007), and aids in the clearance of 
glutamate released from synapses (Huang and Bergles, 2004). However in nerve injured 
animals, following an initial upregulation, this transporter is down-regulated (Sung et al., 
2003). This may lead to elevated concentrations of glutamate at the synapse which can act 
on NMDA receptors, thus modulating neuronal plasticity. The use of pharmacological 
agents to depress activation of astrocytes can reduce tactile mechanical hypersensitivity 
associated with nerve injury (Sweitzer et al., 2001). 
  
T cells 
 
T lymphocytes (or T-cells) are key constituents of the immune system and collectively act 
to defend the body against pathogens or foreign antigens that can cause harm or disease. 
There are two main types of effector T cells which have different functional roles, namely, 
T helper (Th) and T cytotoxic (Tc) (Parkin and Cohen, 2001). Previous studies have 
demonstrated Th cell infiltration in the dorsal horn of the spinal following SNI and is 
associated with the induction of neuropathic pain-like hypersensitivity (Cao and Deleo, 
2008) with interferon (IFN)γ and its receptor - IFNγR1, being a key mechanism (Costigan 
et al., 2002). This infiltration peaked at 14 days post initial injury, a time point which is 
often the peak of behavioural hypersensitivity.  It is not entirely clear how T-cells are able 
to infiltrate the dorsal horn. T-cells can enter the CNS though the blood brain barrier by 
leukocyte extravasation and this process may be substantially elevated in nerve injury 
(White et al., 2007). Other studies support IFNγ in regulating nociception; the intrathecal 
administration of IFNγ elicits behavioural hypersensitivity in naive animals (Vikman et al., 
2005;Xu et al., 1994), which is likely to act on the spinal IFNγR1, where it has been shown 
to sensitise dorsal horn neurons (Vikman et al., 2005;Vikman et al., 2003). A knockout of 
the IFNγR reduces the mechanical hypersensitivity following SNI, and expression of both 
ligand and receptor increases after peripheral nerve injury (Costigan et al., 2009). A more 
recent study has shown that the intrathecal administration of triptolide, a T cell inhibitor, 
attenuates CCI-induced mechanical hypersensitivity in rats (Hu et al., 2012). Taken 
together these studies further support the role of T cells in mediating neuropathic pain.  
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1.4.6 Models of peripheral nerve injury 
 
Neuropathic pain is a complex condition which involves several different underlying 
etiologies, and may elicit a diverse range of symptoms and associated co-morbidities. 
There are both ethical and legal reasons for why humans cannot be subjected to explicit 
experimentation and therefore animal models have become an alternative and useful 
approach to investigate the potential mechanisms and treatments for neuropathic pain. By 
using a living animal the interactions between different organ systems, tissues, and cells 
can be investigated and therefore a better understanding of the pathological process can be 
attained.  
 
Over the past 30 years there has been a focus and development on producing animal 
models of nerve injury that are intended to be a basis upon which mechanisms of 
neuropathic pain can be understood. These animal models have been largely based on 
peripheral nerve injuries usually via traumatic means and the subsequent development of 
hypersensitivity to mechanical stimuli. These animal models have proved useful in 
advancing understanding of pain mechanisms. However there are a number of 
shortcomings in animal models of nerve injury that should be addressed. Firstly, the major 
outcome measure in animal models of peripheral neuropathy is response to evoked hind 
limb withdrawal in response to mechanical stimulation. While the mechanical 
hypersensitivity that develops following nerve injury is a reliable outcome measure, it can 
only be described as ‘pain-like’ behaviour because animals cannot verbally communicate, 
therefore the notion that the animal is in pain cannot be confirmed. It is worth mentioning 
that hyperalgesia and allodynia are terms used to describe types of pain in humans but are 
often used to describe the same phenonomena in rodent models of peripheral nerve injury. 
The use of such terminology is misguided since there are no tools to actually measure pain 
in rodents per se, therefore the word ‘hypersensitivity’ is more appropriate. Secondly, 
while evoked pain is common in neuropathic pain patients, the overwhelming symptom is 
spontaneous and/or lancinating pain. Sponatenous hypersensitivity is not  routinely 
measured in nerve injury animal models (Mogil and Crager, 2004). Although some 
attempts have been made to measure ‘spontaneous pain’ in rodents, through the use of 
grimace scales (Sotocinal et al., 2011),  animals cannot verbally convey the sensation of 
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spontaneous pain; therefore this assumption cannot be made. Thirdly, there are issues on 
how clinically relevant nerve injury models are and how the research is translated to benefit 
humans. Certain types of neuropathic pain maybe more prevalent in females than in males 
e.g. trigeminal neuralgia (Sadosky et al., 2008); additionally certain types of neuropathic 
pain such as PHN demonstrate increase prevalence with age, however studies typically use 
young male rodents. There are practical, ethical, and methodical reasons why young male 
rodents are commonly used, for example, using younger rodents makes experimental 
research cost effective. Additionally, the preference of male rodents is justified on the basis 
that female rats have fluctuations in ovarian hormones that could alter experimental 
outcomes, and could lead to misinterpretation of data. It is to be noted that not all humans 
who obtain nerve injuries develop neuropathic pain; it is only a subset of patients. However 
animal models of traumatic nerve injury for ethical reasons have been especially designed 
to consistently demonstrate a common primary outcome measure of nerve injury models; 
namely mechanical hypersensitivity, in order to minimize the total number of animals used 
in experiments. Neuropathic pain is chronic in nature, however nerve injury animal models 
are usually studied for short periods of time; typically between 2-4 weeks post injury. It is 
currently unclear the extent to which the chronicity of animal models extrapolates to the 
clinical situation. There also seems to be a uniform approach in regards to the species and 
strains of animals used to study, with a large focus on rodents, however rodent models may 
not always prove the best model in investigating aspects of neuropathic pain and perhaps a 
more integrated approach is warranted. Nevertheless, improving or refining a number of 
factors in the design of nerve injury animal models may improve their predictive validity 
when testing the efficacy of new compounds in clinical trials. 
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1.4.6.1 Models of traumatic peripheral nerve injury 
 
The first animal models of peripheral nerve injury involved axotomy of the sciatic nerve 
which resulted in the complete absence of the flexion reflex and the self-mutilation 
(autotomy) of the denervated hind paw (Wall et al., 1979). This model was thought to 
mimic the symptoms of ‘phantom pain’ often experienced in patients with amputation. The 
self-mutilation was often observed and interpreted as a response to pain – the authors 
indicating that the neuroma formed at the site of nerve transection is the source of afferent 
discharge and could be perceived as pain. However it is argued whether the autotomy is 
actually a pain-related behaviour  and not a result of excessive grooming in the absence of 
sensory feedback (Blumenkopf and Lipman, 1991;Coderre et al., 1986;Rodin and Kruger, 
1984). It was later found that the infusion of lidocaine on the transected sciatic nerve could 
reverse autotomy, indicating that this behaviour was a response to ‘pain’ rather than an 
attempt to remove a denervated part of the paw. Destruction of the DRG via suicide 
transport of ricin failed to reverse the automony behaviour; with this conflicting 
observation it is still unclear what the self-mutilation infers (Blumenkopf and Lipman, 
1991). Since the hind paw is completely denervated evoked mechanical hypersensitivity 
cannot be measured. Partial nerve injury models are now used in favor of the older 
neuroma models to avoid complications in the interpretation of autotomy behaviour 
associated with such injury. The first peripheral nerve injury models described were the 
CCI model (Bennett and Xie, 1988), the partial sciatic nerve ligation model (PSNL) 
(Seltzer et al., 1990), and the SNL (Kim and Chung, 1992). The advantage of the partial 
nerve injury models over the neuroma model is that not all of the axons in the sciatic nerve 
are damaged and therefore responses to mechanical and thermal stimuli in the hind paw can 
be measured. In addition, autotomy behaviour is rarely observed in the partial nerve injury 
models. Autotomy is an undesirable outcome measure of nerve injury associated 
behaviour, and there are also ethical issues regarding this behaviour as an experimental 
endpoint in preclinical studies.  
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Figure 1.3 Illustration of the different types of peripheral nerve injury models used. Injury 
to the spinal nerve involves the SNL (spinal nerve ligation) or the SNT (spinal nerve 
transection) models. The sciatic nerve trifurcates into the common, tibial, and sural nerve 
branches. TNT (tibial nerve transection) involves ligation and transection of the tibial nerve 
which is the biggest of the three terminal sciatic nerve branches. SNI (spared nerve injury) 
involves ligation and transection of the common and tibial nerves, leaving the sural nerve 
intact. CCI (chronic construction injury) involves 4 separate loose ligations of the sciatic 
nerve. PSNL (partial sciatic nerve injury) involves a 30-50% ligature of the sciatic nerve 
trunk. Image taken from Wallace and Rice (2008). (Wallace and Rice, 2008). 
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Bennett and Xie (1988) developed the CCI model of peripheral neuropathy that attempted 
to reflect the clinical condition of causalgia or complex regional pain syndrome in patients. 
The CCI model involves 4 loose ligations of the sciatic nerve (1-2mm apart) at the mid-
thigh level with chromic gut sutures. Gait and posture in these animals are altered; animals 
tend to adopt a protective guard-like position, excessive licking, and limping which suggest 
elements of spontaneous pain. Hypersensitivity to mechanical, thermal, and cold stimuli is 
observed following CCI (Bennett and Xie, 1988). The ligation of the sciatic nerve leads to 
swelling in the area surrounding the constriction, with degeneration and loss of the lager 
diameter Aβ and Aδ fibres with the smaller diameter C-fibre population being less affected. 
The PSNL model involves ligation of approximately 30-50% of the trunk of the sciatic 
nerve at the mid thigh level and is associated with both mechanical and thermal 
hypersensitivity in the hind paw that lasts several months (Seltzer et al., 1990). The 
disadvantages of the PSNL and CCI models are that there are intra and inter operator 
differences in the size and tightness of the ligation between each animal, and therefore the 
degree of nerve injury is not the same – this can translate to behavioural differences as well 
as variation in the expression of neurochemical markers. In addition, chromic gut sutures, 
when used to produce the CCI, leads to rats exhibiting more time with the hindpaw in an 
abnormal position compared to CCI conducted with plain gut, or polyglactin (Vicryl) 
sutures, suggestive of greater paw hypersensitivity. This may also suggest that chromic gut 
sutures may have more than just a constrictive effect on the sciatic nerve compared to the 
use of plain gut, or polyglactin sutures, therefore inducing variability amongst the CCI 
model (Kajander et al., 1996). The SNL model represents the most frequent and commonly 
used model and involves the unilateral tight ligation of the L5 or both L5 and L6 spinal 
nerves. The nature of the injury means that the damage can be isolated to a particular DRG 
sparing adjacent DRGs from actual injury – this allows investigations into both the injured 
and uninjured afferents following nerve injury.  For this reason, the SNL model is unique 
because it provides a standardization of nerve injury which in comparison is difficult to 
achieve with the previous PSNL or CCI models. The SNL model results in hypersensitivity 
that lasts for a period of at least 4 months (Kim and Chung, 1992). Moreover, the SNL 
model is also associated with what has been interpreted as  ‘spontaneous pain-like 
behavior’ similar to that observed in the PSNL and CCI models (Kim et al., 1997). One 
disadvantage however is the SNL surgical procedure is more complex than the PSNL or 
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CCI models and requires more extensive surgical exposure which allows the possibility of 
unintentional collateral damage. Nonetheless, the high reproducibility and consistency of 
the mechanical hypersensitivity makes it a popular model. A modification of the SNL has 
been developed which involves the subsequent transection of the spinal nerves following 
ligation (spinal nerve transection (SNT) model) (Bridges et al., 2001a). The consequences 
of this adaptation are identical to that of the SNL animals however this step alleviates any 
concerns regarding the rigidity of the ligation (Decosterd and Woolf, 2000). The ligation of 
the spinal nerve is intended to be so tight that it induces axotomy and therefore 
‘transection’ of the spinal nerve. However, it can be argued the extent to which axotomy 
occurs, therefore completing a true transection would provide confirmation of the axotomy. 
A modification of the SNT has been described that has been proposed as a model of 
‘spontaneous pain’ – this involves the ligation of the L4 spinal nerve (Djouhri et al., 2006). 
The spontaneous activity of intact C-fibre DRG neurons and foot lifting are linked to the 
neuroinflammation of the L4 spinal nerve.  
 
Spared nerve injury  
 
Recently, the ligation or transection of the sciatic nerve branches has been described as a 
model of partial nerve injury. The sciatic nerve forms a trifurcation and branches off into 
the; tibial, common peroneal, and sural nerves. One model that has been described is the 
spared nerve injury model (SNI) which involves ligation of the common peroneal and tibial 
nerves thus leaving the sural nerve intact, which results in a  robust mechanical and cold 
hypersensitivity (Decosterd and Woolf, 2000). The SNI model differs from the earlier 
partial sciatic nerve injuries models in the sense that there is separation of injured and 
uninjured axons in the sciatic nerve, and it permits sensory testing in distinct areas of the 
hind paw associated with axonal injury, as well as those adjacent areas where innervation is 
intact. Behavioural changes are observed in the ipsilateral sural and to a lesser extent in the 
saphenous territories. Ligation and transection of one or a combination of the sciatic nerve 
branches has been associated with the development of hypersensitivity in the hind paw of 
rats (Lee et al., 2000). Out of all the possible combinations, the tibial and sural nerve 
transection, and the tibial nerve transection alone produced the most robust mechanical 
hypersensitivity which is still present at 10 weeks post injury (Lee et al., 2000).  
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Figure 1.4 Illustration of the different zones of the dorsal and plantar surfaces of the rat 
paw innervated by the sciatic nerve terminal branches and saphenous nerve. The lateral 
glabrous part of the paw is innervated by the sural nerve. The mid-plantar region is 
innervated by the tibial nerve and the medial part is innervated by the saphenous nerve. 
(adapted from Decosttered and Woolf, 2000).   
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Tibial nerve transection 
 
Since robust mechanical hypersensitivity can be achieved through the ligation and 
transection of the tibial nerve alone, it has led to the use of TNT injury as a model to study 
neuropathic pain mechanisms (Andrews et al., 2011;Lee et al., 2000;Unal-Cevik and 
Oaklander, 2011). Like the SNL model, the nerve injury is isolated to one nerve region 
which means the distribution of injured and uninjured populations can be standardised and 
is less variable between animals. It is to be noted that the ease of preparation and 
reproducibility is a factor in the development of peripherial nerve injury models. TNT 
surgery offers a less complex and time consuming procedure that is in contrast to the SNL 
which involves removal of the L6 spinal transverse process, increasing the likelihood of 
collateral damage that could prolong recovery. Following TNT injury the mid-plantar 
region of the paw becomes denervated and is reportedly non-responsive towards applied 
mechanical stimuli for up to 63 days (Unal-Cevik and Oaklander, 2011).  The mechanical 
hypersensitivity that develops is evident in the sural nerve territory (lateral region) of the 
paw (Lee et al., 2000;Unal-Cevik and Oaklander, 2011). Although the mid-plantar region 
of the paw is non-responsive towards applied mechanical stimuli, there is evidence to 
suggest the contrary. Mechanical hypersensitivity has been reported 2-3 weeks following 
injury lasting for at least 2 months (Andrews et al., 2011;Hofmann et al., 2003). In 
addition, a response to pin prick is observed in some animals 21 days following injury 
(Unal-Cevik and Oaklander, 2011). This suggests that sensory function in the denervated 
skin may gradually recover, though the reason for this is not clear. One aspect of the TNT 
model is the development of robust cold hypersensitivity. This element of the model could 
provide a suitable platform to investigate cold related neuropathic pain mechanisms.  
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1.4.6.2 Non-traumatic models of peripheral nerve injury 
 
While physical trauma and nerve compression (e.g. radiculopathies) to peripheral nerves 
can trigger neuropathic pain, the most widespread causes arise from a number of different 
aetiologies including; diabetes, herpes zoster, human immunodeficiency virus (HIV) 
infection and its therapy,  and certain cancer chemotherapy agents (Jensen et al., 2001). 
Traumatic animal models of nerve damage are frequently used preclinically to understand 
the mechanisms of neuropathic pain and test new potential drugs, however the majority of 
patients that undergo clinical trials are those with PHN or DPNs (Finnerup et al., 2010a). 
Traumatic models of peripheral nerve injury are used for their high intra and inter user 
reproducibility and reliability (in terms of the development of mechanical hypersensitivity), 
however the relevance to other neuropathic pain states such as PHN or DPN is understated 
since there may be different underlying mechanisms. Several groups have now developed, 
characterized, and refined clinically relevant rat models of peripheral neuropathy that are 
specific to several human neuropathic pain conditions. These include  the VZV associated 
neuropathy (Fleetwood-Walker et al., 1999;Garry et al., 2005;Hasnie et al., 2007), HIV-1 
gp120 induced neuropathy (Herzberg and Sagen, 2001;Wallace et al., 2007a;Wallace et al., 
2007b) and drug-related neuropathy models (Flatters and Bennett, 2004;Joseph et al., 
2004;Wallace et al., 2007a;Wallace et al., 2007b). These animal models may be useful in 
elucidating the mechanisms behind those neuropathic pain states.  
 
VZV-associated neuropathic pain 
 
PHN is the most frequent complication following an outbreak of herpes zoster (shingles) 
and risk factors are associated with those who have a decline in cell mediated immunity, 
especially the elderly (Gilden et al., 2003). PHN is the pain that arises after resolution of 
the herpes zoster rash lesions, usually occurring in 1-3 dermatomes (specific region of the 
skin innervated by a particular DRG) (Gilden et al., 2003). During infection free VZV 
virons are able to infect sensory neuronal terminals and are retrogradely transported to the 
cells bodies of sensory neurones in the DRG where they persist, usually, for the life time of 
the host (Cohrs et al., 2000). In humans the virus persists in a latent state (Kennedy et al., 
2001) whereby the host is asymptomatic.  However, under conditions of depressed cell-
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mediated immunity (e.g. HIV disease) the virus may ‘re-activate’ to cause an acutely 
painful herpes zoster rash in affected dermatomes. It was previously thought that VZV 
could not infect sensory neurons of other species because VZV is largely species specific in 
vitro and in vivo with humans as its preferential hosts. Initial attempts to create a model of 
Varicella or VZV-related neuropathy by experimental inoculation (using VZV infected 
cells) only led to seroconversion with no overt clinical symptoms (Matsunaga et al., 
1982;Myers et al., 1980;Myers et al., 1985). In 1990 Sadzot-Delvaux and colleagues 
reported for the first time an in vivo rat model, the presence of VZV viral proteins and 
nucleic acid in the Lamina 5 (L5) DRG of VZV infected rats at multiple intervals during a 
9 month period (Sadzot-Delvaux et al., 1990). Fleetwood-Walker and colleagues (1999) 
then went on to infect with VZV (Dumas strain). Rats infected with VZV developed 
mechanical and thermal hypersensitivity within 14 days of subcutaneous inoculation of the 
glabrous paw of the hind limb (Fleetwood-Walker et al., 1999;Garry et al., 2005). The 
pain-related behaviour in VZV infected rats was replicated in an identical study (Garry et 
al., 2005). Moreover, in these animals there was evidence of immunoreactivity against viral 
proteins in the L4-L6 DRGs. Western blot techniques has demonstrated the presence of 
activating transcription factor-3 (ATF-3) nerve injury marker and the neuropeptides NPY 
& galanin (Garry et al., 2005), which are all expressed in traumatic nerve trauma models 
(Ma and Bisby, 1997;Ma and Bisby, 1998;Tsujino et al., 2000). The mechanical 
hypersensitivity developed after VZV inoculation has been reported to persist for up to 90 
days (Dalziel et al., 2004) and is sensitive to clinically used analgesics such as gabapentin 
and amitriptyline (Hasnie et al., 2007). In a more recent model where the Dumas strain was 
used, neither thermal nor cold hypersensitivity were observed (Hasnie et al., 2007). 
Although a lower VZV viral “dose” was used, this model improves on the earlier model 
(Fleetwood-Walker et al., 1999) and draws parallels to the clinical situation where there 
can be degree of thermal sensory loss in PHN patients (Besson et al., 2005;Rowbotham and 
Fields, 1996). In addition, the refined model also exhibits anxiety-like behaviours which 
was shown to correlate with the pain-related behaviour (Hasnie et al., 2007) (see Section 
1.4.7.1 Assesment of anxiety-like behaviours). The rat VZV model is proving useful for the 
identification of potential drug targets; two novel histamine H3 receptor antagonists have 
shown efficacy in reversing VZV-associated mechanical hypersensitivity of the hind limb 
when administered orally (Medhurst et al., 2008). The VZV model epitomizes features of 
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neuropathic pain and has been replicated in several laboratories. However, the VZV model 
has some limitations and emphasis should be placed on the fact that this is not a model of 
PHN, nor a model of herpes zoster, but simpily a model whereby ‘pain’ behaviours are 
exhibited in rodents whose DRG are infected by VZV. Aspects of the model draws some 
parallels with the clinical situations of herpes zoster and PHN (Kinchington and Goins, 
2011). The reproducibility of the model depends on the viral virulence which may vary 
between strains, in addition there are posed risks in the handling of virus that is a known 
pathogen to humans. Inoculation of cell associated VZV into the hind limb of rats infects 
sensory neurons; however there is no truly active infection. No varicella-like disease has 
been observed with this rodent model. An ideal model of PHN would constitute a  
resolving period of the primary infection (chickenpox),  followed by a reactivation period 
of herpes zoster and the development of neuropathic pain-related behaviour after resolution 
of the rash. However this is not attainable in the rat model due to the nature of VZV being 
species specific to humans.  
 
HIV disease associated neuropathic pain models 
 
A common complication of HIV disease is the development of peripheral neuropathies, 
which can affect up to 50% of patients (Verma S et al., 2007). These neuropathies may 
develop as a direct consequence of HIV infection (HIV-related neuropathy), or as a result 
of highly active antiretroviral therapy agents (antiretroviral toxic neuropathy (ATN)). Both 
types of neuropathies can lead to the development of neuropathic pain symptoms which are 
characterised by a progressive ‘die back’ degeneration of small fibres, usually affecting 
those with the longest axons - typically the hands and feet.  Although the clinical 
presentations of these two are very similar, they have distinct pathological aetiologies.  
 
Gp-120 associated neuropathy  
 
HIV-related neuropathies are not thought to occur via direct infection of sensory neurons 
(Lipton, 1991;Michaels et al., 1988), but rather via an interaction of the HIV envelope 
glycoprotein 120 (gp120) with neuronally-expressed chemokine receptors such as CCR5 
and CXCR4 (Kaul and Lipton, 1999;Oh et al., 2001). Macrophages also play a significant 
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role in the gp120 associated sensory neurpathy (Kamerman et al., 2012). 
Immunohistochemical analysis has revealed the expression of the CXCR4 and CCR4 
receptors on DRG neurons that also expressed substance P and TRPV1 indicating that they 
are small diameter neurons of a nociceptive phenotype (Oh et al., 2001). The toxic effects 
of soluble gp120 can be observed on cultured DRG neurons where they induce apoptosis 
through caspase-3 dependent mechanisms (Keswani et al., 2003b;Melli et al., 2006) and 
axonal injury resulting in a reduction of neurite length. Furthermore, gp120 when applied 
to DRG neurons results in excitation and the release of substance P (Oh et al., 2001). In 
line with in vitro findings, a number of studies have now reported toxic effects that is 
associated with the development of mechanical hypersensitivity following either intrathecal 
or perineural administration of gp120 in rats (Bhangoo et al., 2007;Herzberg and Sagen, 
2001;Milligan et al., 2000;Wallace et al., 2007a) and mice (Minami et al., 2003). Thermal 
hypersensitivity has additionally been observed (Herzberg and Sagen, 2001;Milligan et al., 
2000), and may be related to the higher doses of gp120 protein used in those studies, or the 
spinal administration as performed in Milligan et al (2000). The intrathecal administration 
may be considered a more robust approach since the spinal cord is usually acknowledged 
as an immunological privileged area. The mechanical hypersensitivity that develops is 
linked with the infiltration of microglia in the spinal cord and macrophages in the sciatic 
nerve and DRG (Wallace et al., 2007a). These immune cells can increase the production of 
cytokines such as TNFα, nitric oxide, ecisaonoids and other proinflammatory mediators 
(Holguin et al., 2004) which when released can act to senstisise neurons. Inflammatory 
responses such as these are known to contribute towards neuropathic pain mechanisms, and 
the microglial response in this model is sensitive to treatment with microglial inhibitor 
minocycline (Ledeboer et al., 2005). Several studies have reported that inflammatory 
mediators released by HIV-infected macrophages may contribute indirectly to the 
neurotoxicity (Hahn et al., 2008;Jones et al., 2005;Zhang et al., 2003). Hahn et 
al., (2008) demonstrated that supernatant taken from cultured human monocytic cells 
infected with HIV can inhibit neurite growth in cultured human foetal DRGs. Experiments 
using recombinant HIV-1 clones derived from virus extracted from peripheral nerves of 
HIV-infected individuals has been shown to increase the expression of IL-1β and TNF-α  
mRNA in cultured rat DRG, with the most likely source being macrophages (Jones et al., 
2005).  
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The presence of ATF-3 and caspase-3 in the DRG of gp120 sciatic-nerve treated animals 
suggests nerve injury and apoptotic processes, with small diameter cells particularly 
affected (Wallace et al., 2007a).  This correlates with the decreased intra epidermal nerve 
fibre density which mirrors the ‘dying back’ of small fibres that is observed clinically 
(Martin et al., 2003). An increase in the expression of the NPY, galanin, GFAP (satellite 
cell marker) are additionally observed, these findings are features associated with traumatic 
nerve injury models (Ma and Bisby, 1997;Ma and Bisby, 1998;Wynick et al., 2001). 
Collectively, this in vivo evidence suggests a likely role of gp120 facilitating neuropathic 
pain in humans. In addition to the sensory changes, the gp120 model also develops 
correlates of anxiety like behavior when placed in the open field, reflecting the emotional 
burdens of neuropathic pain (Wallace et al., 2007a). An important requisition of animal 
models is the demonstration of predictive (pharmacological) validity. Analgesics such as 
morphine and gabapentin which are effective for treating neuropathic pain in the clinic 
both demonstrate efficacy in reversing mechanical hypersensitivity in the gp120 model 
(Wallace et al., 2007a). Although, it is to be noted that the effectiveness of morphine and 
gabapentin reducing mechanical hypersensitivity associated with peripheral nerve injury 
(including trauma) is a phenomenon well documented in the literature (Abdi et al., 
1998;Backonja et al., 1995;De Vry et al., 2004;Lee et al., 1994). Nevertheless, the use of 
amitriptyline (which was not effective in reducing mechanical hypersensitivity associated 
with gp120 exposure to the sciatic nerve) (Wallace et al., 2007a) further validates the use 
of this model, given that this drug has been shown not to be effective for treatment in HIV 
related neuropathy (Kieburtz et al., 1998;Shlay et al., 1998). The CB1 agonist WIN55,212-
2 was equally efficacious, which may have positive ramifications for therapy. Recently, 
there has been an increasing amount of literature proposing an alternative hypothesis for 
gp-120 related toxicity, involving an interaction with Schwann cells and their release of 
TNFα (Keswani et al., 2003b). Although this is data gathered from in vitro studies, it is a 
plausible in vivo hypothesis given gp-120 can induce TNFα release in the spinal cord of gp-
20 treated animals (Ledeboer et al., 2005). Since the HIV infected individuals are subjected 
to the toxic antiretroviral treatments a model of this has been described to address this 
scenario. The combination of both gp120 + ddC to rats produces a mechanical 
hypersensitivity that is more robust than either treatment alone which indicates a 
synergistic action (Wallace et al., 2007b). This hypersensitivity has been shown to be 
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related to a further increase in microglia infiltration into the spinal cord. An alternative 
approach has additionally been described whereby the oral administration of didanosine 
(ddI) to transgenic mice expressing gp120 under a GFAP promoter results in mechanical 
hypersensitivity (Keswani et al., 2006). These findings indicate that the gp120 model may 
be useful for investigating the mechanism of HIV related pain in humans.  
 
Antiretroviral associated neuropathy 
 
The treatment of HIV infection involves the use of nucleoside analog reversetranscriptase 
inhibitors (NRTIs) which are known to be toxic to humans, and patients are likely to 
develop a painful neuropathy at the beginning of treatment. Risk factors have been shown 
to be associated with increasing age, height, and TNFα genotype (Affandi et al., 2008). A 
model of NRTI induced peripheral neruopathy has been described in many research 
laboratories whereby rats injected with NRTIs (e.g d4T, ddC, ddI) develop a dose-
dependent bilateral behavioral mechanical hypersensitivity (Bhangoo et al., 2007;Dorsey et 
al., 2009;Joseph et al., 2004;Wallace et al., 2007b). Additional studies have demonstrated 
the development of thermal hypersensitivity (Joseph et al., 2004). These behaviours are 
robust and occur within 3 days of a single injection and can last up to 45 days before it is 
resolves to pre-injury levels (Wallace et al., 2007b). The induction of mechanical or 
thermal hypersensitivity has been shown to occur through a variety of administration routes 
including intravenous and intraperitoneal at doses raging from 10-50mg/kg. Drugs are best 
when prepared fresh in saline on the day of injection. The arrival of the ATN model has 
allowed an opportunity to study potential mechanisms of the disease process. Biochemical 
and anatomical studies have revealed that an eminent feature of ATN is the associated 
mitochondrial toxicity caused by persistent exposure to treatment (Zhu et al., 2007); 
however the exact mechanisms are not entirely clear. NRTIs inhibit mitochondrial DNA 
polymerase gamma - the enzyme responsible for the replication of mtDNA. Affected 
animals also demonstrate myelin splitting and intramyelin oedema in the sciatic nerve 
following chronic oral administration (20 weeks) (Schmued et al., 1996). Furthermore, 
injected animals demonstrate a loss of intraepidermal nerve fibre (IENF) density (Wallace 
et al., 2007b), but do not experience some of the features observed in traumatic injury such 
as microgliosis in the spinal cord (Zheng et al., 2011a). The analgesics morphine, 
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gabapentin, and the CB1 agonist WIN55,212-2 demonstrated efficacy in reversing 
mechanical hypersensitivity associated with the NRTI peripheral neuropathy model, while 
amitriptyline was not effective (Wallace et al., 2007b). Further experiments using the NRTI 
peripheral neuropathy model have demonstrated the presence of anxiety-like behaviours in 
the open field (Wallace et al., 2007b), a co-morbidity frequently observed in neuropathic 
pain patients. Co-morbid conditions may also contribute towards the painful neuropathy - 
alcohol abuse, which alone also produces a recognized neuropathy, is one of the most 
important co-morbid risk factors for peripheral neuropathy in patients with HIV/ acquired 
immunodeficiency syndrome (AIDS). A model has been described that combines both 
alcohol consumption and NRTI treatment, which results in profound mechanical 
hypersensitivity (Ferrari and Levine, 2010), and could be used to study aspects of this 
clinical scenario.  
 
Diabetic model 
 
Although patients with diabetic related neuropathic pain can improve symptoms by 
appropriate management of circulating blood glucose, neuropathic pain can still persist in 
those patients. A model of diabetic neuropathy has been developed; this involves the 
systemic administration of streptozotocin, which selectively ablates the beta islets of 
langerhans cells in pancreas. This treatment leads to pathological changes in peripheral 
nerves which are associated with the development of both bilateral mechanical and thermal 
hypersensitivity (Courteix et al., 1993). The nature of the sensory changes is complex since 
both tactile and thermal changes are observed at various time points post injury. This 
model has nonetheless been frequently used in the testing of new pharmaceuticals such as 
gabapentin (Field et al., 1999). A recognizable feature of the model is the associative ill 
health of the animals which not only raises ethical questions but it can be argued the extent 
to which it influences behaviroual sensory thresholds (Fox et al., 1999). 
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Trigeminal neuralgia 
 
Trigeminal neuralgia is a disease characterized by paroxysmal and sharp lancinating 
attacks of pain in the facial area innervated by the trigeminal nerve (Shakur et al., 2011). 
The pain can be brought about via light touch and is often initiated by innocuous tasks such 
as chewing and talking. A model has now been described in the literature that involves CCI 
injury to the infra-orbital branch of the trigeminal nerve (Idanpaan-Heikkila and Guilbaud, 
1999;Martin and Avendano, 2009).This injury results in the development of mechanical 
and thermal hypersensitivity in the vibrissal pad (whisker area). This model has acquired 
wide acceptance for investigating mechanisms of trigeminal neuralgia. The fan-like 
geometry of the multi-fascicled infra-orbital nerve results in different degrees of 
constriction on different fascicles; this could be a possible shortcoming of the model 
however that is natural consequence of the injury given the anatomy of the nerve. The ease 
of performing sensory threshold testing on the hind paw makes the sciatic nerve associated 
injury models a more appropriate choice in neuropathic pain research studies. 
 
Summary 
 
In summary, although the past 30 years has seen developments in neuropathic pain models 
there still many concerns that need to be addressed.  Currently, with the different treatment 
options available for neuropathic pain, only one third of patients achieve pain relief of 50% 
or more, usually at the consequence of undesirable side effects (Dworkin et al., 
2007;Finnerup et al., 2010b;Hempenstall et al., 2005;Phillips et al., 2010). These side 
effects may reduce patient compliance and thus further decrease quality of life for the 
patient. While it is of comfort that some patients achieve sufficient pain relief, the majority 
of patients will not receive adequate pain relief. This may be regarded as a therapeutic 
failure, which in part, may be explained by flaws in the approaches used to assess new 
therapies preclinically. Many studies investigating neuropathic pain mechanisms or 
examining potential therapies rely on the use of clinically non-relevant animal models of 
neuropathic pain (Mogil, 2009;Rice et al., 2008). These models involve direct injury to a 
peripheral nerve e.g. PSNL, CCI or SNL. While physical trauma to peripheral nerves can 
trigger neuropathic pain, the most widespread causes include other conditions such as 
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diabetes, herpes zoster, and HIV infection (Jensen et al., 2001) (see Section 1.4.1). There is 
an appreciation that animal models need to be refined in order to reflect the clinical 
scenario and thus improve their predictive accuracy for clinical trials (Mogil, 2009). In 
humans, only a few develop pain as a consequence of nerve injury, while in animal models, 
most will develop mechanical hypersensitivity that is analogous to pain in humans. The 
intricacies of this have not yet been addressed in animal models. Researches may need to 
analyse the ‘global picture’ of pain encompassing the emotional burdens such as anxiety or 
depression, therefore providing more outcome measures which will reduce the reliance on 
evoked sensory testing that only answers to one facet of a multi-dimensional condition. The 
risk factors of certain aetiologies of neuropathic pain, such as PHN are associated with the 
elderly; however this factor is rarely of concern in studies that use young rodents (Legg et 
al., 2009). The strain of the rodent, supplier, sex, and testing procedures are also important 
factors to consider. Experimental bias is acknowledge to negatively influence experimental 
outcome measures and therefore observer blinding and experimental bias should not be 
understated  (Rice et al., 2008). Other more subtle factors are related to husbandry, dietary, 
and handling of animals all of which can affect experimental outcomes (Deacon, 2006).  In 
light of the preceding discussion, the use of animal models has furthered understanding of 
neuropathic pain mechanisms, but it is clear that many improvements to the way animal 
models are designed and utilized are needed  to overcome this ‘therapeutic failure’. These 
improvements may be time consuming, labour intensive or expensive, but ultimately may 
be necessary to address the obvious challenges that face neuropathic pain research and the 
discovery of new treatments.  
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1.4.7 Co-morbidities of neuropathic pain  
 
Patients that suffer from neuropathic pain syndromes exhibit co-morbidities such as 
insomnia, stress, anxiety, and depression, that can affect quality of life, and are of a direct 
consequence of living with chronic pain  (Daniel et al., 2008;Meyer-Rosberg et al., 
2001;Nicholson and Verma, 2004). In certain neuropathic pain syndromes such as CRPS, 
cormorbidities such as migraine, asthma, and osteoporosis have all been associated with the 
CRPS, thus presenting further clinical burdens. It is possible that the medical history of the 
patient prior to the onset of CRPS might provide an insight into its risk factors and 
potential underlying disease mechanisms (de Mos et al., 2008). 
 
One factor that could explain an individual’s poor response to treatment is the inability to 
appropriately address these comorbidities related to pain which may exacerbate the 
patient’s entire experience of pain. For that reason, there has been a continuing drive to 
make animal models of neuropathic pain more ‘clinically relevant’ by assessing co-
morbidities such as anxiety and depression in order to make them more predictive for 
efficacy in clinical trials. Although some progress has been made, there are obvious 
challenges since such co-morbidities are heterogeneous in origin, with symptoms at the 
psychological, behavioural, and physiological level.  
 
1.4.7.1 Assessment of anxiety like behaviours 
 
Behavioural tests such as the open field paradigm are classically used as a measure of 
anxiety-like behaviour in rodents (Cryan and Holmes, 2005;Suaudeau et al., 2000;Vaeroy 
et al., 2005) and are minimally invasive. This test takes advantage of ethologically relevant 
behaviour that consists of aversion to exposed well-lit areas, and the tendency to explore 
new environments. In the context of the open field, thigmotaxis is a wall hugging 
behaviour which is thought to reflect predator avoidance strategies (Prut and Belzung, 
2003), and is sensitive to anxiolytics (Treit and Fundytus, 1988), therefore it demonstrates 
predictive (pharmacological) validity. A potential confounding factor of the open field 
paradigm is that it is based on the ambulation, and in nerve trauma injured models, full 
motor function may be of concern. In order to rule out any motor dysfunction the total 
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distance travelled inside the arena is often measured - if identical to sham or naïve control 
animals, this can rule out the likelihood of motor deficits. Previous studies using the open 
field have demonstrated anxiety-like behaviours in animal models of traumatic (Hasnie et 
al., 2007;Roeska et al., 2008;Seminowicz et al., 2009;Wallace et al., 2007c), HIV-related 
neuropathy (Wallace et al., 2007a;Wallace et al., 2007c;Wallace et al., 2007b), and VZV 
induced neuropathy (Hasnie et al., 2007). Other well characterized paradigms exist for 
analyzing anxiety-like behaviour such as the elevated plus maze (EPM) and the light dark 
box (Walf and Frye, 2007). The EPM consists of two exposed open arms and two closed 
arms whereas the light-dark box consists of a brightly lit chamber separated by an 
accessible dark chamber. It is likely that the various paradigms differ in their sensitivity to 
demonstrating anxiety-like behaviours. It is important to recognize that protocols regarding 
lighting and external factors such as noise can vary between laboratories; these are factors 
that are particularly sensitive to the outcome of these paradigms. Male rats should be 
considered for these sensitive assays since fluctuations in ovarian hormones in female rats 
could lead to behavioural changes that may be related to emotionality or anxiety (Palanza, 
2001). Reductions in anxiety-like behaviour in female rats have been reported during the 
phases of proestrous and oestrus, when compared to the other stages metaestrous and 
diestrous (Mora et al., 1996). Finally, the genetic background of the rat could influence the 
reflex and behavioural parameters as seen in nerve injury models (Lopez-Rubalcava and 
Lucki, 2000;Palanza, 2001;Shepard and Myers, 2008). 
 
1.4.7.2 Assessment of depressive-like behaviors 
 
The forced swim test (FST) and the tail suspension test (TST) are two of the most widely 
used tools for assessing antidepressant activity preclinically (Cryan et al., 2005;Cryan and 
Holmes, 2005). Both tests have been pharmacological validated based on their responses to 
clinically utilized antidepressants i.e. the persistence of escape-directed behaviors for 
longer time periods. The FST (also known as behavioural despair or learned helplessness) 
was initially developed by Porsolt and colleagues (1977). It involves two swim sessions in 
a glass cylinder: an initial 5 minute pre-test followed 24 hours later by a 15 minute actual 
test session. In the first session (pre-conditioning) - the animal is able to discover the test, 
explore the water surface and dive. The first session is where the animal realizes that it 
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cannot escape.  In the second session (test session) - the rat is familiarised to the FST, and 
will not try to dive (Petit-Demouliere et al., 2005). The depth of the water ensures rats will 
not try to support themselves by touching the bottom of the cylinder with their paws (Detke 
et al., 1995). Behavioural despair is judged when the rodent is immobile, and both hind 
legs are not moving, and no additional activity is observed other than that required to keep 
its head above water (Porsolt et al., 1977). The FST has been used preclinically to observe 
the effect of drugs in nerve injured rats (Gonalves et al., 2008;Hu et al., 2009;Hu et al., 
2007). Like the FST, the TST is based on immobility when placed in an inescapable 
situation; mice are hung upside down by the tail until they cease to struggle (Cryan et al., 
2005). The TST however is not an appropriate test for rats given that they are unable to 
support their own body weight when suspended.    
 
Since anxiety and depression can co-exist within an individual neuropathic pain patient, 
one study have attempted to co-analyse this phenomena (Gonalves et al., 2008). Caution 
should be exerted when interpreting data, because experiments have shown that there is an 
order effect when the FST is executed before the EPM test (Andreatini and Bacellar, 1999), 
with animals showing more anxiety-like behaviour in the EPM (after the initial FST), even 
after a one week interval. Other groups have reported a decrease in exploratory behaviour 
in rodents following previous maze experience (Bertoglio and Carobrez, 2000;Holmes and 
Rodgers, 1998). It is therefore important to establish the ideal sequence and timing of the 
emotional behaviour tests, so that the behaviours displayed in one test does not go on to 
then influence the observed behaviours in another test.  
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1.5 Neurochemical markers in the DRG 
 
The DRG contains cell bodies of peripheral sensory neurons which synapse onto second 
order CNS neurons in the dorsal horn of the spinal cord. These cell bodies in the DRG vary 
in size, with the smaller sized cells representing the C-fibre & Aδ populations, and larger 
sized cells representing the Aβ population. Over the past 30 years a wide range of cell 
markers have been developed based on the expression of neurofilaments and/or receptors in 
order to classify the different sensory neurons and study their respective roles in sensory 
processes (see Table 1.2). 
  
Markers  Cell size 
diameter 
Information 
Peripherin Small Peripherin is a type III intermediate filament protein 
that is expressed in many small diameter peripheral 
and some CNS neurons 
Transient 
receptor 
potential 
vanilloid 1 
(TRPV1)  
Small TRPV1 receptors are members
 
of the TRP/vanilloid 
receptor ion channels and are expressed on C-fibres 
and involved in the process of thermal nociception 
Isolectin 
Bandeiraea 
simplicifolia 
(IB4) 
Small-medium IB4 is a plant lectin that binds to a subgroup of 
small diameter sensory neurons. IB4 labelled DRG 
cells represent the non-peptidergic population of 
sensory neurons and relys on GDNF in postnatal 
development 
Calcitonin 
gene related 
peptide 
(CGRP) 
Small-medium CGRP is a member of the calcitonin family of 
peptides and is abundant within the nervous system 
where its activity has been linked to the 
transmission of nociception. CGRP expression 
neurons relys on NGF for postnatal development 
Neurofilament 
200 (NF-200)  
Large NF-200 is a neurofiament protein is pariculary 
abundant in the soma of large diameter neurons 
where it is slowly transported within axons towards 
the synaptic terminals.  
 
Table 1.2 List of different markers used to identify distinct populations of DRG cells  
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The neurofilaments are one of the five major groups of intermediate filaments (distinct 
class of heterogeneous protein subunits, 10nm diameter) found in the PNS and CNS, which 
are composed of three major proteins of molecular weights 68kD, 160kD, and 200kD 
(Perry et al., 1991). Once synthesized in the neuronal cell body, they are slowly transported 
within axons towards the synaptic terminals. Large myelinated neurons in the DRG can be 
labelled with an antibody that detects phosphorylated neurofiliment-200 (NF-200, also 
known as N52)  (Lawson and Waddell, 1991), whereas the smaller sized unmylenated 
neurons express the type III intermediate filament protein, peripherin (Yu et al., 2008). 
Peripherin is expressed within the cell of many peripheral and some CNS neurons in the 
adult rat (Barclay et al., 2007) and co-localises with TRPV1, the receptor responsible for 
transducing sensations of noxious heat and pain (Veronesi and Oortgiesen, 2006). Small-
diameter sensory neurons can be further divided into two main subtypes based on their 
neurochemical biomarkers and their response to growth factors (Snider and McMahon, 
1998). These are the Isolectin Bandeiraea simplicifolia (IB4) binding, P2X containing 
neurons (non-peptidergic) (Bennett et al., 1996b), and the Substance P/ CGRP containing 
peptidergic neurons. The IB4 positive neurons rely on GDNF for development whereas the 
IB4-negative (peptidergic) population depend on NGF for survival during postnatal 
development (Molliver et al., 1997). This differential response to growth factors suggests 
that these two populations of cells may play different roles in processing of nociceptive 
inputs. IB4 positive neurons have a longer action potential duration and higher densities of 
TTX resistant sodium ion channel currents than the peptidergic population of sensory 
neurons, therefore both populations of these small diameter sensory neurons have distinct 
electrophysiological functions (Lawson and Waddell, 1991). CGRP is a member of the 
calcitonin family of peptides and expressed in the CNS as well as the PNS and its activity 
has been linked to the transmission of nociception, particularly migraine (Benemei et al., 
2009). CGRP co-localises with the TrkA receptor for which NGF is the ligand (Bennett et 
al., 1996b). While it may be common practice to classify nociceptive cells as either 
peptidergic or non-peptidergic, it is important to note that there is a degree of overlap with 
some cells co-expressing both CGRP and IB4 (Bergman et al., 1999). Other populations of 
DRG neurons may exist to which are yet to be defined electrophysiologically or by cellular 
markers.  
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Figure 1.5 Schematic summary of the different neuronal cell populations in the DRG based 
on the markers expressed. Nociceptive unmyelinated neurons comprise of small-medium 
diameter cells that express CGRP and IB4. There is an overlap between DRG cells 
expressing CGRP and IB4.  Non-nociceptive myelinated cells can be identified by NF200 
and represent ~40% of DRG cells or even up to ~50% (Goldstein et al., 1991). Nociceptive 
unmyelinated cells can be identified by peripherin and represent ~50-60% of DRG cells. 
There is also an overlap between NF-200 and CGRP cells and ~6% of peripherin/NF-200 
cells (Goldstein et al., 1991). Arrows around the edge of the pie chart represent receptor 
components for neurotrophic factors expressed by different populations of cells; trkA for 
NGF-responsive; GFRα1, GFRα2, GFRα3 for GDNF-responsive; trkC for neurotrophin-3 
(NT-3) responsive cells. The boxes represent the peptides that are additionally expressed in 
the relevant subpopulations. Image edited from McMahon & Koltzenburg: Wall and 
Melzack’s textbook of pain, 5th Edition. 
FRAP, P2X3, 
TRPV 1 
 
                
Carbonic anhydrse, 
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GFRα1 or GFRα2 
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somatostatin, 
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 TrkA, TrkC, 
GFR-α1 
                
 TrkA 
                
GFRα3 
                
Peripherin  
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1.6 Dysregulated proteins in the DRG 
 
The DRG is a frequently analysed tissue in neuropathic pain research, since it is a key 
junction where peripheral sensory information travels.  It was once assumed that the DRG 
was not involved in nociceptive signal generation or processing and its role limited to 
metabolic demands of neurons, however evidence suggested a more direct role. 
Spontaneous discharge of DRG neurons may occur, which may be perpetuated by 
peripheral nerve injury and there is evidence of cross excitation of cell soma (Amir and 
Devor, 1996). Electrophysiological and immunohistochemical evidence exists for the 
expression of the receptors for NPY, galanin, and SP, and their activation by their 
respective ligands can modulate membrane excitability after micropipette application 
(Abdulla et al., 2001;Abdulla and Smith, 1999;Kerekes et al., 2003). The release of 
substance P from the DRG following potassium/chloride (KCL) stimulation further 
supports this notion (Huang and Neher, 1996). Peripheral nerve injury results in a variety 
of changes which involves alterations in gene expression, protein expression, and post-
translational protein modification which can alter neuronal excitability (Lacroix-Fralish et 
al., 2011;Woolf and Salter, 2000;Zimmermann, 2001). The proceeding section will expand 
on the neurochemicals that have exhibited robust changes in their expression following 
peripheral nerve injury, namely; ATF-3, the neuropeptides NPY & galanin, and GAP-43.  
 
1.6.1 Activating transcription factor- 3 (ATF-3) 
 
Activating transcription factor- 3 (ATF-3) is a member of the ATF/cAMP responsive 
element-binding (CREB) family of transcription factors and is an immediate early gene 
protein (Hai et al., 1989;Ziff, 1990). ATF-3 regulates transcription by binding to DNA sites 
as a homodimer or heterodimer with jun proteins (Chen et al., 1994;Hai and Curran, 1991). 
The biological effect of ATF-3 in vivo is less clear than that of the neuropeptides (i.e. NPY 
and galanin), but a previous study has shown that ATF-3 deficient mice injected with a 
sublethal dose of murine cytomegalovirus possess significantly reduced titres and 
pathology in their livers 3 days after injection, compared to wild type (Rosenberger et al., 
2008). A previous in vitro study has shown that ATF-3 expression in macrophages 
represses IL-6, IL-12, and other cytokine genes downstream of toll-like receptor 4 (TLR4) 
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(Litvak et al., 2009). Taken together, this evidence suggests ATF-3 reduces the 
inflammatory response and is therefore involved in the regulation of the immune system. 
Other studies have demonstrated ATF-3 to be involved in tumour suppression, (Thompson 
et al., 2009), however a more detailed understanding of how ATF-3 regulates oncogenic 
signalling pathways is required. The actual mechanisms regulating ATF-3 expression are 
not clear, but ATF-3 expression can be induced experimentally in preparations such as the 
mechanically injured liver and ischaemic heart, accordingly it is likely to play a role in 
stressed tissues (Chen et al., 1996).  
 
A study by Tsujino and colleagues (2000) identified ATF-3 as a novel marker of the DRG 
cell body response to peripheral nerve trauma. In naïve animals mRNA for ATF-3 was not 
expressed, however following spinal nerve axotomy, ATF-3 was dramatically induced 
(within 24 hours) in virtually all ipsilateral L5 DRG neurons. Thereafter the expression 
remained until its downregulation at 10 weeks where it was then detected at low levels. 
ATF-3 expression in the spinal cord was modest and limited to the ventral horn where 
motor axons terminate, and not the dorsal horn which receives sensory input, thus 
indicating differential regulation of gene expression. Other studies using microarray 
technologies have demonstrated limited ATF-3 expression following dorsal root injury 
compared to spinal root injury indicating that ATF-3 is more associated with nerve injury 
to the PNS rather than CNS (Stam et al., 2007). The upregulation of ATF-3 observed by 
Tsujino and colleagues (2000) was present in the formalin nerve injury model, but not the 
CFA model where there is only inflammation and no tissue injury per se. Moreover, 
stimulation of neurons at C-fibre strength did not induce ATF-3 expression in the DRGs. 
Other experiments have shown that mustard oil, capsaicin, and methanol, and again 
formalin can all induce ATF-3 expression in the DRG, and this occurs in distinct 
subpopulations of sensory neurons (Braz and Basbaum, 2010). Taken together this 
information further suggests that nerve damage is the basis of ATF-3 expression rather than 
increased nociceptive transmission or inflammation (Tsujino et al., 2000). The subsequent 
labelling of the ATF-3 protein via immunohistochemistry revealed that ATF-3 co-localized 
with c-jun (Tsujino et al., 2000), which is a well characterized immediate early gene 
induced in neurons following axotomy (Herdegen et al., 1991). ATF-3 has since been 
suggested as a reliable marker for nerve injury in human tissue following dorsal root 
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avulsions (Linda et al., 2011). Additional studies have demonstrated that ATF-3 expression 
is not just limited to neurons but also to Schwann cells, epineurium, and glia following 
sciatic nerve axotomy and is associated with Wallerian degeneration (Hunt et al., 
2004;Isacsson et al., 2005;Saito and Dahlin, 2008). When the nerve is reattached following 
transection, therefore allowing the regeneration of axons, ATF-3 expression reduces, which 
suggests that ATF-3 may be a indicator of disturbed axonal processes (Hunt et al., 
2004;Saito and Dahlin, 2008). Indeed, reduced ATF-3 expression has also been observed 
following reinneravation of muscle after crush lesion, thus allowing normal retrograde 
transport of growth factors (Kataoka et al., 2007). Previous studies have demonstrated that 
both NGF and GDNF can influence ATF-3 expression. The intrathecal administration of 
trophic factors NGF or GDNF attenuates ATF-3 expression in the DRG following axotomy 
(Averill et al., 2004). However, even in the absence of nerve repair ATF-3 expression in 
Schwann cells in the distal section of the sciatic nerve decreases over time suggesting that 
regenerating axons are not entirely responsible for the downregulation (Kataoka et al., 
2007). In vitro studies have demonstrated that the over expression of ATF-3 (using a viral 
vector) in cultured DRG neurons taken from naïve animals results in increased neurite 
outgrowth (Seijffers et al., 2006). This observation has been further supported in transgenic 
studies where mice constitutively expressing ATF-3 experience enhanced peripheral nerve 
regeneration in DRG neurons comparable to that of a preconditioning nerve injury 
(Seijffers et al., 2007). Co-expression studies have showed that a variety of neurochemical 
makers associated with traumatic nerve injury are additionally expressed in ATF-3 positive 
cells such as galanin, NPY, NOS, and reg-2 (Averill et al., 2002;Shortland et al., 2006). 
ATF-3 has been shown to be induced in a number of other non-trauma neuropathic pain 
models such as the VZV model using western blot techniques (Garry et al., 2005) and HIV-
1 gp120 induced neuropathy model (Wallace et al., 2007a), but not the antiretroviral related 
peripherial neuropathy model (Wallace et al., 2007b). The physiological significance of 
ATF-3 expression is unknown. The amount of ATF-3 expression has been shown to be 
proportional to the degree of thermal behavioural hypersensitivity exhibited, but not 
mechanical (Obata et al., 2003). However the transient-dynamic expression of ATF-3 
following peripheral nerve injury does not correlate with the chronic pain-related 
behaviours observed in the animal models. It has been demonstrated that L5 SNL induces 
ATF-3 expression in the supposedly uninjured L4 DRG and these changes are associated 
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with upregulation of neuropeptides (Shortland et al., 2006) and  downregulation of TTXr 
sodium ion channels Nav1.8, and Nav1.9 (Fukuoka et al., 2012). These expression patterns 
are similar to what is frequently observed in the directly injured L5 DRG following L5 
SNL. However it can be argued that these findings are related to collateral damage incurred 
during surgical manipulations which is heavily influenced by the surgical operator. Even in 
sham operated animals, limited expression of ATF-3 can occur in the DRG. In any case, 
the very nature of surgery results in unavoidable damage, but can be minimized by careful 
attention, in order to carefully reflect the consequences of the intended injury (and 
subsequent ATF-3 expression).  
 
1.6.2 Neuropeptide Y (NPY) 
 
Neuropeptide Y (NPY) is an abundant and widespread neurotransmitter within the nervous 
system and is involved in regulating physiological events such as appetite, 
vasoconstriction, and pain (Intondi et al., 2008;Ji et al., 1994b). The 36 amino acid peptide 
was originally isolated in the porcine hypothalamus where it was found to be particularly 
abundant in the paraventricular and arcurate nucleus of the hypothalamus (Gibson et al., 
1984;Tatemoto et al., 1982). Since its discovery, numerous studies have denoted NPY to be 
a potent stimulator of food intake that can decrease energy expenditure and promote weight 
gain (White, 1993). Later studies have now implicated NPY in the regulation of pain 
responses. NPY and its receptors are located in regions of the spinal cord that are 
associated with nociceptive transmission such as the superficial lamina of the dorsal horn 
(Gibson et al., 1984;Ma and Bisby, 1998). The intrathecal administration of NPY 
attenuates behavioural responses to noxious heat in normal animals (Hua et al., 1991) and 
inflammatory model of pain (Taiwo and Taylor, 2002), and mechanical and cold 
hypersensitivity in the SNI peripherial nerve injury model (Intondi et al., 2008). Equally 
the administration of NPY Y1 and Y2 receptor antagonists can reverse the NPY mediated 
antinociceptive effects, but only when co-administered since the effect of either antagonist 
is limited when administer individually (Intondi et al., 2008). Conversely, pronociceptive 
effects have been observed in the flexor reflex model  of naive animals but this is likely 
attributed to the low doses used in the respective studies (White, 1997;Xu et al., 1999). 
After nerve injury the Y1 receptor, normally present on small DRG neurons, is down-
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regulated, and the Y2 receptor is robustly up-regulated on large neurons (Zhang et al., 
1997). The knockout of the NPY Y1 receptor induces a hypersensitive state to mechanical 
stimuli (Naveilhan et al., 2001;Shi et al., 2006). Sciatic nerve axotomy in these Y1 receptor 
knockouts protects mice from the associated loss of DRG neurons that is observed in wild 
type animals with similar injury (Shi et al., 2006). NPY is virtually undetectable in healthy 
rat DRG neurons (Gibson et al., 1984), or present at very low levels (Zhang et al., 1993b), 
but is present in superficial dorsal horn neurons. Following nerve injury NPY is 
dramatically upregulated in L4/L5 DRG and axonal fibres in superficial and deeper spinal 
lamina. This upregulation occurs primarily in large diameter DRG neurons, but some small 
cells are affected. NPY co-localises with other neuropeptides that have been associated 
with nerve injury such as vasoactive intestinal peptide (VIP) & galanin (Landry et al., 
2000;Ma and Bisby, 1998), reg-2 (Averill et al., 2002), and ATF-3 (Shortland et al., 2006). 
The histological, transgenic, pharmacological, and behavioural studies together support the 
notion that NPY plays a role in regulating nociceptive transmission as well as nerve injury, 
and thus neuropathic pain.   
 
1.6.3 Galanin 
 
Galanin is a 29 (rat)/ 30 (human) amino-acid neuropeptide first identified in the porcine 
intestine (Tatemoto et al., 1983) and is widely distributed throughout the PNS and CNS. 
Galanin is thought to regulate numerous physiological actions in the adult nervous system 
such as energy homeostasis, and can rapidly stimulate food intake following acute injection 
into the hypothalamic paraventricular, lateral and ventromedial nuclei, and the central 
nucleus of the amygdala (Gundlach, 2002). In the gastrointestinal tract, where galanin is 
abundant, it inhibits gastric acid secretion and the release of numerous pancreatic peptides, 
including insulin, amylase, glucagon, and somatostatin (Lang et al., 2007). Galanin also 
regulates osmotic functions, and the intracerebroventricular administration of galanin has 
been shown to decrease free water intake in rats (Brewer et al., 2005). Other putitive 
actions includes regulation of arousal/sleep, reproduction, anxiety (induces anxiolytic 
effects), and cognition where the ventral hippocampal administration of galanin has 
negative effects on learning and memory tests  (Lang et al., 2007). The actions of galanin 
are mediated and regulated via interaction with three gene protein coupled receptors 
 81 
 
 
(GPCRs), GalR1-3 (Mitsukawa et al., 2010). The anatomical location of galanin and its 
receptors in DRG and the superficial dorsal horn is of interest and suggests that galanin 
may also participate in the regulation of nociceptive transmission and thus pain (Hokfelt et 
al., 1987;Michener et al., 1990). Galanin is constitutively expressed in healthy animals 
(<10% in the DRG) and exhibits diffuse granule-like cytoplasmic staining. There is 
evidence from electron and confocal microscopy that galanin expression in the DRG is 
even greater than what has been observed under light microscopy (>90%) but this 
technique has not got sufficient power to detect these differences (Zhang et al., 1993a). 
Following peripheral nerve injury galanin mRNA and protein is robustly upregulated 
(Landry et al., 2003;Ma and Bisby, 1997;Villar et al., 1989;Wang et al., 2002). This 
upregulation occurs early (4 days) following partial nerve injury and peaks at 10-14 days 
with medium-large diameter cells being proportionally affected in L4/L5 DRGs (Ma and 
Bisby, 1997). Complete transection of the sciatic nerve (axotomy) shifts the distribution so 
that small diameter cells increase expression of galanin. The proportion of galanin 
immunoreactivity in DRG neurons are significantly higher in partial nerve injuries 
compared to complete nerve transection 14 days after nerve injury, which suggests galanin 
expression also occurs in uninjured fibres (Ma and Bisby, 1997). This is corroborated by 
another study that has demonstrated approximately 50% of galanin labelled cells in the L5 
DRG co-express the nerve injury marker ATF-3 14 days after injury indicating that those 
cells are damaged, but also intact neurons are equally affected (Averill et al., 2002). 
Expression of galanin also increases in the deeper lamina of the dorsal horn, where large 
fibres terminate. Early pharmacological experiments revealed that intrathecal 
administration of galanin in rats at high or low doses could facilitate or inhibit respectively 
the flexor reflex in response to noxious stimulation (Wiesenfeld-Hallin et al., 1988). Low 
dose galanin (10 ng) caused facilitation of the flexor reflex. Low dose galanin (0.1 and 1 
nmol) has additionally been shown to facilitate decreases in mechanical PWTs in the rat 
(Kuraishi et al., 1991). The antinociceptive response is mediated by the activation of the 
galanin receptor-1 (Gal1R) which has been suggested to inhibit the release of substance P 
(Hua et al., 2005), and glutamate in the spinal cord (Hua et al., 2004). The Gal1R mediated 
hyperpolarisations of sensory neurons may account for the reported synergistic effects with 
opiates (Hua et al., 2004). Other experiments have shown that the administration of galanin 
antagonist and antisense nucleotides can reduce galanin expression in the DRG and this is 
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associated with a higher rate of autotomy after axotomy, a facet that is argued to be an 
outcome measure of neuropathic pain related behaviour (Ji et al., 1994a;Verge et al., 1993). 
The physiological stimuli that results in the release of galanin in the spinal cord of healthy 
animals is yet to be identified, however it is not released in response to noxious, thermal, or 
mechanical stimulation. The location of galanin in small GABA and enkephalin putative 
inhibitory interneurons of the spinal lamina II (Simmons et al., 1995;Zhang et al., 1993c) in 
conjunction with data corroborated from various studies suggest that galanin main actions 
are mainly antinociceptive. The knockout of galanin in mice impairs the ability of 
peripheral nerves to regenerate following sciatic nerve crush and is associated with long-
term sensorimotor functional deficits and therefore galanin may play a role in nerve 
regeneration (Holmes et al., 2000). These effects however are not thought to be mediated 
through the Gal1R since animals with a knock out in this receptor have no reduction in 
regenerative capacity following sciatic nerve crush (Blakeman et al., 2003). Rather the 
Gal2R is thought to be involved given that these events are observed in the Gal2R 
knockouts (Hobson et al., 2006). Furthemore, mice carrying a loss-of-function mutation of 
galanin exhibited a 13% reduction in the total number of adult DRG neurons (Holmes et 
al., 2000). These deficits were associated with a 2.8-fold increase in the number of 
apoptotic cells at postnatal day 3 (Holmes et al., 2000). Galanin expression may also act as 
a neuroprotective agent in peripheral nerve injury baised on the preceeding evidence and 
such neuroprotection has been demonstrated in the CNS, in the hippocampus of galanin 
overexpressing transgenic animals after kainate injection (Elliott-Hunt et al., 2004). This 
highlights some of the potential of galanin, and the reported effects of galanin in the 
literature could be explored fully for its therapeutic potential. Galanin has been shown to 
reduce action potentials in the locus coeruleus  (LC) and the dorsal raphe nucleus by 
causing hyperpolarisations most likely through activation of potassium channels, thus 
reducing the release of serotonin and noradrenaline (Hokfelt et al., 1998;Seutin et al., 
1989;Sevcik et al., 1993), indicating galanin is involved in the modulation of 
neurotransmitter release 
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1.6.4 Growth associated protein-43 (GAP-43) 
 
Nerve growth or axonal elongation coincides with the expression of growth associated 
proteins (GAPs) in the cell bodies of corresponding neurons. The interest in GAPs led to 
the discovery of GAP-43, a membrane-associated phosphoprotein that is significantly 
expressed during axonal growth and synapse formation (Meiri et al., 1986). The precise 
biological actions of GAP-43 remains to be determined, however GAP-43 is considered to 
be an early marker of post-mitotic neurons and is highly expressed in the developing 
nervous system and exhibits significantly lower expression in the adult nervous system 
(Meiri et al., 1986). GAP-43 appears to be involved in transducing intra- and extracellular 
signals to regulate cytoskeletal organization in nerve endings (Benowitz and Routtenberg, 
1997). Later studies have also demonstrated GAP-43 to be present in non-neuronal cells 
such as non-myelin forming Schwann cells (Curtis et al., 1992). Over expression of GAP-
43 in mice leads to neuronal sprouting and conversely, the down-regulation of GAP-43 is 
associated with the regression of neurons in vivo (Aigner et al., 1995;Moya et al., 1988). In 
the mature ganglia GAP-43 is present in few small-diameter cells in DRG, and is 
undetectable in large diameter cells (Reynolds et al., 1991;Sommervaille et al., 1991). 
GAP-43 exhibits cytoplasmic staining but also labels axons. Following traumatic 
peripheral nerve injury, damaged neurons have the capacity to regenerate and this has been 
associated with the increased expression of GAP-43 mRNA or protein in the terminals of 
peripheral afferents, DRG, and the superficial lamia of the dorsal horn (Nahin et al., 
1994;Schreyer and Skene, 1991;Schreyer and Skene, 1993;Woolf et al., 1990). This 
increased expression occurs early after injury (within at least 3 days) with the 
immunoreactivity pattern initially predominant in small-diameter neurons, and peaks at 
approximately 21 days, before becoming undetectable at 9 weeks following crush injury or 
36 weeks following sciatic nerve cut (Woolf et al., 1990). There is evidence for differential 
regulation since at later time points; medium-large diameter cells have been shown to 
express GAP-43 mRNA at >4-10 days (Wiese et al., 1992), and protein >14 days post 
injury (Sommervaille et al., 1991). Increased GAP-43 expression is not thought to be 
directly related to the onset of mechanical hypersensitivity in nerve trauma (indicative of 
neuropathic pain like behaviour) (Jaken et al., 2011). Given the role of GAP-43 in the 
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nerve regeneration and association with nerve injury, it represents a suitable candidate for 
study when investigating neuropathic pain mechanisms.   
 
1.7 Distribution of tibial nerve neurons within the DRG 
 
To date it is unclear with regards to the literature the distribution of tibial nerve neurons 
found within the DRG.  It is worth recognizing the relative distributions of tibial axons to 
the lower lumbar/sacral DRGs since this will reveal the proportion of damaged/undamaged 
neurons in affected DRGs. This is important because varying degrees of damage may 
reflect in the expression profiles of biochemical markers e.g. neuropeptides and ATF-3. 
Retrograde tracers are frequently used in experimental studies of the PNS to determine the 
number and origin of neurons projecting to a specific area (Zele et al., 2010). Early tracing 
studies used Horseradish peroxidase (HRP) which is taken up by axons and into the cell 
soma, and has previously been used to describe tibial nerve distribution in the DRG (Swett 
et al., 1991). Recent years has seen the introduction of newer retrograde tracers that are 
superior to HRP. Fluorogold (FG) and cholera toxin β subunit (CTB) have become one of 
most frequently used tracers for retrograde labelling studies (Kobbert et al., 2000). One 
advantage of FG over the earlier tracer HRP is that it is not taken up by undamaged axons 
of passage (Schmued and Fallon, 1986). FG has a wide range of survival times ranging 
from one day to over a month whereas HRP has a short window in which tissue as to be 
harvested which is usually between 3-5 days (Kobbert et al., 2000). FG is a hydrophilic 
tracer and therefore is evenly distributed throughout the cytotoplasm and survival times 
range from a day to several months, although 7-10 days are the typical time frames for 
study (Zele et al., 2010). FG is taken up by virtually all neurons (Schmued and Fallon, 
1986) however there is evidence to suggest that CTB has a differential distribution 
following nerve injury (Tong et al., 1999). As a result FG will is the more suitable choice 
for retrograde experiments involving traumatic nerve inury.  
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1.8 Macrophage associated neuroinflamation  
 
Macrophages are immune cells that are produced by the differentiation of monocyes that 
originate from the bone marrow. In the PNS, the macrophages reside in the endoneruium 
accounting for up to 9% of the cell population, and are often in close proximity to blood 
vessels (Mueller et al., 2001).  Within the DRG, macrophages are present around neurons 
where they lie outside the basal lamina of satellite cells. The main role of macrophages is 
to phagocytose cellular debris and pathogens in order to stimulate other immune cells to 
respond. This is enabled by the presence of MHC class II protein expressed on the cell 
surface, which makes macrophages special antigen presenting cells in the immune system 
(Griffin et al., 1993). Macrophages can be identified immunohistochemically in neuronal 
tissue (e.g. sciatic nerve or DRG) by the presence of cell surface markers e.g. CD68 (also 
known as ED-1) or CD11b (recognized by the OX-42 antibody) (Scholz and Woolf, 2007). 
A high density of macrophages in the DRG is suggestive of an active immune response 
(Bisby and Chen, 1990). 
 
Following traumatic peripheral nerve injury, Wallerian degeneration takes place; distal 
axons degenerate, Schwann cells differentiate, and macrophages become activated (Stoll et 
al., 1989), where they co-ordinate an immune response releasing proinflammatory 
mediators such as cytokines, interlukins, interferons, prostanoids, growth factors, and nitric 
oxide (Scholz and Woolf, 2007). A macrophage infilitration has also been described in the 
DRG of ddC (HIV-antiretroviral drug) treated rats (non-traumatic neuropathy model) 
(Wallace et al., 2007b). Fundamentally, the infiltration of macrophages has also been 
reported in human nerve biopsies and the severity of the response is related to the degree of 
neuropathic pain (Bennett et al., 2008). This suggests that macrophage infiltration may be 
involved in the initation (or maintainence) of neuropathic pain – experiments have shown 
that mice exhibiting slowed Wallerian degeneration (Myers et al., 1996;Ramer et al., 1997) 
or depleted macrophages (Liu et al., 2000a) have reduced hind paw hypersensitivity after 
traumatic peripheral nerve injury. The recruitment of macrophages and subsequent release 
of proinflammatory mediators after peripheral nerve injury in rodents can interact and 
activate their respective receptors on sensory neurons, directly altering transduction 
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properties of nociceptive afferents, leading to increased responsiveness (sensitization) 
(Calvo et al., 2012b).  
 
The macrophage response to nerve damage is important for the regeneration of injured 
sensory neurons (Bisby and Chen, 1990), and the suppression of the inflammatory response 
via toxic mediated macrophage distruction (Barrette et al., 2008) or combinded ablation of 
IL-1β and TNFα (Nadeau et al., 2011) impairs axon regeneration in mice. The therapeutical 
challenge is to modulate the inflammatory response to reduce persistent pain without 
impairing the important repair process. 
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1.9 Modulation of neuroinflamation via omega-3 poly unsaturated fatty acids 
 
Since macrophages play a role in neuropathic pain pathophysiology (Watkins et al., 
2001a), one approach to counteract this phenomena may involve ω-3 long chain poly 
unsaturated fatty acids (PUFAs). There are different types of PUFAs but the most 
frequently described in the literature are the ω-3 and ω-6 fatty acids (Holub and Holub, 
2004). The ω-6 PUFAs such as arachidonic acid (AA) are considered to be 
proinflammatory whereas ω-3 PUFAs such as eicosapentaenoic (EPA) and 
docosahexaenoic acid (DHA) have anti-inflammatory properties (see Figure 1.6 for 
structure). A large body of evidence now exists documenting the health benefits of ω-3 in 
the prevention and management of various inflammatory conditions including chronic 
inflammatory joint pain (Goldberg and Katz, 2007), inflammatory bowel syndrome (IBS), 
chronic spinal pain, multiple sclerosis, and coronary artery disease (Oomen et al., 2000). 
Much of these benefits are likely attributed to DHA, a major constituent of fish oil (Dyall 
and Michael-Titus, 2008). Several studies, both in vitro and in vivo, have demonstrated the 
neuroprotective effects of DHA (Belayev et al., 2009;Menard et al., 2009;Ward et al., 
2010). This neuroprotective effect may be related to a potential modulation of macrophages 
and the immune response to nerve injury. Data from in vitro experiments supports a dose 
dependent inhibition of IFNγ/lipopolysaccharide (LPS) induced macrophage activation 
when exposed to DHA (Dustin et al., 1990;Lu et al., 2010;Ward et al., 2010). This 
inhibition is associated with a reduction of eicosanoids such as leukotrienes and 
prostaglandins (Lokesh et al., 1988), both of which contribute towards the sensitization of 
neurons (Ji and Strichartz, 2004). Of particular interest is a series of studies demonstrating 
that dietary or systemic administration of DHA following SCI in rats can reduce the 
associative spinal inflammatory response, and improve both the morphological and 
functional outcomes of nerve injury (Huang et al., 2007;King et al., 2006;Ward et al., 
2010). Although DHA has been shown to be beneficial in SCI, few studies have 
investigated whether DHA or other ω-3 PUFAs are relevant in peripheral neuropathic pain 
syndromes.  
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Figure 1.6 The structure of ω-3 PUFAs: Eicosapentaenoic (EPA) and Docosahexaenoic 
acid (DHA). The first of the double bonds is adjacent to the third carbon atom (when 
counting from the methyl carbon end of the molecule) hence the term omega-3. Figure 
adapted from Holub and Holub (2004). 
 
No preclinical study has specifically investigated the modulation of the macrophage 
response via ω-3 PUFAs following peripheral nerve injury. Although there is no direct 
clinical evidence for the role of omega-3 PUFAs in neuropathic pain syndromes, they form 
an essential part of the diet, and their anti inflammatory properties can possibly be 
exploited to form a safe, cost-effective, and efficient approach in the management of 
neuropathic pain. 
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1.10 Aim of thesis  
 
Peripheral nerve injury results in a variety of changes which involves alterations in gene 
expression and protein expression in sensory neurons (Elliott-Hunt et al., 2004;Lacroix-
Fralish et al., 2011;Maratou et al., 2009;Woolf and Salter, 2000;Zimmermann, 2001). 
These neurobiological events often occur in the DRG, and therefore this tissue represents a 
topical point of study in neuropathic pain research. Understanding these biochemical 
changes may reveal possible mechanisms regarding some features of neuropathic pain such 
as spontaneous pain and hyperalgesia. Biochemical changes include the expression of 
neuronal injury marker ATF-3 (Tsujino et al., 2000), upregulation of neuropeptides, 
particularly NPY (Ma and Bisby, 1998), galanin (Hokfelt et al., 1987;Ma and Bisby, 1997), 
and GAP-43 (Sommervaille et al., 1991;Woolf et al., 1990). These responses have even 
been proposed as generic biomarkers of neuropathic pain, and in the case of galanin 
suggested as a drug development target (Hulse et al., 2012). Although the expressions of 
these markers have been investigated in various nerve trauma models, the results of these 
studies are difficult to compare due to different analysis methodologies, variability of nerve 
injury which may reflect in reported expression patterns, and differences in species and 
strains of animals used. Moreover, these neurochemical markers have not been 
comprehensively investigated in non-traumatic nerve injury models such as the d4T-
induced neuropathy model where nerve damage and pain related behaviours are also 
evident. Lastly, the temporal expression profiles encompassing both the acute and chronic 
stages of nerve injury as well as phenotypic cell effects have not been comprehensively 
documented. 
 
One way to try to counteract the long term maladaptive changes is to provide 
neuroprotection. The ω-3 PUFAs have been described in the literature as a potent 
neuroprotector and their benefits are already acknowledged in other disease areas such as 
the cardiovascular and joint pain field. There are some indications that ω-3 PUFAs are 
beneficial following spinal nevre injury in animal models (Huang et al., 2007). However, 
ω-3 PUFAs have not been comprehensively investigated in the context of peripheral 
neuropathic pain.  
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The TNT model of nerve injury has been chosen for investigation because TNT surgery 
offers a less complex and time consuming procedure that avoids potential collateral 
damage that could prolong recovery. 
 
The d4T model of nerve injury was chosen for investigation because d4T is widely used in 
resource limited settings due to its low cost and widespread availability and is associated 
with sensory neuropathy and pain and therefore understading the mechanisms of this 
sensory neuropathy is still relevant (Cherry et al., 2012;Gilks et al., 2006;Makinson et al., 
2008;Renaud-Thery et al., 2007). Previously, the ddC and ddI models has been examined 
(Bhangoo et al., 2007;Joseph et al., 2004;Wallace et al., 2007b), but the d4T model to date 
is yet to be characterised in rats. 
 
Aims of the thesis:  
 
 To provide temporal profile expressions of commonly dysregulated neurochemical 
markers (i.e. ATF-3, GAP-43, NPY, and galanin) in traumatic and non-traumatic 
nerve injury using the TNT and d4T induced models of peripheral nerve injury 
respectively.  
 To compare and contrast these changes in both models. 
 Characterize, compare, and contrast evoked sensory parameters (limb withdrawal 
responses) in both models. 
 Investigate whether DHA (ω-3 PUFA) can reverse mechanical and thermal 
hypersensitivity associated with TNT injury and alter the expression of 
neurochemical markers in the DRG.  
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1.11 Hypothesis 
 
Peripheral nerve damage initiates neurochemical changes in the dorsal root ganglion, and 
the development pain-like behaviours, which can be modulated via the administration of ω-
3 polyunsaturated fatty acids. 
 
Specific investigations: 
 
 To investigate the expression of specific neurochemical markers indicative of 
pathological process in two distinct models of peripheral nerve injury: (1) traumatic 
nerve injury and (2) non-traumatic HIV-antiretroviral drug induced nerve injury at 
both the acute (24 hours) and chronic stages of nerve injury. Further investigations 
will reveal how this relates to changes in outcome measures of neuropathic pain-
like behaviours (i.e mechanical hypersensitivity). A key part of the study will seek 
to make comparisons between the two models described. This will highlight the 
mechanistic differences between the two nerve injury models that are likely 
reflective of the mechanistic differences that occur between neuropathic pain 
patients with different ateiologies. This can support the idea of targeted treatment 
stratigies baised on mechanisms, which could be more effective.  
 
 Determine whether chronic administration of DHA (an ω-3 PUFA) can modulate 
neuropathic pain-like behaviours and provide neuroprotection following traumatic 
peripheral nerve injury. This will be conducted with particular attention to the 
mechanism, i.e. the expression of neurochemical markers in DRG (referred to in 
Section 1.6). Assessment of simple reflex withdrawal behaviours in response to 
punctate mechanical stimuli will be the outcome measure of behavioural like pain.  
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Chapter 2 
 
2 General methods 
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2.1 Animal maintenance 
 
Adult male Wistar rats weighing 200-250g were used for all experiments (Charles River, 
UK), and were housed in individually ventilated cages (2-4 animals per cage) in a 
temperature controlled environment. Animals were provided with food and water ad 
libitum and maintained on a 12:12 hr light–dark cycle. All experiments were performed in 
accordance with the UK Animals (Scientific Procedures) Act 1986 and the International 
Association for the Study of Pain (IASP) guidelines.  
 
Project licence number: 70/7162  
Personal licence number: 70/21129 
 
2.2 Randomisation and blinding 
 
All behavioural studies and immunohistochemical analysis procedures were conducted 
using randomisation and blinding to reduce allocation and observer bias, respectively. 
Experiments were conducted in accordance to Macleod Good Clinical Practice: Preventing 
Introduction of Bias at the Bench (Macleod et al., 2009).  
 
Randomisation was performed by using a computerized random sequence generator 
(www.random.org) in which the range of numbers required are entered into specific fields 
on a computer program (animal’s cage number) and the computer generates a list of the 
numbers in a randomized fashion. 
 
Peripheral nerve injured animals (tibial nerve transection (TNT) and stavidune (d4T) 
treated animals, see Section 2.9 for sample size analysis) were assigned per cage in a 
randomized fashion (as described above) and the investigator performing the sensory 
assessments analysis was not aware of each treatment group until the cessation of study i.e. 
when the animals were culled. Assessment of the immunohistochemical analysis was 
conducted by ‘re-blinding’ via the masking of animal and cage identification’s on slide 
labels and assigning a number to each slide. Before analysis, slide labels of nerve injured 
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and sham/control animals were randomised as previously described using the random 
sequence generator.  
 
2.3 Allocation concealment 
 
The allocation of DHA/saline to the animals was conferred by selecting pre labelled 
identification’s out of a hat by and therefore treatments were not assigned per cage. Upon 
initial administration of DHA the treatments were coded (by an independent investigator) 
as either ‘A’ or ‘B’ and maintained the same code so throughout the study. The visual of 
the solution were indistinguishable and therefore there was no likely potential for bias. The 
‘blinding’ of the surgical procedure was not necessary in this case, since both experimental 
groups received identical nerve trauma injuries (TNT surgery).  
 
2.4 Inclusion/exclusion criteria 
 
In order to maintain the consistency of the studies, a specific set of inclusion/exclusion 
criteria were established to retrospectively include/excude data from analysis: 
 
Inclusion criteria 
 
 Confirmation of tibial nerve transection upon postmortem   
 
Exclusion criteria 
 
 <30% reduction in mechanical PWT from baseline 
 Significant weight loss (>20% of pre surgery body weight),  
 Autotomy of more than 1 digit 
 Infected wound 
 Excessive motor defect or paralysis  
 
 
2.5 Reporting of animals excluded from analysis 
 
All randomized animals (both overall and by treatment group) were accounted for in the 
data presented. A flow chart in the beginning of the each results section illustrates the total 
numbers of animals used and the total number of exclusions. 
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2.6 Fluorogold injections 
 
Following confirmation of adequate anaesthesia, the tibial nerve was exposed in naive 
animals (n=2) in a similar manor required to that of TNT surgery. Fluorogold (FG; 3µl, 4% 
solution in 0.9% saline) was injected into the tibial nerve using a 10μl Hamilton syringe 
with a 30G needle. Following injection, haemostasis was confirmed and the wound was 
sutured at both the muscle and skin level with 4/0 silk suture. Animals received appropriate 
post operative analgesia (as indicated in Section 2.7.1).  
 
2.7 Induction of peripheral nerve injury  
 
2.7.1 TNT surgery 
 
TNT/sham surgery was performed under general anaesthesia with isoflurane in O2 (2-3%, 
1.5L/min), using an aseptic technique (Lee et al., 2000). Following confirmation of 
adequate anaesthesia (absence of front paw reflex), a skin incision was made over and in 
line with the femur in the left hind limb. Connective tissue was cleared under the skin via 
blunt dissection and an incision made along the fascial plane between the gluteus 
superficialis and biceps femoris muscles to expose the trifurcation of the sciatic nerve. The 
tibial nerve was identified in terms of its anatomical position and 7/0 silk suture was used 
to ligate the nerve 2-3 mm distal to the tibial nerve junction from the sciatic nerve. A 
subsequent ligature was made approximately 5mm further distally on the tibial nerve 
proximal to the subsequent branching of the nerve (see Figure 2.1). On completion of the 
tight ligations the tibial nerve was transected between the two ligatures and the nerve 
gently placed back into its correct anatomical position. Haemostasis was confirmed and the 
wound was sutured at both the muscle and skin level with 4/0 silk suture. Sterile cotton bud 
swabs with sterile saline were used to clean blood away from the surgical procedure. Sham 
surgery was performed by exposing the trifurcation of the sciatic nerve as described above, 
but ligation and transection of the nerve were not performed. Care and attention was taken 
not to touch/damage the nerve itself. Transection of the tibial nerve was confirmed 
postmortem. All animals received postoperative analgesia consisting of a single s.c. 
infiltration of Bupivacaine (Astra) (0.25% 0.05ml) around the wound site. Carprofen (20%, 
0.1ml/200g body weight) was administered i.p. 2-4 hours post-operatively. Animals were 
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monitored closely post-surgery for any potential complications such as infection, 
insufficient closure of wound, or excessive motor defects (i.e. complete motor loss in one 
limb so that locomotion only possible by ‘dragging’ that limb, see Table 2.1 for motor 
impairment scale). 
 
 
 
 
 
Figure 2.1 Schematic view of sciatic nerve trifurcation. The tibial nerve branch of the 
sciatic nerve is the final, and thickest, nerve portion to appear from the sciatic nerve.  
Ligation areas are illustrated in this diagram with two thick red lines, and transection 
between these ligations occurs on this branch before the subsequent trifurcation of the tibial 
nerve (Illustration adapted from Lee et al., 2000). 
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Motor impairment scale 
1 Normal motor function 
 
2 Weight bearing on all four paws. Normal locomotor rhythm 
but some eccentric placement of paws. Speed of locomotion 
within normal range. 
 
3 Temporary dragging of up to two paws (occurring within 2 
days of operation and lasting up to 1 week) with impaired 
locomotor function for that period (but animals still able to 
rapidly reach food and water). After 1 week, motor 
impairments as in 1 above. 
 
4 Temporary motor impairment of up to two paws (starting 
within 2 days and persisting for up to 1 week) but animals still 
able to rapidly reach food and water. After 1 week, persistent 
motor impairment of paws resulting in incorrect limb 
placement, delayed and/or incomplete swing phase of 
walking, but animals still able to move, albeit at less than half 
the normal speed to reach food or water. 
 
5 Permanent motor impairment of one paw. Locomotion only 
possible by ‘dragging’ that limb.  
 
 
 
Table 2.1 The motor impairment scale used to determine the degree of motor deficit after 
recovery from TNT surgery. Each animal was assessed independently and the gait 
examined inside and outside cage of their cage on a raised platform. Assessment was 
approximately 1 minute per animal.  The scale was extracted from Seltzer et al., 1990. 
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2.7.2 d4T administration 
 
Injections were performed under brief general anaesthesia using isoflurane in O2 (2-3%, 
1.5L/min). Following confirmation of adequate anesthesia (absence of front paw reflex), 
animals received 0.5ml of d4T (i.v. 50 mg/kg in saline; gift from Pfizer) or saline via a tail 
vein. Fresh solutions were prepared as required using 0.9% sterile saline.  d4T/saline 
injections were repeated 4 days after initial injection. Once haemostasis was confirmed in 
the tail vein, animals were returned to their cages. The repeated administration regime was 
chosen based on a pilot study from a parallel d4T project within the group which 
demonstrated that this regime was optimum.  
 
2.8 Behavioural reflex testing 
 
2.8.1 Reflex withdrawal to mechanical stimuli  
 
Reflex responses to static punctate mechanical stimuli were assessed using a hand held 
electronic von Frey device (Moller et al., 1998) at baseline and at a time point post-surgery 
or initial d4T injection shortly before cessation of study. At the time of testing the animal 
was placed into a Plexiglas clear box (23 x 18 x 14cm) with a 0.8cm diameter mesh floor, 
and allowed to acclimatise to the testing environment until exploratory  behaviour had 
ceased (approximately 10-15 minutes). A calibrated force transducer (0.5mm
2
 diameter tip) 
was applied at a rate of 8-15 grams/sec to the mid-plantar surface of each hind paw in turn 
until an active limb withdrawal response was observed. A minimum of 1 minute was 
allowed before sampling the same hind paw. Readings were discarded when the animal did 
not actively withdraw its hind limb. A mean paw withdrawal threshold (PWT) was then 
calculated after 5 applications. At the end of each experiment the animal was placed back 
into its cage and the Plexiglas box cleaned thoroughly with disinfectant.  
 
2.8.2 Reflex withdrawal to thermal stimuli  
 
Behavioural reflex responses to thermal stimuli were assessed using a Hargreaves device at 
baseline and at a time point post surgery shortly before cessation of study (Bridges et al., 
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2001a;Hargreaves et al., 1988). At the time of testing the animal was placed into a clear 
Plexiglas box to acclimatize for 15 minutes. The Hargreaves device was then calibrated: 
the infrared intensity level was set to 70; and the heat source was set to a maximum 
exposure time of 21.4 seconds (this was to ensure that there was no permanent tissue 
damage to the animal). Upon testing, the Hargreaves device was placed directly below the 
mid-plantar region of the hind paw and switched on. The timer automatically starts on heat 
emission and automatically stops on withdrawal of the hind paw. A minimum of 1 minute 
was allowed before sampling the same hind paw. A mean paw withdrawal latency (PWL) 
from the radiant heat source was then calculated after 3 applications for each hind paw. At 
the end of each experiment the animal was placed back into its cage and the Plexiglas box 
cleaned thoroughly with disinfectant. 
 
2.9 Experimental study groups 
 
A sample size analysis was performed based on previous data using the SNT and ddC 
model: 
 
Sample size calculation for TNT rats based on previous data using SNT rats (Hasnie et al., 
2007): 
 
 The minimum detectable difference in the mean PWTs in SNT rats was 25g and the 
standard deviation was 8g. Using SigmaStat v3.5, a sample size of 4 animals was 
calculated per group at the desired power of 0.8 and alpha 0.05.  
 
Sample size calculation for d4T treated rats based on previous data using ddC treated rats 
(Wallace et al., 2008): 
 
 The minimum detectable difference in the mean PWTs in ddC animals was 16g and 
the standard deviation was 5g. Using SigmaStat v3.5, a sample size of 4 animals 
was calculated per group at the desired power of 0.8 and alpha 0.05.  
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The time points examined using the TNT and d4T treated rats differ due to the nature of the 
hypersensitivity in the respective models: 
 
 TNT/sham animals were sacrificed at days 1, 7, 14, 28 and 43 post surgeries, 
shortly after recording of behavioural responses (Chapter 3). These time points 
represent the early (day 1 and 7), peak (day 14), and chronic stages of nerve injury 
(day 28 and 43) (Lee et al., 2000).  
 
 d4T/saline treated animals were sacrificed at day 7, 22, and day 43 following initial 
injection, shortly after recording of behavioural responses (Chapter 4). Day 7 
represents an early time point post injury (3 days post second d4T injection) that 
has not previously been examined. Day 22 represents a time at which peak 
behavioural hypersensitivity is generally observed towards mechanical stimuli in 
this model (Wallace et al., 2008). Day 43 represents a time at which  
hypersensitivity is still evident, but past the peak (Wallace et al., 2007b).  
  
2.10 DHA preparation  
 
Pure docosahexaenoic acid (DHA) solution (25µl, Sigma, UK) was opened and handled in 
a bubble sealed nitrogen gas atmosphere and 276μl of 100% ethanol was added to the pure 
DHA to make a 1M solution. Following this step, 5μl of pure DHA was aliquoted into 1ml 
light-protective glass screw top vials, using a pipette gun and glass pipette tips. The 
nitrogen gas atmosphere was required to protect the DHA from being oxidized, which is 
possible at normal atmosphere conditions. DHA is also light sensitive and therefore was 
handled at low light levels and required the use of light-protective vials. Pure DHA aliquots 
(5μl) were subsequently stored at -80oC.  
 
Immediately before animals were prepared for DHA administration, a vial of DHA was 
taken from the -80
o
C freezer and placed in a bubble sealed nitrogen gas atmosphere. 
Animals were planned to have DHA administration at 2.5mls/kg. The 5ul of DHA was 
diluted to form a working concentration of 200µM by using serial dilutions to achieve a 
dilution equivalent to 25ml. The cap of the vial was unscrewed and 1ml of sterile saline 
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was added to stock DHA solution, and this solution was then extracted via an electronic 
pipette gun and aliquoted into a 10ml glass vial, where a further 4mls of sterile saline was 
added (total 5mls). Following this step, 1ml of the DHA-saline solution in glass vial was 
extracted via an electronic pipette gun and aliquoted into another 10ml glass vial, where a 
further 4 ml of sterile saline was added, thus producing a final 5ml solution of 500 nmol/kg 
of DHA-saline. The final ethanol concentration was negligible (8.0 pmol/ml). 
 
2.11 DHA administration 
 
Following TNT surgery animals were kept anesthetized in preparation for the 
administration of treatments. Animals received an i.v. tail vein injection of either saline 
(sterile, 0.9%) or DHA (500 nmol/2.5mls/kg; Sigma, UK) 30 minutes after transection of 
the tibial nerve. Animals were then placed back into their respective cages following 
recovery from anesthetic. Animals continued treatment of either saline or DHA every 3 
days following surgery until day 28 when animals were sacrificed. Mechanical and thermal 
behaviour assessment was conducted every 7 days post surgery. The treatment groups were 
coded as either ‘A’ or ‘B’ and were administered in the order originally received upon 
initial administration.  
 
2.12 Tissue preparation 
 
All animals were sacrificed with an intraperitoneal injection of pentobarbital (300 mg/kg 
Animal Care Ltd) and transcardially perfused with 200ml of heparinised 0.9% saline 
followed by 300ml of 4% paraformaldehyde (PFA) solution (pH 7.4) in 0.1 phosphate 
buffer. DRG tissue from lumbar segments L4 and L5 were harvested and subsequently 
post-fixed in 4% PFA for 2-4 hours before being submerged in a 30% sucrose solution (in 
phosphate buffered saline (PBS)) for 72 hours. The L4 and L5 DRG was identified via 
position relative to the iliac crests and rib cage (Rigaud et al., 2008). Following incubation 
with 30% sucrose solution the DRGs were then embedded in optimum cryostat temperature 
(OCT) compound (VWR; Poole, UK) under liquid nitrogen or dry ice. Embedded tissue 
was stored at -80
oC. Serial cryostat sections (10μm) were taken and tissue was thaw-
mounted on superfrost slides (VWR) before storage in a -20
o
C freezer.   
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2.13 DRG Immunohistochemistry  
 
All fluorescence immunohistochemistry experiments were conducted at room temperature 
(25
o
C).  DRG L5 sections were rinsed in 0.1M PBS solution. Slides were then pre-
incubated for 1 hour in 0.1M PBS containing 0.3% triton X-100 and 10% normal donkey 
or goat serum where appropriate,  in order to block non-specific binding. In this thesis, the 
following primary antibodies were used (also see Table 2.2); anti-rabbit polyclonal 
activating transcription factor-3 (1:200, 1:200, Santa Cruz Biotechnology, CA); anti-rabbit 
polyclonal galanin (1:4000, Peninsula Laboratories, CA); anti-rabbit polyclonal 
neuropeptide Y (1:1000, Peninsula Laboratories, CA); anti-rabbit polyclonal growth 
associated protein-43 (1:1000, Chemicon); and anti-mouse ED-1 (1:500, Serotec). Primary 
antisera consisted of 0.1M PBS and 0.3% triton X-100. Double labelling experiments with 
previously mentioned antibodies were performed using anti-mouse peripherin (1:100, Santa 
Cruz); anti-mouse peripherin (1:1000, Abcam); or anti-mouse Neurofilament 200 (1:1000, 
Sigma) primary antisera to label small diameter and large diameter cells respectively. 
Following incubation of primary antisera, slides were rinsed with 0.1 PBS and incubated 
using the following secondary anti-sera where appropriate: Cy3-goat anti-rabbit (1.300, 
Jacksons Laboratories), FITC-donkey anti-mouse (1:200, Jacksons Laboratories), Alexa 
flour 568 goat anti-mouse (1:400, Invitrogen), Alexa flour 488 goat anti-rabbit (1:400, 
Invitrogen). Secondary antisera consisted of 0.1M PBS and 0.3% triton X-100. For the 
double labelling experiments, two sets of primary antisera were applied and developed 
sequentially to avoid any possible cross immunoreactivity.  After 2 hour incubation with 
secondary reagents, sections were washed in 0.1M PBS and incubated with 2μg/ml of 
Hoechst 33342 for 2 minutes, thoroughly rinsed with distilled water, before being 
coversliped with PBS/glycerol (1:8). 
 
Controls: 
 
Negative controls were carried out for each primary antibody used. This involved using an 
identical protocol as above but with omission of primary antisera on slides. 
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 Antibody Host Dilution Supplier 
Primary’s 
 ATF-3 Rabbit 1:200 Santa Cruz 
 GAP-43 Rabbit 1:1000 Chemicon 
 NPY Rabbit 1:1000 Peninsula Laboratories 
 Galanin Rabbit 1:4000 Peninsula Laboratories 
 NeuN Mouse 1:1000 Chemicon 
 Peripherin Mouse 1:100 Santa Cruz 
 Peripherin Mouse 1:1000 Abcam 
 NF-200 Mouse 1:1000 Sigma 
Secondary’s 
 Alexa flour 
488 (green) 
goat  
(anti-rabbit) 
1:400 Invitrogen 
 Alexa flour 
568 (red) 
goat  
(anti-mouse) 
1:400 Invitrogen 
 
Table 2.2 Summary of primary and secondary antibodies used in thesis 
 
 
2.14 Image analysis 
 
Fluorescent images were visualised using a Leica fluorescence microscope (DMR model 
020-575-719, Leica, Milton Keynes, UK), equipped with the appropriate filter blocks, 
namely FITC (adsorption 492, emission 520; Leica, part # L5 513840), TRITC (absorption 
550nm, emission 570nm; Leica, part # A4 513839) and UV (adsorption 350nm, emission 
450nm; Leica, part # N2.1 513812) and captured at consistent exposure times using a 
Hamamatsu CCD camera (model 3CCD c5810, Japan). Images were analysed using Leica 
QWin v.3.0 software (Leica, Milton Keynes, UK).   All images were taken at x10 
magnification from 3-4 serial sections (100-150μm apart). Monochromatic grey scale 
images were loaded onto QWin software and the detection threshold level for 
immunolabelled cells was determined for each section taking into account background 
immunoreactivity which was determined by selecting an area of the DRG where 
 104 
 
 
immunolabeing was not present. An ‘intensity versus number of pixels’ graph was 
constructed and a binary overlay was constructed to identify immunoreactive cells (see 
Figure 2.2). Positive immunolabeling was conferred when there was a clear demarcation 
point between background (large number of pixels with low intensity) and the 
immunopositive reaction (relatively small number of pixels with high intensity).  
 
The number of peripherin/NF-200 neurons that co-labelled with investigative markers (i.e. 
ATF-3, GAP-43, NPY, and galanin) and the total number of peripherin/NF-200 cells in the 
ipsilateral L5 DRG were calculated and expressed as a percentage at each time point 
studied and plotted in a line graph.The cell size area (μm2) for each peripherin/NF-200 
immunoreactive cell was subsequently calculated based on the number of pixels (at x10 
magnification, 1 pixel= 1.42μm) using the measure feature function in the QWin software. 
The cell size analysis data was exported into an Excel (Microsoft) spreadsheet and each 
peripherin/ NF-200 and immunoreactive neuron along with the co-labeled investigative 
marker (i.e. ATF-3, GAP-43, NPY, and galanin) were then categorized according to cell 
size area in groups of increasing 100μm2 increments. The percentage cell size distribution 
of investigative markers was then plotted on bar graphs for both peripherin and NF-200 
populations of sensory DRG neurons. Parallel color images were taken with nuclear marker 
Hoechst 33342 and the immunolabeling cross checked during analysis so that only those 
neurons that demonstrated a nucleus were included in the analysis. To quantify 
macrophage infiltration in the DRG (ED-1 immunohistochemistry), the mean percentage 
area of ED-1 immunoreactivity per 250,000μm2 (500µm x 500µm) was calculated. 
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2.15 Statistical analysis 
 
Statistical analysis for behavioural data was performed using Sigmastat (version 3.5, Systat 
Software, Inc). All data is represented as mean ± standard error of the mean (sem).  
 
 To compare mean behavioural response at baseline and at each time point, a 
Student’s paired t test was performed. 
 To compare mean ipsilateral (or left hind limb) behavioural responses between 
nerve injured and control animals; a Student’s unpaired t test was performed.  
 A one way analysis of variance (ANOVA) was performed to identify specific trends 
in the temporal profile expressions of investigative markers in both peripherin and 
NF-200 DRG populations.  
 A two way ANOVA followed by Holm-Sidak post hoc test was used to analyse 
treatment effects (nerve injury vs. controls) and cell size effects (NF-200 vrs 
peripherin) 
 A one way ANOVA followed by a Dunnett’s post hoc test was performed to 
identify significant differences at each time point compared to baseline values in 
DHA/saline treated animals.  
 A one way ANOVA followed by a Tukey post hoc test was used for pairwise 
comparisons between ipsilateral and contralateral paws at each time point in 
DHA/saline treated animals.  
 Where equal variance test failed a Kruskal-Wallis one way ANOVA on ranks was 
performed followed by a Tukey test.  
 Significance level for data was taken at p<0.05 unless indicated otherwise. 
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Chapter 3 
 
3 Evaluation of DRG neurochemical markers in an animal model of tibial nerve 
transection induced peripheral nerve trauma injury  
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3.1 Introduction 
 
Neuropathic pain may arise due to a disease or injury to the peripheral nervous system 
(PNS) and a number of peripheral nerve trauma animal models have been developed to in 
an attempt to understand the resulting pathophysiology (Treede et al., 2008). Both 
peripheral and central mechanisms contribute towards the development of neuropathic 
pain, although in most cases initial injury occurs to the PNS (Dworkin et al., 2003). Of 
consequence, much research has focused on addressing peripheral mechanisms of 
neuropathic pain.  All sensory information from the periphery travels to the cell soma 
which resides in the dorsal root ganglion (DRG), which subsequently relays information to 
the spinal cord. Following experimental peripheral nerve injury there are a number of 
neurochemical changes that occur within associated DRG cells which may be related to the 
induction or maintenance of neuropathic pain. These changes include the dysregulation of 
neuropeptides, ion channels, and release of inflammatory mediators. The use of global gene 
expression in the DRG via microarray technologies and/or quantitative polymerase chain 
reactions (qPCR) has become a useful strategy in identifying genes that maybe involved in 
neuropathic pain processing.  
 
Significant preclinical effort however is required to translate an observation based on a 
change in gene expression into a clear demonstration of a key role for that gene in the 
manifestation of neuropathic pain (Kinloch and Cox, 2005). Although gene microarrays, 
qPCR, and even Western blotting techniques are useful in demonstrating the presence of a 
dysregulated protein in the DRG, they are all limited by the inability to demonstrate the 
actual cellular localization of a particular protein. A more informative technique which can 
identify cellular localization of proteins in cells is immunohistochemistry and is a well 
utilized technique. Furthermore there is the possibility of double/triple labelling which can 
maximize study efficiently. Amongst the proteins that are dysregulated in nerve injury 
models, activating transcription factor-3 (ATF-3), Neuropeptide Y (NPY), and galanin 
represent some of the most frequently studied upregulated proteins (Hokfelt et al., 1987;Ma 
and Bisby, 1998;Tsujino et al., 2000;Woolf et al., 1990). Although these markers are 
commonly investigated in nerve injury studies, there are some reasons that would require 
the revaluation of their expression profiles. Expression profiles in the DRG are usually 
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examined at a single time point post injury, i.e. the peak of behavioural hypersensitivity 
towards mechanical von Frey stimuli, which is usually 14 days following initial nerve 
injury. The temporal expression profiles in the acute and chronic stages of nerve injury are 
often not investigated. Single time point studies are informative but they are limited in their 
approach since they only provide a snapshot and do not encompass the dynamic changes 
that can occur over time. In addition, different models of traumatic nerve injury encompass 
varying degrees of nerve injury which may reflect in the expression patterns, therefore 
making it difficult to draw conclusions when making comparisons between studies. The 
methods used to analyse and quantify immunolabeling has varied between studies as many 
laboratories employ different immunohistochemical image analysis protocols, some of 
which involve manual counting, others a semi-automated approach using imaging software. 
Furthermore, an observer judgement of the immunolabeling is an inherent step in the 
analysis and therefore there is potential for observer bias. This can be alleviated via 
adequate blinding and randomisation, but this prerequisite is seldom declared and may 
influence reported outcomes. Therefore, there may be different reported expression patterns 
in some studies even where the study time point and model used are matched. 
Characterizing the temporal expression profiles of these markers will allow for direct 
comparisons to be made between time points since variables such as nerve injury, image 
analysis, and strain of animals are all standardized. In addition the temporal expression 
patterns can be correlated with the outcome measures of neuropathic pain-like behaviours 
which may provide further insight to their role in neuropathic pain. Although the 
behavioural profiles of the tibial nerve transection (TNT) injured animals has been 
previously reported, no study to date has provided immunohistochemical characterization 
of dysregulated proteins associated with nerve injury in this model.  
 
No study to date has described the distribution of tibial nerve neurons in the DRG using the 
more modern FG tracer and therefore this project attempted to address this issue. This 
study would reveal the proportion of damage exhibited by the the respective DRGs and 
give an indication of the proportion of damage acquired as a result of TNT injury.  
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3.1.1 Aims of study  
 
There are a number of aims in the following study: 
 
1) Characterize behavioural responses towards mechanical and thermal stimulus 
following TNT surgery in both the acute and chronic stages injury and compare to 
sham rats. 
 
2) Provide a temporal profile expression of ATF-3, NPY, galanin, and growth 
associated protein (GAP-43) in the ipsilateral L5 DRG following TNT injury using 
immunohistochemical techniques and characterize the cellular phenotype of cells 
with profiles via double labelling using markers of small (peripherin) and large 
diameter (NF-200) neurons.  
 
 
3) Perform a cell size analysis of investigative markers to validate 
immunohistochemical/phenotype data. 
 
4) Correlate mechanical behavioural hypersensitivity with expression of investigative 
markers. 
 
 
5) Determine in naïve animals the distribution of tibial nerve terminals in the L3-S1 
DRGs using the retrograde tracer FG in order to gain insight into the proportion of 
nerve damage. 
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3.2 Results 
 
Animals were sacrificed at days 1, 7, 24, 28, and 43 post TNT/sham surgery shortly after 
recording of mechanical and thermal behavioural responses. Animals exhibited no obvious 
signs of motor impairment; this was assessed by observing gait when animals were freely 
moving within the cage.  A total of 44 animals were used (Figure 3.1). 
 
Total animals used in Study: 
 
Figure 3.1 Animals were divided into the following groups: Naïve (n=4), Fluorogold 
injected (n=2), TNT surgery (n=17), and sham surgery (n=19) and further sub divided 
according the time of sacrifice (1, 7, 14, 28, and 43 days post TNT/sham surgery). All 
animals were checked post mortem to identify transection of tibial nerve with aid of a 
dissecting microscope. Two animals were excluded from the analysis due to incorrect 
nerve injury. Naïve animals were used as additional controls. 
Total animals used in 
study: (n=44) 
TNT study: (n=38) 
TNT group: (n=19) 
Sham group: (n=19) 
Naive group: (n=4) 
 
TNT group (n=17) 
 
Day 1       n=3 
Day 7       n=3 
Day 14     n=3 
Day 28     n=4 
Day 43     n=4 
 
Exclusions 
 
TNT groups (n=2):  
Day 1 (n=1) and day 
14 (n=1): tibial nerve 
not transected 
 
Sham group (n=19) 
 
Day 1         n=4 
Day 7         n=3 
Day 14       n=4 
Day 28       n=4 
Day 45       n=4 
 
Fluorogold injections: 
(n=2) 
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3.3 Distribution of tibial neurons in the L3-S1 DRG 
 
 
In order to determine the extent of damage in the DRG produced by TNT injury, FG was 
injected into the tibial nerve of naïve animals (n=2) which were culled after 7 days. 
Immunohistochemistry for neuronal specific nuclear marker (NeuN) was conducted to 
identify nucleated neurons (since I could not use DAPI/Hoechst because FG excites at 
similar wavelength). The total number of NeuN and FG labelled neurons were counted for 
L3-S1 DRGs and the percentage co-expression from the total number of colabelled NeuN 
neurons was calculated. The results reveal that FG was taken up in only L4 and L5 and not 
in L3, L6, and S1 DRGs (see Table 3.1). There are large values for the standard error in 
both experimental animals; however the percentage co-expression was consistently greater 
in the L4 compared to the L5 DRG. The immunohistochemical images and cell size 
analysis suggests that FG labelling was present in mainly small size DRG cells but also 
some large size cells (Figure 3.2). 
 
Table 3.1  
Fluorogold/NeuN labelling percentages across DRG L3-S1 
Data presented as mean ± SEM 
(n=number of nucleated neuronal profiles) 
DRG 
Rat 1 
Fluorogold/NeuN 
Rat 2 
Fluorogold/NeuN 
Mean (Rat 1 & 
Rat 2) 
Fluorogold/NeuN 
L3 0% (n=153) 0% (n=263) 0% 
L4 21.3% (n=89) 55.6% (n=171) 38.5 ± 17.2 % 
L5 19% (n=122) 35.5% (n=180) 27.5 ± 8.3 % 
L6 0% (n=141) 0% (n=200) 0% 
S1 0% (n=107) 0% (n=172) 0% 
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Figure 3.2 Representative images of immunoreactivity and cell size analysis of NeuN 
/Fluorogold labelled neurons in the L3-S1 DRGs of naïve animals  (n=2). Magnification 
x20, Scale bars 50μm. 
 
L3 
L4 
L5 
L6 
S1 
  NeuN/Fluorogold   
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3.3.1 Assessment of mechanical behaviours  
 
From at least 7 days following TNT injury, animals exhibited significant mechanical 
hypersensitivity in the ipsilateral but not the contralateral mid-plantar region of the hind 
paw with respect to baseline values (Figure 3.3B-E). No significant hypersensitivity was 
observed in sham-operated animals at the various time points throughout the study. 
However at days 28 post TNT surgery in the contralateral paw, animals demonstrated a 
significant increase in paw withdrawal thresholds (PWTs). A significant increase in PWTs 
was also observed in the ipsilateral paw of sham animals at 43 days post surgery. The 
ipsilateral PWTs of animals at baseline and at day 1 post TNT injury were 39.1 ± 2.0 g and 
30.1 ± 2.8 g respectively (Figure 3.3A), thus representing a mean percentage decrease of 
22.0 ± 11.4, but no significant change. Ipsilateral PWTs at baseline and at day 7 post TNT 
injury were 47.1 ± 3.0 g and 25.5 ± 1.0 g respectively (Figure 3.3B), representing a mean 
percentage decrease of 45.1 ± 6.1 (p<0.05). The ipsilateral PWTs of animals sacrificed at 
14 days decreased to 25.3 ± 1.0 g from a baseline value of 40.4 ± 0.6 g, representing a 
mean percentage decrease of 37.3 ± 3.4 (p<0.01). This was a slightly smaller decrease than 
responses observed in the TNT day 7 group. Behavioural mechanical hypersensitivity 
reached a peak at 28 days post TNT injury with ipsilateral PWTs decreasing to 18.3 ± 2.0 g 
compared to baseline values of 48.3 ± 5.6 g (Figure 3.3D), representing a  mean percentage 
decrease of 61.6 ± 2.9 (p<0.05). In the longest experimental time of 43 days post TNT 
surgery, ipsilateral PWTs decreased to 27.3 ± 2.5 g from a baseline of 44.3 ± 3.8 g (Figure 
3.3E), representing a mean percentage decrease of 37.6 ± 5.8 g. There were significant 
differences in the mean percentage decrease from baseline when comparing the ipsilateral 
paws of TNT animals and their sham counterparts at days 7, 14, 28, and 43 post surgery 
(p<0.05, Figure 3.5A). Sham animals at 43 days post surgery demonstrated 46.5 ± 8.0 % 
increase in the ipsilateral PWT from baseline.  
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Figure 3.3 Mean paw withdrawal thresholds (PWT) to punctate mechanical stimuli 
measured using an electronic von Frey device at various time points post TNT/sham 
surgery in different groups of rats. Data presented as mean ± SEM. **P<0.01 and *P<0.05 
vs. respective baseline value using a Student’s paired t test.  
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3.3.2 Assessment of thermal behaviours  
 
Thermal hypersensitivity in the ipsilateral paws of TNT animals at day 1,7,14, and 43 post 
surgery was not evident, however significant responses were observed at day 28 post TNT 
injury. Ipsilateral PWLs at baseline and at day 1 post TNT injury were 13.5 ± 0.8 s and 
14.3 ± 0.5 s respectively (Figure 3.4A), representing a mean percentage increase of 6.1 ± 
2.7 s.  The ipsilateral PWL at baseline and at day 7 post TNT injury were 9.0 ± 0.1 s and 
6.8 ± 0.8 s respectively (Figure 3.4B), representing noticeable but not significant mean 
percentage decrease of 23.5 ± 9.4. Similarly at day 14 there was a decrease in thermal PWL 
that did not reach significance, with recorded PWLs of 8.3 ± 1.5 s from baseline PWLs of 
10.7 ± 2.1 s (mean percentage decrease of 16.5 ± 24.9, Figure 3.4C). Significant thermal 
hypersensitivity in the ipsilateral paw was only evident in TNT animals at post operative 
day 28 with a mean PWL of 6.3 ± 0.5 s when compared to the respective mean baseline 
value of 8.9 ± 0.6 s (p<0.05, Figure 3.4D), representing a mean percentage decrease of 29.0 
± 3.9. At post operative day 43, there were no significant changes in PWL from baseline, 
9.7 ± 0.8 s and 10.0 ± 1.1 s respectively (mean percentage decrease of 0.7 ± 10.3, Figure 
3.4E). No thermal hypersensitivity was observed in the contralateral paws of all study 
animals. Similarly, no thermal hypersensitivity was evident in sham animals at all time 
points within the study. There was however a significant increase in thermal PWL in the 
contralateral paws of sham animals at post operative day 14 from preoperative values (14.2 
± 0.3 s and 11.6 ± 0.5 s respectively, p<0.05, Figure 3.4C). On comparison of the ipsilateral 
mean percentage decrease from baseline between TNT and sham operated animals, 
significant differences were only observed in the 28 days post surgery group 
(p<0.05,Figure 3.5). 
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Figure 3.4 Mean paw withdrawal latencies (PWL) to thermal stimuli measured using a 
Hargreaves’ device at various time  point post TNT/sham surgery in different groups of 
rats. Data presented as mean ± SEM.  *P<0.05 vs. respective baseline value using a 
Student’s paired t test.  
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Figure 3.5 Mean percentage change from baseline at various time points post TNT injury 
in response to (A) punctate mechanical stimulation (using electronic von Frey device) and 
(B) Thermal Hargreaves device. *P<0.05 vs. respective baseline value using a Student’s 
paired t test. (PWT, paw withdrawal threshold; PWL, paw withdrawal latency). Sham 
animals at 43 days post surgery demonstrated a 46.5 ± 8.0 % increase in the ipsilateral 
PWT from baseline; an unusual finding. 
   * 
A 
B 
 *  * 
 * 
  * 
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3.3.3 Temporal profile expression of ATF-3 in ipsilateral L5 DRG  
 
As previously reported, ATF-3 has been described as a marker of neuronal injury, 
and is not normally expressed or is present in low levels in uninjured animals (Tsujino et 
al., 2000). Consistent with this, ATF-3 immunoreactivity was not evident in DRGs 
harvested from naïve rats (see Table 3.2 for percentage immunoreactivity/mean cell size 
analysis and Figure 3.9 for immunohistochemistry images).  
TNT injury was associated with significant ATF-3 immunoreactivity in both NF-
200 and peripherin cell populations compared to sham operated rats except at 1 day post 
injury in peripherin characterised cells, and 43 days post injury in NF-200 characterised 
cells (Figure 3.6). A significant temporal profile effect was observed in the NF-200 
characterised population in TNT injured rats, which was particularly evident one day after 
nerve injury but not in the peripherin characterised population. Other populations of DRG 
cells (e.g. IB4 or CGRP) could not be simultaneously examined because labeling with an 
additional fouth distinct colour was not possible due to the design of the experiment (all 
three filters were already designated).  
One day post TNT injury ATF-3 immunoreactivity was robustly upregulated with 
71.1 ± 7.2 % immunoreactivity observed in NF-200 characterised cells and was 
significantly different to values obtained from respective sham operated rats. ATF-3 
immunoreactivity in peripherin characterised cells at this time point was 11.9 ± 5.6 %, a 
value that was not significantly different to that observed in respective sham operated rats, 
but was significantly different compared to that observed in NF-200 characterised cells. 
ATF-3 immunoreactivity was nuclear and present in neuronal cells only (Figure 3.7). 
Labeling was limited in sham animals (Figure 3.8). By 7 days post TNT injury ATF-3 
immunoreactivity reduced to 25.7 ± 7.7 % in NF-200 characterised cells but increased 
slightly to 19.0 ± 5.0 % in peripherin characterised cells. There were no significant 
differences in the percentage of ATF-3 immunoreactivity between these two characterised 
cell populations, however both values were significantly different compared to that 
observed in respective sham operated rats. At 14 days post TNT injury, ATF-3 
immunoreactivity was similar to that observed in day 7 rats, with 30.4 ± 8.6 % in NF-200 
characterised cells and was not significantly different compared to the 18.9 ± 6.6 % 
observed in the peripherin characterised population. Percentage ATF-3 immunoreactivity at 
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this time point in both characterised cell populations was significantly different compared 
to that observed in respective sham operated rats. By 28 days post TNT injury, ATF-3 
immunoreactivity was observed in 18.7 ± 6.0 % of NF-200 characterised cells and was not 
significantly different compared to the 15.2 ± 1.4 % observed in peripherin characterised 
cells, however both values were significantly different to those obtained from respective 
sham operated rats. At 43 days post injury, ATF-3 immunoreactivity was still evident, with 
11.5 ± 4.2 % in NF-200 characterised cells, but was not significantly different compared to 
the 25.4 ± 8.3 % observed in peripherin characterised cells. Both values at this time point 
were significantly different to those obtained from respective sham operated rats.  
A cell size analysis reinforced immunohistochemical observations regarding ATF-3 
immunoreactivity following TNT injury in large diameter (≥ 900 μm2) and small diameter 
cells (≤ 500 μm2) at all time points investigated. The distribution was homogeneous in both 
neuronal populations up until day 14 (Figure 3.10 and Figure 3.11), but at day 28 post TNT 
injury and thereafter, ATF-3 immunoreactivity in large size NF-200 immunoreactive cells 
demonstrated a skewed distribution to the left (Figure 3.11) which coincides with the 
decreasing mean cell size area in this population (see Table 3.3 for mean cell size areas of 
ATF-3 immunoreactive cells across time in peripherin/NF-200 cells). 
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Figure 3.6 Mean percentage of total peripherin and NF-200 immunoreactive cells 
expressing ATF-3 in TNT, sham, and naïve animals (ipsilateral L5 DRG n=3-4 animals per 
group). Data presented as mean ± SEM. Statistical test at each time point was conducted 
using a two way ANOVA followed by Holm-Sidak post hoc analysis: *P<0.05 vs. 
respective sham; 
+
P<0.05 vs. respective TNT (NF-200) immunoreactive cells. In TNT 
injured rats, ATF-3 immunoreactivity in NF-200 immunoreactive cells demonstrated a 
significant temporal profile expression, while ATF-3 immunoreactivity in peripherin 
immunoreactive cells did not exhibit a significant temporal profile.  
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Figure 3.7 Representative images of ATF-3 immunoreactivity in peripherin (small 
diameter) and NF-200 (large diameter) neuronal sub-populations at 1 and 28 days 
following TNT injury (Ipsilateral L5 DRG), magnification x20. Arrows indicate co-
localisation of immunolabeling.  
 
DAY 28 
DAY 1 
ATF-3  NF-200  Merged 
ATF-3  Peripherin  Merged 
ATF-3  Peripherin  Merged 
ATF-3  NF-200  Merged 
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Figure 3.8 Representative images of ATF-3 immunoreactivity in peripherin (small 
diameter) and NF-200 (large diameter) neuronal sub-populations at 1 and 28 days 
following sham surgery (Ipsilateral L5 DRG). Magnification x20, Scale bar 50μm.  
  
DAY 1 
DAY 28 
ATF-3  Peripherin  Merged 
ATF-3  NF-200  Merged 
ATF-3  Peripherin  Merged 
ATF-3  NF-200  Merged 
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Figure 3.9  Representative images of ATF-3 immunohistochemistry in naive L5 DRG. 
Double labelling was conducted to identify ATF-3 immunoreactivity in both peripherin and 
NF-200 sub-populations of DRG cells; magnification x20. Bottom montages are 
representative images of negative controls (omission of primary antisera) taken from TNT 
ipsilateral L5 DRGs at post operative day 14.  
Naive 
Negative control: TNT Day 14 
Alexa Flour 488  Alexa Flour 568  
 
Merged 
ATF-3  Peripherin  Merged 
ATF-3  NF-200  Merged 
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Figure 3.10 Percentage cell size distribution of ATF-3 immunoreactivity in peripherin immunoreactive cells 
(ipsilateral L5 DRG) at various time points following TNT/sham surgery and in naive animals (n= total 
number of nucleated peripherin immunoreactive cells). 
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Figure 3.11 Percentage cell size distribution of ATF-3 immunoreactivity in NF-200 immunoreactive cells 
(ipsilateral L5 DRG) at various time points following TNT/sham surgery and in naive animals (n= total 
number of nucleated NF-200 immunoreactive cells).  
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3.3.4 Dynamic expression of GAP-43 in ipsilateral L5 DRG cells 
 
GAP-43 immunoreactivity in naïve ganglia was relatively low (<2%) and only 
observed in periphern immunoreactive cells (see Table 3.2 for mean percentage 
immunoreactivity/mean cell size analysis and Figure 3.13 for immunoreactivity images).  
TNT injury was associated with significant GAP-43 immunoreactivity in both NF-
200 and peripherin characterised cell populations at different time points post injury 
compared to sham operated rats (Figure 3.12). Significant temporal profile effects were 
evident in the NF-200 but not the peripherin characterised cell populations. GAP-43 
immunoreactivity was cytoplasmic in nature, and was observed in both NF-200 and 
peripherin DRG cell populations, and additionally observed in axons (Figure 3.14 and 
Figure 3.15). 
At one day post TNT injury, GAP-43 immunoreactivity was not significantly 
differently compared to sham operated rats. However at 7 days post TNT injury, GAP-43 
immunoreactivity had increased in the peripherin characterised population to 7.2 ± 0.7 % 
and was significantly different to values obtained from respective sham operated rats. 
GAP-43 immunoreactivity in NF-200 characterised cells at this time point was 0.3 ± 0.3 %, 
a value that was not significantly different to that observed in respective sham operated 
rats, but was significantly different compared to that observed in peripherin characterised 
cells. By 14 days post TNT injury, GAP-43 immunoreactivity had peaked in both 
characterised DRG cell populations examined, with 15.9 ± 4.8 % immunoreactivity in NF-
200 characterised cells and 15.7 ± 1.8 immunoreactivity in peripherin characterised cells. 
There were no significant differences in the percentage of GAP-43 immunoreactivity 
between these two characterised cell populations, however both values were significantly 
different compared to that observed in respective sham operated rats. At 28 days post TNT 
injury, GAP-43 immunoreactivity had reduced to 10.0 ± 1.9 % in NF-200 characterised 
cells and was not significantly different to the 11.6 ± 2.5 % observed in peripherin 
characterised cells, however both values were significantly different to those obtained from 
respective sham operated rats. At 43 days post TNT injury, GAP-43 immunoreactivity 
further reduced in both NF-200 and peripherin characterised cell populations and was not 
significantly different compared to those values obtained from respective sham operated 
rats. GAP-43 immunoreactivity was observed in 8.3 ± 1.0% of NF-200 cells and was not 
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significantly different compared to the 10.0 ± 6.4% observed in the peripherin 
characterised cells.  
A cell size distribution analysis of GAP-43 expression in TNT animals revealed a 
homogenous distribution in peripherin characterised cells at all time points (Figure 3.16); 
mean cell size area (≤ 500 μm2, Table 3.3). However a skewed distribution to the left was 
observed in large diameter NF-200 characterised cells (Figure 3.17); mean cell size area (≥ 
600 μm2). See see Table 3.3 for mean cell size areas of GAP-43 immunoreactive cells 
across time in peripherin/NF-200 cells. 
 
Figure 3.12 Mean percentage of total peripherin and NF-200 immunoreactive cells expressing 
GAP-43 in TNT, sham, and naïve animals (ipsilateral L5 DRG n=3-4 animals per group). Data 
presented as mean ± SEM. Statistical test at each time point was conducted using a two way 
ANOVA followed by Holm-Sidak post hoc analysis: *P<0.05 vs. respective sham; +P<0.05 vs. 
respective TNT (NF-200) immunoreactive cells. In TNT injured rats, GAP-43 expression in 
NF-200 immunoreactive cells demonstrated a significant temporal profile expression, while 
GAP-43 expression in peripherin immunoreactive cells did not exhibit a significant temporal 
profile.  
GAP-43 
  * + 
  *   * 
   *   
* 
Naïve 
Peripherin                       0 %               
NF-200             1.73 ± 1.73 %              
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Figure 3.13 Representative images of GAP-43 immunohistochemistry in naive L5 DRG. 
Double labelling was conducted to identify GAP-43 immunoreactivity in both peripherin 
and NF-200 sub-populations of DRG cells; magnification x20. 
Naive 
ATF-3  NF-200  Merged 
    GAP-43 Peripherin  Merged 
GAP-43  NF-200  Merged 
GAP-43  Peripherin  Merged 
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Figure 3.14 Representative images of GAP-43 immunoreactivity at 1,14, and 43 days post 
TNT injury (ipsilateral L5 DRG) in peripherin and NF-200 neuronal sub-populations, 
magnification x20. Arrows indicate co-localisation of immunolabeling. 
DAY 1 
DAY 14 
DAY 43 
ATF-3  NF-200  Merged 
Gap-43  NF-200 Merged 
Gap-43  Peripherin  Merged 
Gap-43  NF-200 Merged 
Gap-43  Peripherin  Merged 
Gap-43  Peripherin  Merged 
Gap-43  NF-200 Merged 
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Figure 3.15 Representative images of GAP-43 immunoreactivity at 1, 14, and 43 days post 
sham surgery (ipsilateral L5 DRG) in peripherin and NF-200 neuronal sub-populations, 
magnification x20. 
DAY 1 
DAY 14 
DAY 43 
                       Gap-43  NF-200 Merged 
                        Gap-43    Peripherin  Merged 
Gap-43  NF-200 Merged 
Gap-43    Peripherin  Merged 
Gap-43  NF-200 Merged 
Gap-43  Peripherin   Merged 
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Figure 3.16 Percentage cell size distribution of GAP-43 immunoreactivity in peripherin immunoreactive 
cells (ipsilateral L5 DRG) at various time points following TNT/sham surgery and in naive animals (n= total 
number of nucleated peripherin immunoreactive cells). 
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Figure 3.17 Percentage cell size distribution of GAP-43 immunoreactivity in NF-200 immunoreactive cells 
(ipsilateral L5 DRG) at various time points following TNT/sham surgery and in naive animals (n= total 
number of nucleated NF-200 immunoreactive cells).  
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3.3.5 NPY exhibits dynamic temporal expression in ipsilateral L5 DRG cells  
 
NPY immunoreactivity in naïve ganglia was only observed only in few NF-200 
immunoreactive cells (<0.3 %, Table 3.2) and not in the peripherin characterised 
population. 
Following TNT injury, NPY exhibited significant temporal profile expressions in 
both NF-200 and peripherin characterised DRG cells (Figure 3.18, p<0.05, one way 
ANOVA). NPY immunoreactivity remained relatively low in peripherin characterised cells 
across time (<6.5%), compared to immunoreactivity in NF-200 cells, which was more 
robust (peak of ~51% at 14 days survival). NPY immunoreactivity was cytopastic in nature 
(see Figure 3.20 and Figure 3.21), and some immunoreactivity was additionally observed 
in axons (Figure 3.22).  
At one day post TNT injury, NPY immunoreactivity was not observed in injured 
ganglia. However, at 7 days post injury NPY immunoreactivity was robustly upregulated, 
with 51.3 ± 4.8 % observed in NF-200 characterised cells and was significantly different to 
values obtained from respective sham operated rats. NPY immunoreactivity in peripherin 
characterised cells at this time point was 2.1 ± 0.6 %, a value that was not significantly 
different to that observed in respective sham operated rats, but was significantly different 
compared to that observed in NF-200 characterised cells. By 14 days post injury, NPY 
immunoreactivity was comparable to that observed at 7 days post injury. NPY 
immunoreactivity was 51.7 ± 8.3 % in NF-200 characterised cells and significantly 
different to values obtained from respective sham operated rats. NPY immunoreactivity in 
peripherin characterised cells at this time point was 3.4 ± 1.4 %, a value that was not 
significantly different to that observed in respective sham operated rats, but was 
significantly different compared to that observed in NF-200 characterised cells. At 28 days 
post injury, NPY immunoreactivity had reduced to 27.3 ± 3.4 % in NF-200 characterised 
cells, while immunoreactivity in peripherin characterised cells peaked at 6.5 ± 0.8 %, with 
significant differences present between these two cell populations and their respective 
sham counterparts. NPY immunoreactivity further reduced at 43 days post injury in NF-
200 characterised cells to 14.5 ± 2.9 %, while immunoreactivity in peripherin characterised 
cells stabilized at 5.0 ± 0.8 % – significant differences were present between these two cell 
populations and their respective sham counterparts.  
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A cell size distribution analysis supported immunohistochemical observations 
regarding NPY immunoreactivity following TNT injury in NF-200 large diameter (≥ 900 
μm2) and peripherin immunoreactive small diameter cells (≤ 600 μm2) at all time points 
investigated (see Table 3.3 for mean cell size areas of NPY immunoreactive cells across 
time in peripherin/NF-200 cells, and Figure 3.23 and Figure 3.24 for cell size distribution 
analysis).  
 
 
 
Figure 3.18 Mean percentage of total peripherin and NF-200 immunoreactive cells 
expressing NPY in TNT, sham, and naïve animals (ipsilateral L5 DRG n=3-4 animals per 
group). Data presented as mean ± SEM. Statistical test at each time point was conducted 
using a two way ANOVA followed by Holm-Sidak post hoc analysis: *P<0.05 vs. 
respective sham; 
+
P<0.05 vs. Respective TNT (peripherin) immunoreactive cells. In TNT 
injured rats, NPY immunoreactivity in both NF-200 and peripherin immunoreactive cells 
demonstrated significant temporal profile expressions. 
NPY  
  * + 
 * + 
  * + 
  * + 
 *  
 *  
Naïve 
Peripherin                       0 %            
NF-200            0.28 ± 0.28 % 
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Figure 3.19  Representative images of NPY immunohistochemistry in naive L5 DRG. 
Double labelling was conducted to identify NPY immunoreactivity in both peripherin and 
NF-200 sub-populations of DRG cells; magnification x20.  
 
 
 
 
 
 
NPY  Peripherin  Merged   i i    
NPY  NF-200  Merged 
Naive 
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Figure 3.20 Representative images of NPY immunoreactivity in peripherin (small 
diameter) and NF-200 (large diameter) neuronal sub-populations at 1 and 14 days 
following TNT injury (ipsilateral L5 DRG), magnification x20. Arrows indicate co-
localisation of immunolabeling. 
 
DAY 1 
DAY 14 
NPY  NF-200  Merged 
NPY  Peripherin  Merged 
NPY  Peripherin  Merged 
NPY  NF-200  Merged 
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Figure 3.21 Representative images of NPY immunoreactivity in peripherin (small 
diameter) and NF-200 (large diameter) neuronal sub-populations at 43 days post TNT 
injury & 14 days after sham surgery (ipsilateral L5 DRG), magnification x20. Arrows 
indicate co-localisation of immunolabeling. 
 
 
DAY 43 
NPY  NF-200  Merged 
Day 14 Sham 
NPY  NF-200  Merged 
NPY  Peripherin  Merged 
NPY  NF-200  Merged 
NPY  Peripherin  Merged 
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Figure 3.22 Representative image of NPY immunoreactivity in the mid-section of the L5 
DRG at 14 days post TNT injury using rabbit polyclonal antisera. NPY is induced in the 
cytoplasm of mainly large diameter cells but is also induced in axons as indicated by the 
red arrows. Neuronal magnification x20, scale bars 50μm.  
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Figure 3.23 Percentage cell size distribution of NPY immunoreactivity in peripherin immunoreactive cells 
(ipsilateral L5 DRG) at various time points following TNT/sham surgery and in naive animals (n= total 
number of nucleated peripherin immunoreactive cells). 
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Figure 3.24 Percentage cell size distribution of NPY immunoreactivity in NF-200 immunoreactive cells 
(ipsilateral L5 DRG) at various time points following TNT/sham surgery and in naive animals (n= total 
number of nucleated NF-200 immunoreactive cells).  
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3.3.6 Dynamic expression of galanin in ipsilateral L5 DRG cells  
 
Galanin immunoreactivity in naïve ganglia was relatively low with 0.56 ± 0.56 % of 
galanin immunoreactivity in peripherin immunoreactive cells and no immunoreactivity 
present in NF-200 immunoreactive cells (see Table 3.2 for mean percentage 
immunoreactivity/mean cell size analysis and Figure 3.26 for immunohistochemistry 
images).  
Following TNT injury, galanin exhibited dynamic expression, upregulating at similar 
levels in both peripherin and NF-200 characterised cells at 7 and 14 days, before down-
regulating at 28 and 43 days post injury (Figure 3.25). These patterns were significant in 
both cell populations (p<0.05, one way ANOVA). Galanin exhibited granular cytoplasmic 
staining (Figure 3.27), not evident in sham controls (Figure 3.28).  
At one day post TNT injury, galanin immunoreactivity was <2% in peripherin and 
NF-200 cells examined and no different to respective sham operated rats. However at 7 
days post injury, galanin immunoreactivity increased to 11.8 ± 1.2 % in NF-200 
characterised cells and 15.7 ± 2.7 % in peripherin characterised cells. There were no 
significant differences in the percentage of galanin immunoreactivity between these two 
characterised cell populations, however both values were significantly different compared 
to that observed in respective operated sham rats.  At 14 days post TNT injury, galanin 
immunoreactivity had peaked in both characterised DRG cell populations examined, with 
25.8 ± 4.2 % immunoreactivity in NF-200 characterised cells and 19.3 ± 4.8 
immunoreactivity in peripherin characterised cells. By 28 days post TNT injury, galanin 
immunoreactivity had reduced to 5.8 ± 1.60 in NF-200 characterised cells and was not 
significantly different to the 5.7 ± 1.3% observed in peripherin characterised cells, however 
both values were significantly different to those obtained from respective sham operated 
rats. Percentage galanin immunoreactivity appeared to stabilize at 43 days post TNT injury 
with 7.8 ± 2.0 % immunoreactivity in NF-200 characterised cells which was not 
significantly different compared to that observed in respective sham operated rats. Galanin 
immunoreactivity at this time point was 7.7 ± 1.7 % in peripherin characterised cells and 
was significantly different compared to that observed in NF-200 characterised cells and to 
that observed in respective sham operated rats.  
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A cell size analysis supported immunohistochemical observations regarding galanin 
immunoreactivity in NF-200 large diameter (≥ 900 μm2) and peripherin immunoreactive 
small diameter cells (≤ 600 μm2) at all time points following TNT injury (see Table 3.3 for 
mean cell size areas of galanin immunoreactive cells across time in peripherin/NF-200 
cells. The distribution appeared to be homogenous (Figure 3.29 and Figure 3.30). 
 
 
 
 
Figure 3.25 Mean percentage of total peripherin and NF-200 immunoreactive cells 
expressing galanin in TNT, sham, and naïve animals (ipsilateral L5 DRG n=3-4 animals 
per group). Data presented as mean ± SEM. Statistical test at each time point was 
conducted using a two way ANOVA followed by Holm-Sidak post hoc analysis: *P<0.05 
vs. respective sham, 
#
P<0.05 TNT (peripherin) vs. Sham (peripherin). In TNT injured rats, 
galanin immunoreactivity in both NF-200 and peripherin immunoreactive cells 
demonstrated significant temporal profile expressions. 
Galanin  
 *  
  *  
  *  
 *  
  * *  
Naïve 
Peripherin      0.56 ± 0.56 % 
NF-200                             0 %             
 
                
 #  
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Figure 3.26 Representative images of galanin immunohistochemistry in naive L5 DRG. 
Double labelling was conducted to identify galanin immunoreactivity in both peripherin 
and NF-200 sub-populations of DRG cells; magnification x20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATF-3  Peripherin  Merged 
Galanin  NF-200  Merged 
Galanin
Naive 
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Figure 3.27 Representative images of galanin immunoreactivity at 1, 14, and 43 days post 
TNT injury (ipsilateral L5 DRG) in peripherin and NF-200 neuronal sub-populations, 
magnification x20. Arrows indicate co-localisation of immunolabeling. 
DAY 1 
DAY 14 
NPY  NF-200  Merged 
DAY 43 
Galanin  NF-200 Merged 
Galanin  Peripherin  Merged 
Galanin  NF-200 Merged 
Galanin  Peripherin  Merged 
Galanin  Peripherin  Merged 
Galanin  NF-200 Merged 
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Figure 3.28 Representative images of galanin immunoreactivity at 1, 14, and 43 days post 
sham surgery (ipsilateral L5 DRG) in peripherin and NF-200 neuronal sub-populations, 
magnification x20 
NPY  Peripherin  Merged 
NPY  NF-200  Merged 
DAY 1 
DAY 14 
Galanin  F-200  erged 
Galanin
Galanin  NF-200  Merged 
DAY 43 
Galanin  Peripherin  Merged 
Galanin  Peripherin  Merged 
Galanin  Peripherin  Merged 
Galanin  NF-200 Merged 
Galanin  NF-200 Merged 
Galanin  NF-200 Merged 
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Figure 3.29 Percentage cell size distribution of galanin immunoreactivity in peripherin immunoreactive cells 
(ipsilateral L5 DRG) at various time points following TNT/sham surgery and in naive animals (n= total 
number of nucleated peripherin immunoreactive cells). 
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Figure 3.30 Percentage cell size distribution of galanin immunoreactivity in NF-200 immunoreactive cells 
(ipsilateral L5 DRG) at various time points following TNT/sham surgery and in naive animals (n= total 
number of nucleated NF-200 immunoreactive cells).  
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Naïve L5 DRG 
Markers Mean % immunoreactivity Mean cell area μm2 
ATF-3 
Peripherin 
NF-200 
 
0 
0 
 
n/a (0/632) 
n/a (0/326) 
GAP-43 
Peripherin 
NF-200 
 
0  
1.73 ± 1.73 
 
 
n/a  (0/833) 
997.5 ± 100.5 (7/285)  
 
NPY 
Peripherin 
NF-200 
 
0 
0.28 ± 0.28 
 
n/a (0/996) 
1609.1 (1/268) 
Galanin 
Peripherin 
NF-200 
 
0.56 ± 0.56 
0 
 
477.2 ± 33.0 (6/893) 
n/a (0/345) 
 
Table 3.2  Mean percentage immunoreactivity and mean cell area (μm2) of ATF-3, GAP-43, NPY, 
and galanin in NF-200 and peripherin characterised cell populations in naïve L5 DRG. Data 
presented as mean ± SEM). The numbers of ATF-3, GAP-43, NPY, and galanin immunoreactivity 
cell profiles out of the total number of peripherin/NF-200 DRG immunoreactive cells are indicated 
in brackets (n/a = not applicable as no data was available). 
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 TNT/sham operated animals [ mean cell area μm2 ± standard error of mean ]  
Markers   Day1 Day 7 Day 14 Day 28 Day 43 
ATF-3 
TNT 
Peripherin 
NF-200 
Sham 
Peripherin 
NF-200 
 
 
429.1 ±  21.2  (50 of 337) 
1773.5 ± 42.4 (181 of 252) 
 
n/a (0 of 491) 
2032.8 (1 of 377) 
 
 
433.1 ± 13.8 (154 of 780) 
1389.8 ± 53.9 (93 of 353) 
 
253.1 ± 115.9 (2 of 696) 
1141.3 (1 of 203) 
 
 
366.7 ± 39.9 (94 of 338) 
1210.5  51.8 (95 of 298) 
 
307.1 ± 39.9 (8 of 637) 
1391.1 ± 186.9 (10 of 380) 
 
 
350.5 ± 12.5 (131 of 836) 
997.0 ± 43.1 (76 of 370) 
 
425.5 ± 14.1 (2 of 935) 
n/a (0 of 325) 
 
 
416.3 ± 15.4 (132 of 615) 
996.5 ± 66.5 (37 of 308) 
 
320.4 ± 99.0 (2 of 757) 
1174.5 ± 125.8 (6 of 283) 
GAP-43 
TNT 
Peripherin 
NF-200 
Sham 
Peripherin 
NF-200 
 
 
442.0 ± 7.2 (23 of 543) 
1195.4 ± 135.3 (7 of 246) 
 
500.1 ± 63.6 (9 of 661) 
982.2 ± 96.0 (10 of 219) 
 
 
427.3 ± 16.2 (73 of 995) 
609.0 (1 of 307) 
 
550.5 ± 108.9 (2 of 753) 
1218.4 ± 213.2 (4 of 261) 
 
 
336.9 ± 16.2 (60 of 393) 
1024.3 ± 59.6 (47 of 296) 
 
380.9 ± 37.6 (27 of 755) 
1005.2 ± 148.9 (13 of 322) 
 
 
401.9 ± 15.7 (126 of 1044) 
970.6 ± 59.2 (33 of 347) 
 
471.8 ± 50.3 (6 of 900) 
740.0 (1 of 288) 
 
 
469.7 ± 30.8 (34 of 721) 
1127.0 ± 76.5 (39 of 470) 
 
457.1 ± 50.7 (4 of 552) 
1385.7 ± 101.3 (15 of 427) 
NPY 
TNT 
Peripherin 
NF-200 
Sham 
Peripherin 
NF-200 
 
 
n/a (0 of 218) 
n/a (0 of 268) 
 
n/a (0 of 471) 
n/a (0 of 419) 
 
 
574.6 ± 75.9 (20 of 1044) 
1488.3 ± 38.0 (208 of 403) 
 
137.1 (1 of 649) 
n/a (0 of 283) 
 
 
388.6 ± 31.9 (11 of 323) 
1323.1 ± 34.5 (149 of 270) 
 
378.3 ± 63.4 (6 of 618) 
1417.7 ± 282.9 (3 of 358) 
 
 
564.1 ± 24.2 (72 of 1050) 
971.0 ± 35.9 (96 of 354) 
 
n/a (0 of 909) 
1594.0 ± 376.1  ( 2 of 376) 
 
 
541 ± 40.4 (34 of 782) 
1154.2 ± 60 (49 of 368) 
 
n/a (0 of 706) 
1144.3 ± 27.8 (2 of 306) 
Galanin 
TNT 
Peripherin 
NF-200 
Sham 
Peripherin 
NF-200 
 
 
n/a (0 of 655) 
1564.4  ± 1071.1 (2 of 259) 
 
419.4 (1 of 694) 
1608.4 ± 256.8 (8 of 429) 
 
 
400.2 ± 12.9 (110 of 696) 
1064.8 ±  55.2 (34 of 299) 
 
n/a (0 of 696) 
n/a (0 of 208) 
 
 
319.8 ± 18.2 (76 of 371) 
1190.6 ± 48.7 (83 of 321) 
 
364.7 ± 29.1 (29 of 723) 
1568.1 ± 187.0 (9 of 292) 
 
 
410.1 ± 28.8 (51 of 878) 
981.5 ± 63.5 (20 of 311) 
 
501.3 ± 102.7 (5 of 1046) 
1359.1 ± 174.4 (4 of 377) 
 
 
538.4 ± 33.1 (48 of 750) 
1292.1 ± 78.3 (47 of 561) 
 
n/a (0 of 925) 
1282.1 ± 117.9 (11 of 403) 
 
 
Table 3.3  Mean cell area (μm2) of ATF-3, GAP-43, NPY, and galanin immunoreactivity in NF-200 and peripherin characterised cell populations in 
ipsilateral L5 DRG of TNT/sham animals at 1, 7, 14, 28, and 43 days post surgery.  Data are presented as means ± SEM. The numbers of ATF-3, GAP-43, 
NPY, and galanin immunoreactivity cell profiles out of the total number of peripherin/NF-200 DRG immunoreactive cells are indicated in brackets (n/a = 
not applicable as no data was available). 
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3.3.7 No correlation of investigative markers with mechanical hypersensitivity 
 
In order to determine if there were a relationship between the temporal expression of 
investigative markers in both cell populations (peripherin and NF-200) and the degree of 
behavioural mechanical hypersensitivity, a Pearson’s correlation co-efficient was 
calculated. The results of the study indicate that there is no correlation between TNT 
induced mechanical hypersensitivity and the expression of ATF-3, GAP-43, NPY, and 
galanin (see Figure 3.31 and Figure 3.32).  However there appears to be a trend towards 
an association in both peripherin and NF-200 cells with regards to GAP-43, NPY, and 
galanin and with ATF-3 in peripherin characterized cells.  
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Figure 3.31 Relationship between TNT-induced mechanical hypersensitivity and mean 
percentage immunoreactivity of (A) ATF-3, peripherin immunoreactive cells; (B) ATF-3, 
NF-200 immunoreactive cells (C) GAP-43, peripherin immunoreactive cells (D) GAP-
43, NF-200 immunoreactive cells. Key: (■) NF-200 and (◊) Peripherin immunoreactive 
cells.  (Ipsilateral L5 DRG n=3-4 animals per group). Data presented as mean ± SEM.  
 
A  B 
ATF-3  
Correlation coefficient,  
R= -0.118, P value = 0.85 
Correlation coefficient, 
R= 0.72, P value = 0.168 
C D 
GAP-43 
Correlation coefficient,  
R= -0.455, P value = 0.441 
Correlation coefficient,  
R= -0.202, P value = 0.745 
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Figure 3.32 Relationship between TNT-induced mechanical hypersensitivity and mean 
percentage immunoreactivity of (A) NPY, peripherin immunoreactive cells; (B) NPY, 
NF-200 immunoreactive cells (C) Galanin, peripherin immunoreactive cells (D) Galanin, 
NF-200 immunoreactive cells. Key: (■) NF-200 and (◊) Peripherin immunoreactive cells.  
(Ipsilateral L5 DRG n=3-4 animals per group). Data presented as mean ± SEM.  
 
 
NPY  
A   B 
Correlation coefficient,  
R= -0.182, P value = 0.095 
Correlation coefficient,  
R= -0.445, P value = 0.452 
C  D  
Galanin  
Correlation coefficient,  
R= -0.215, P value = 0.73 
Correlation coefficient,  
R= -0.087, P value = 0.89 
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3.4 Discussion 
 
The aim of the investigation was to characterize the behavioural responses to mechanical 
and thermal stimuli following TNT injury and to provide temporal profile expressions of 
neurochemical markers in the DRG that have been associated with traumatic nerve injury 
using immunohistochemical techniques. The other aim of this investigation was to 
determine the distribution of tibial nerve neurons in the DRG via FG retrograde tracing. 
 
3.4.1 Distribution of tibial nerve axons in L3-S1 DRGs 
 
At the present time, the tibial nerve distribution between different lumbar DRGs is not 
known. Seven days following FG injections into naive animals, labelling was present in 
the L4 and L5 DRGs suggesting that these ganglia receive the majority of tibial nerve 
axons. The mean percentage FG/NeuN co-labelling in the L4 DRG was higher than that 
observed in the L5 DRG. This result reflects similar observations by Swett et al., 1991 
(using retrograde tracer horseradish peroxidase) which reported 99% of labelling in the 
L4 and L5 DRGs (with higher proportions in L4 DRG [68%] compared to L5 DRG 
[31%]) following injection in to the tibial nerve. Further experiments regarding the TNT 
model focused on investigating neurochemical changes in the L5 DRG since the L5 DRG 
is bigger than the L4 DRG and more sections could be made which was important given 
the number of sections required to complete the study. In addition, the results could be 
compared to other studies involving mixed neuronal injury (i.e. PSNL and CCI) and also 
the SNT or spinal nerve ligation (SNL) model where the L5 is commonly assessed. The 
variability between the two animals examined limits the strengths of the study which 
could be improved with a larger sample size. I propose two main reasons that could 
explain the variability. Firstly, the injected FG may have dispersed to the spinal cord – 
such tissue samples were not examined in analysis. Secondly, the fact that some FG 
labelled cells did not co-label NeuN meant that these cells were not included in the 
analysis and thus likely underestimated the percentage expression. Nonetheless, this tract 
tracing study has been an informative approach to estimate DRG neuronal damage that 
occurs following TNT injury. 
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3.4.2 TNT associated mechanical hypersensitivity 
 
Behavioural mechanical hypersensitivity in the mid-plantar paw was assessed using an 
electronic von Frey device.  In the acute stages of TNT injury (day 1 post surgery), 
mechanical hypersensitivity was not evident. However, at 7 days following TNT injury, 
and at subsequent time points (day 14, 28, and 43), animals demonstrated a robust 
mechanical hypersensitivity that was not apparent in sham animals. Once established, the 
mechanical hypersensitivity remained persistent. These results are in concordant with 
previous findings which depict mechanical hypersensitivity following TNT surgery 
(Andrews et al., 2011;Lee et al., 2000;Unal-Cevik and Oaklander, 2011). Although it is 
to be noted that there are some differences regarding the site of sensory testing. In the 
present study the mid-plantar region of the paw (which receives tibial nerve innervation) 
was used to neasure behavioural responses towards a mechanical stimulus, a method that 
mirrors that of Andrews et al., 2011. However other studies have used the lateral part of 
the paw which is innervated by the sural nerve. This lateral part of the paw is reported to 
be the initial hypersensitensive part since it remains surgically intact (Lee et al., 
2000;Unal-Cevik and Oaklander, 2011). The advantage of the assessing the mid-plantar 
part of the paw is that it is more accessible than the lateral part of the paw for testing and 
the results are comparable to other studies that mostly assess the mid-plantar paw. The 
disadvantage of assessing the mid-plantar paw, with respect to the TNT model, is that the 
paw maybe hyposensitive, whereas the lateral paw maybe hypersensitive with an 
appropriate response – the lateral paw is less accessible than the mid-plantar paw and 
more patience and time is required during testing to reflect this. Despite the differences at 
the site of stimulation, the latency to the onset of mechanical hypersensitivity in the 
current study is comparable to what has been described in other studies that has been 
reported to be as early as 3 (Unal-Cevik and Oaklander, 2011) and 4 days (Lee et al., 
2000) post injury. The lack of behavioural hypersensitivity in the acute stages of nerve 
injury (day 1 post TNT injury) may be related to the lack of sensory input that is likely to 
occur following the transection of the tibial nerve. Alternatively, this occurrence maybe 
explained by delayed neurochemical changes in the DRG that might underlie behavioural 
hypersensitivity. At days 28 post TNT surgery in the contralateral paw, animals 
demonstrated a 22.8 ± 18.8 % increase in PWTs. Sham animals at 43 days post surgery 
demonstrated a 46.5 ± 8.0 % increase in the ipsilateral PWT from baseline. These results 
may be explained by an increase in the weight of the animals which subsequently results 
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in increases in PWTs over time, a phenomenon that seems to occur at longer time points. 
This is further discussed in Section 6.6.1 of the general discussion (assessment of 
mechanical hypersensitivity) in context of study limitations. 
  
3.4.3  TNT injury induces transient thermal hypersensitivity 
 
In this study, thermal PWLs were assessed using a Hargreaves device. Following TNT 
injury thermal hypersensitivity was only apparent in the day 28 group (29% decrease 
from baseline). Several models of peripheral nerve trauma injury (e.g. partial sciatic 
nerve ligation (PSNL); chronic constriction injury (CCI), and spinal nerve 
transection(SNT)) are known to exhibit thermal hypersensitivity of similar magnitudes 
and therefore this observation falls in line with previous findings (Bennett and Xie, 
1988;Kim and Chung, 1992;Seltzer et al., 1990). Although, in one particular study, there 
were no reported changes in PWL following spared nerve injury (SNI) or sciatic nerve 
crush, but an increase in duration of withdrawal was observed (Decosterd and Woolf, 
2000). The results of the current study are the first to describe thermal hypersensitivity in 
the TNT model. However this hypersensitivity was not consistent across time points.  
TNT animals at 7 and 14 days post injury demonstrated a decreasing but not significant 
trend in PWLs. There appears to be large standard deviation values that reflect the 
variations amongst PWL readings. The reason for this is not clear but may relate to 
alterations in thermal coding as a consequence of nerve injury. Thermal hyperalgesia is 
not thought to be a common feature of neuropathic pain in humans and this inconsistency 
may reflect this notion (Koltzenburg, 1998). Data from animal studies suggests 
inflammation may play a role and has been shown to be critical for the development of 
thermal hypersensitivity in the CCI model (Clatworthy et al., 1995). Moreover the 
administration of IL-10, an anti-inflammatory cytokine at the site of injury can reduce the 
thermal hypersensitivity associated with CCI (Wagner et al., 1998) and adds further 
weight to this argument.  
 
3.4.4 Temporal profile expression of ATF-3 
 
ATF-3 was examined because it is a widely used marker of damaged DRG neurons 
following peripheral nerve injury. In this study, ATF-3 expression was not observed in 
the L5 DRG of naive animals, which is in agreement with previous observations (Tsujino 
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et al., 2000). After TNT injury, ATF-3 was robustly upregulated in ipsilateral L5 DRG in 
both peripherin and NF-200 cells. The percentage immunoreactivity in peripherin/NF-
200 diameter cells remained similar and constant across time (10-25%), except at the 
acute stage of nerve injury (day 1), where percentage immunoreactivity was evidently 
greater in NF-200 cells (71%). The robust upregulation of ATF-3 has been observed in 
various types of peripheral nerve injury (Averill et al., 2004;Averill et al., 2002;Djouhri 
et al., 2006;Fukuoka et al., 2012;Obata et al., 2003;Peters et al., 2005;Shortland et al., 
2006;Tsujino et al., 2000;Wright et al., 2004). The method used to quantify ATF-3 
expression (i.e. double labelling to determine phenotype) differs to that of previous 
studies. The majority of studies calculate the percentage expression of the total nucleated 
neuronal DRG population. The percentage expression of ATF-3 varies amongst the use 
of different trauma models. For example,  Shortland et al., 2006 using the SNT model 
demonstrated greater expression levels than that observed in the present study (L4/L5 
DRG 1 and 14 days post injury, >98%). Obata et al., 2003 using the CCI model noted 9-
39% ATF-3 expression in L4/L5 DRG 14 days post injury. Other studies involving 
complete axotomy of the sciatic nerve have demonstrated differing levels of expression: 
Averill et al., 2002 (L5 DRG, within 30 days of injury, 58-73%), Averill et al., 2004 (L4 
DRG,14 days post injury, 82%) and Linda et al., 2011 (L4-L6 DRG, 1-21 days of injury, 
45-60%). The reason for the variability between studies is not entirely clear, but I 
propose three plausible arguments. Firstly, the nature of the nerve injury varies between 
studies and more severe injuries may increase ATF-3 expression. Secondly, there may be 
differences in the level of surgical expertise; less experienced operators are more likely to 
incur unnecessary collateral damage that may influence ATF-3 expression. Lastly, the 
potential differences in response to nerve injury amongst various rat strains could be an 
influential factor. The results of the study indicate that the large diameter neurons are 
primarily responsible for the down-regulation that is commonly observed following 
ATF-3 induction, a reflection on the differing degrees of injury sustained between small 
and large diameter neurons. In certain types of nerve trauma injury, large myelinated 
fibres incur massive microscopic damage and degeneration with less severe changes 
evident in smaller unmyelinated fibres (Basbaum et al., 1991;Munger et al., 1992). 
Though such changes have been observed at 10-14 days post injury, similar process 
could occur in the in the early part of TNT injury, leading to increased ATF-3 expression 
(indication of nerve damage). The subsequent down-regulation of ATF-3 observed at 7 
days post TNT injury could be due to a loss of some large diameter neurons, a 
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phenomena that has been observed in certain neuropathic states (Coggeshall et al., 1993). 
This finding is suggestive of a partial recovery. Double labelling experiments, in 
conjunction with the cell size distribution analysis reinforced the evidence regarding the 
down-regulation of ATF-3 in large cells. Despite this down-regulation, ATF-3 expression 
is still evident in the chronic stages of nerve injury which ties in with the persistent 
mechanical hypersensitivity observed 43 days post TNT injury. The ATF-3 expression at 
this stage may be suggestive of other processes. For example, ATF-3 has been linked to 
regeneration of peripheral sensory neurons (Hunt et al., 2004;Saito and Dahlin, 2008). 
When the sciatic nerve is transected and reattached, allowing the regeneration of axons, 
ATF-3 expression down-regulates 30 days post surgery (Hunt et al., 2004). Transgenic 
studies have revealed that the over expression of ATF-3 in non-injured adult mice is 
associated with an increased rate of peripheral nerve regeneration comparable to nerve 
injured animals, although not through GAP-43 mechanisms but through the expression of 
another growth associated protein named small proline rich protein 1A (SPRR1A) 
(Seijffers et al., 2007). ATF-3 may even bind with the closely related c-jun proteins 
(Chen et al., 1994;Hai and Curran, 1991) since they have been shown to co-localize in 
the injured DRG (Tsujino et al., 2000) and therefore this could precipitate regeneration. 
The co-transfection of ATF-3 and c-Jun into neuronal cell lines has been shown to 
produce greater neurite outgrowth than transfection with either genes alone (Pearson et 
al., 2003) and therefore a plausible hypothesis. The expression of ATF-3 in the DRG 
could also indicate neuroprotective strategies. The over expression of ATF-3 to 
sympathetic neurons via a viral vector has been shown to reduce cell death associated 
with growth factor deprivation, and additionally enhanced neurite outgrowth by a specific 
pathway involving c-jun protein (Nakagomi et al., 2003). 
 
3.4.5 Temporal profile expression of GAP-43 
 
Following traumatic peripheral nerve injury, damaged neurons have the capacity to 
regenerate and this has been associated with an increased expression of GAP-43 in the 
L4/L5 DRG (Woolf et al., 1990). GAP-43 has also been identified in the growth cones of 
regenerating axons in culture (Meiri et al., 1988;Meyer et al., 1994) and in vivo (Hall et 
al., 1992) which can influence neuron survival in vivo (Aigner et al., 1995). The results of 
this study show that GAP-43 was expressed at low levels in naïve L5 DRG tissue (0%, 
Peripherin; <2% NF-200). Previous studies have shown higher expression levels in naïve 
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animals: ~35% lightly labelled and <10% heavily labelled in L4/L5 ganglia, (Schreyer 
and Skene, 1991); and 50% of GAP-43 expression in large diameter cells (Sommervaille 
et al., 1991). However, observations by Schreyer and Skene, 1991 included lightly 
labelled cells which were omitted in the current study due to the ambiguous 
immunoreactivity. This could additionally explain discrepancies regarding observations 
by Sommervaille et al., 1991. Following TNT injury, GAP-43 was upregulated in both 
peripherin and NF-200 cells in ipsilateral L5 DRG; temporal profile expressions were 
similar amongst both cell populations. These observations were reinforced by the cell 
size distribution analysis. The mean size of GAP-43 immunoreactive cells in peripherin 
and NF-200 cells throughout the study was <500μm2 and >1200μm2 respectively. Past 
research findings have shown GAP-43 expression in predominantly small-medium 
diameter neurons during the early stages (4 days) of nerve injury (Woolf et al., 1990) 
which correlates with the observations  of this study at 7 days post TNT injury. The 
temporal expression pattern also corroborates with data from in situ hybridization studies 
showing GAP-43 mRNA upregulation in initially small cells before a subsequent 
increase in large diameter cells after unilateral ligation of the sciatic nerve (Wiese et al., 
1992). Peak GAP-43 mRNA expression in Wiese et al., 1992 was observed at 10 days in 
both small and large cells which are comparable to the peak expression time of 14 days 
observed in the current study. Although it is to be noted that large cells did not 
demonstrate similar intensities of hybridisation signal when compared to smaller cells. 
Previous studies have shown higher percentages of GAP-43 expression following nerve 
injury. For example, Schreyer and Skene, 1991 demonstrated ~45% of L4/L5 DRG cells 
expressing high intensity labelling of GAP-43, 7 and 14 days following nerve crush 
injury (compared to ~15% observed in both cell populations in TNT animals). 
Sommervaille et al (1991) examined the expression of GAP-43 in RT 97 labelled cells 
(large diameter cells), in the ipsilateral L5 DRG at various time points following sciatic 
nerve section injury. In the acute stages of nerve injury (4 days), GAP-43 expression was 
reported to be 8% in large diameter cells, a figure that is greater than the 3.2 % observed 
at in the current study (day 1 post TNT). Moreover at 14 days post sciatic nerve 
transection, 29% of the GAP-43 labelled cells were found to be in large diameter cells, a 
figure once more greater than the 15.9% observed in NF-200 immunoreactive cells at 
identical time points in the present study. The comparatively modest GAP-43 expression 
observed (compared to literature findings) may be explained by the differing nature of 
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the nerve injury, since sciatic nerve transection arguably results in greater proportions of 
axotomized axons than TNT injury. 
 
3.4.6 Temporal profile expression of NPY  
 
The results of the study demonstrated that in naïve animals, NPY is not expressed in L5 
DRG. After TNT injury, NPY was robustly upregulated in ipsilateral L5 DRG, exhibiting 
a dynamic temporal profile expression which was predominant in NF-200 characterised 
cells (~30-51%). An increase in NPY immunoreactivity was additionally observed in the 
smaller peripherin immunoreactive cells amongst the various time points (1-6.5%) and 
was confirmed via a cell size distribution analysis. These results are consistent with 
previous findings regarding NPY expression following nerve injury (Ma and Bisby, 
1997;Ohara et al., 1994;Wakisaka et al., 1991;Wakisaka et al., 1992), although the 
method of analysis used to quantify NPY expression differs amongst the various studies.  
For example, Ma and Bisby (1997) calculated the total percentage expression in 
ipsilateral L4/L5 ganglia, comparing three different types of sciatic nerve injury; 
complete sciatic nerve transection (CSNT), partial sciatic nerve transection (PSNT), and 
CCI injury. NPY expression was found to be similar amongst the nerve injury types (~7-
10%).  In a model of complete median nerve transection where C6 and C7 DRGs were 
examined, NPY expression remained ~70% and ~20% amongst medium and large 
diameter fibres respectively across various time points within a 20 week time period 
(Tsai et al., 2007). Finally, in experiments conducted by Brumovsky et al., 2004, the 
number of NPY immunoreactive profiles per 100,000 micrometers method was used to 
quantify expression in L4 and L5 DRG following single ligature CCI. (Brumovsky et al., 
2004).  
 
While there have been contradictory reports regarding the effects of NPY, much of the 
evidence points towards NPY eliciting anti-nociceptive actions (Hua et al., 1991;Intondi 
et al., 2008;Taiwo and Taylor, 2002), through the NPY Y1 & Y2 receptors (Intondi et al., 
2008;Naveilhan et al., 2001;Shi et al., 2006). After peripheral nerve injury the 
Y1 receptor, normally present on small DRG neurons, is down regulated, and the Y2 
receptor is robustly up-regulated on large diameter neurons (Zhang et al., 1997). A 
proposed mechanism of neuropathic pain relates to ectopic discharges originating from 
large diameter fibres or phenotypic switching so that they begin to convey nociceptive 
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signals  (Devor, 2009). The increased NPY observed in large diameter cells, upon 
release, may represent an attempt to reduce this ectopic activity by acting on the Y1 
receptors, thus restoring normal nociceptive processing. It has been argued that NPY 
enhances the effect of noradrenaline in peripheral nerve injury, increasing the discharge 
rate of damaged neurons (Benoliel et al., 2001); a facet of sympathetically maintained 
pain. While this may be a phenomenon observed in some traumatic models (e.g. PSNL 
and CCI) (Shir and Seltzer, 1991), it is unlikely in the TNT model which has been 
described as a sympathetically independent model of peripherial nerve injury (Lee et al., 
2000). 
 
3.4.7 Temporal profile expression of galanin 
 
Galanin expression in naïve L5 DRG was low (<1%) in both peripherin and NF-200 
cells, a figure comparable the 2-3% expression observed by Hokfelt et al (1987) but less 
then that observed by Ma and Bisby, 1997 in L5 DRG (~12%) and Shortland et al 2006 
in L4 DRG (10%). After TNT injury, galanin was upregulated in peripherin and NF-200 
cells in ipsilateral L5 DRG, with expression peaking at 14 days in both cell populations 
(~20%) before dramatically reducing at 28 and 43 days post injury (<10%). The temporal 
expression profiles remained similar between both cell populations. A cell size 
distribution analysis indicated a uniform distribution of galanin immunoreactivity in 
peripherin immunoreactive cells across all time points studied. Although in NF-200 
immunoreactive cells (most notably at day 7 and 14 post TNT injury), the distribution 
was slightly skewed to the left indicating that these were most likely medium-diameter 
cells.  The mean size of galanin immunoreactive cells in peripherin and NF-200 cells 
throughout the study was <600μm2 and >900μm2 respectively. The upregulation of 
galanin has been observed at various time points in several models of peripheral nerve 
injury, mainly in small diameter cells (Averill et al., 2002;Fukuoka et al., 1998;Hokfelt et 
al., 1987;Hokfelt et al., 1994;Holmes et al., 2003;Ma and Bisby, 1997;Shi et al., 
1999;Shortland et al., 2006;Villar et al., 1989). In the acute stage of nerve injury (one day 
post TNT injury), like NPY, galanin expression is no different to sham operated or naive 
control rats in peripherin/NF-200 cell populations (<2%).This percentage expression of 
galanin, one day after nerve trauma differs markedly from those reported by Villar et al 
1989 (~25% after sciatic nerve crush), Averill et al., 2002 (22.5% after CSNT), and 
Shortland et al 2006 (17% after L5 SNT). One possible explanation for this is the 
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differing nature of the nerve injury. SNT surgery involves the removal of L6 transverse 
process (hemi-laminectomy) and extensive manipulation of muscle which increases the 
likelihood of collateral damage that could enhance nerve injury, thus increasing galanin 
expression. SNT is also more robust in terms of the nerve injury since the nerve damage 
is more proximal to the DRGs compared to the TNT model where the nerve injury is 
more distal. This may additionally explain the lower galanin expression observed at 14 
days post TNT injury in the current study (20-25%) compared to that observed by 
Shortland et al 2006 (77% after L5 SNT); Ma and Bisby, 1997 (~50-60% after CSNT, 
PSNT and CCI); Hokfelt et al., 1994 (40-50% after CSNT); and Shi et al., 1999 (20-40% 
after PSNL and CCI,). The sensitivity of the immunohistochemical techniques between 
studies also cannot be ruled out when explaining variability amongst studies. Despite this 
disagreement, my results are in concord with other studies that have reported the peak of 
galanin expression to be at 14 days post nerve injury (Averill et al., 2002). Although the 
expression of galanin down-regulates 14 days post TNT injury, expression is still 
maintained at chronic stages of nerve injury (43 days post TNT surgery) when pain 
related behaviours are still evident. These findings differ to that reported by Villar et al 
1989, in which a return of galanin to near normal expression levels in L4/L5 ganglia was 
observed 45 days following sciatic nerve transection. Again, the nature of the nerve 
injury differs here. Nevertheless, it is conceivable that the galanin protein is expressed at 
43 days post TNT injury and beyond, given the mRNA for galanin is still abundant at 60 
days after traumatic peripheral nerve injury (Villar et al., 1989).   
 
3.4.8 Mechanisms underlying neuropeptide upregulation 
 
Following peripheral nerve injury many neuopeptides in the DRG become dysregulated 
(Maratou et al., 2009;Valder et al., 2003;Wang et al., 2002). A well known regulatory 
factor of DRG neuropeptide expression is nerve growth factor (NGF) (Pezet and 
McMahon, 2006). The decreased expression of substance P (SP) and calcitonin gene 
related peptide (CGRP) and the increased expression of galanin, NPY and other 
neuropeptides (e.g. Vasoactive intestinal peptide (VIP) and cholecystokinin (CCK)) in 
DRG cells following axotomy are attenuated by the administration of exogenous NGF 
(Verge et al., 1995). The evidence from the literature supports a negative regulation of 
NPY and galanin with NGF. It is possible that following TNT injury, the resulting 
decrease in NGF release deprives peripheral axons of tropic support, causing an 
  
163 
 
 
increased synthesis of NPY and galanin in the DRG. Galanin could be more affected here 
given that the TrkA - the receptor for NGF, is present predominately on small diameter 
DRG cells (Verge et al., 1992). Further evidence regarding the role of NGF is supported 
by experiments demonstrating an increase in CCI-induced NPY expression following the 
administration of antisera against NGF (Obata et al., 2004). Other growth factors have 
been implicated such as brain derived neurotrophic factor (BDNF), glial derived 
neurotrophic factor (GDNF), Neurotrophin-3 (NT-3), and leukemia inhibitory factor 
(LIF) (see Figure 3.33). Under normal circumstances, BDNF is constitutively expressed 
in 11-38% of DRG neurons, mainly in small TrkA-positive neurons (Michael et al., 
1999). After a peripheral nerve transaction, BDNF mRNA is upregulated mainly in 
medium-large diameter neurons expressing the TrkB and TrkC receptors (NGF-
insensitive) (Fukuoka et al., 2001). BDNF can stimulate the promoter for NPY 
(Minthworby, 1994;Wernersson et al., 1998;Williams et al., 1998) which may result in 
increased NPY protein production. GDNF, like NGF, is critical for the maturation of 
sensory neurons in development and may play a role in the regulation of NPY and 
galanin following nerve injury. Intrathecal administration of GDNF (or NGF) via an 
osmotic pump to nerve injured rats (L5/L6 SNT) can prevent the upregulation of NPY 
and galanin (and ATF-3) in the DRG and additionally prevent the development of pain 
related behaviours (Wang et al., 2003a). The predominant expression of NPY in large 
diameter neurons observed in the current study may be explained by a loss of neuronal 
trophic factor 3 (NT-3), which can suppress NPY expression (Ohara et al., 1995).  
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Figure 3.33 The neurotrophin interactions of the Trk receptors. Nerve growth factor 
(NGF) is the preferred ligand for trkA, neurotrophin-4/5 and brain-derived nerve factor 
(BDNF) are the preferred ligands at the trkB receptor, and neurotrophin-3 (NT-3) is the 
preferred ligand at the trkC receptor, although it will bind to all the trk receptors (albeit 
with different potencies). All the neurotrophins bind the p75 receptor with equal affinity. 
NGF negatively regulates NPY, galanin, and ATF-3 expression and therefore is a 
proposed main mechanism regarding their dysregulation. Image taken from Wall and 
Melzacks Textbook of Pain 5
th
 Edition.  
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After peripheral nerve injury, Wallerian degeneration takes place and there is a reduction 
in the release of NT-3 from the endonerium (Ji et al., 1994a). This reduction may result 
in reduced activation of trkC (the receptor for NT-3) which is expressed predominately 
on large diameter neurons (Hendry et al., 1992). Indeed the exogenous administration of 
NT-3 through nerve grafting in sciatic nerve transected rats has been shown to attenuate 
the upregulation of NPY (Sterne et al., 1998). The reduced presence of NT-3 at the site of 
injury will additionally affect adjacent non-axotomised neurons, which could lead to 
upregulation of NPY in non-injured neurons. In regard to galanin, evidence from 
previous studies has demonstrated that galanin upregulation is impaired in mice lacking 
the gene for LIF (Rao et al., 1993) and  IL-6 (Murphy et al., 1999). This suggests that 
LIF and/or IL-6 is required for galanin to be expressed and is likely that this is the case in 
the TNT injured animals since LIF and IL-6 are upregulated in Schwann cells following 
traumatic nerve injury (Murphy et al., 1993;Murphy et al., 1999;Sun and Zigmond, 
1996). Both intact and injured sensory neurons express the receptors for LIFβ and gp130 
(Scott et al., 2000). The presence of LIF and IL-6 can also elicit the release of galanin, 
therefore its upregulation could have potential consequences of modulating nociceptive 
processing (McMahon et al., 2005). NGF can negatively regulate the expression of LIF 
(Corness et al., 1998). It is likely that a reduction in NGF expression following TNT 
injury could initiate an increase in LIF synthesis, thus leading towards increased galanin 
production in the cell soma. The down-regulation of both NPY and galanin at day 43 post 
TNT injury suggests there is a partial reversal of nerve injury and is supported by the 
down-regulation of ATF-3 this time point. Regenerated axons may restore the normal 
expression levels of neuroptopic factors thus leading to a normal expression of trophic 
factors, and a reduction of NPY and galanin expression. However the reduction of 
neuropeptide expression over time did not result in a reduction of TNT induced 
mechanical hypersensitivity, which indicates that other factors must be involved in 
maintaining chronic neuropathic pain responses.  
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3.4.9 ATF-3, GAP-43, NPY, and galanin do not correlate with mechanical 
hypersensitivity 
 
Data from this study indicates a lack of correlation between the temporal profile 
expression of investigative markers (i.e. ATF-3, GAP-43, NPY and galanin) in both 
peripherin and NF-200 DRG cells and the degree of mechanical hypersensitivity 
exhibited after TNT injury. Although there was a noticeable trend towards an association 
in both peripherin and NF-200 cells with regards to GAP-43, NPY, and galanin 
immunoreactivity and also with ATF-3expression in peripherin characterized cells. A 
significant association may have been a possibility through the use of increased 
experimental group sizes. The nervous system is extremely plastic and pain as well as 
being highly sensory/discriminative, also involves both affective-motivational and 
cortical processing, so perhaps such a correlation was oversimplified. The observed lack 
of correlation regarding ATF-3 is consistent with previous observations using the SNL 
model (Djouhri et al., 2006;Shortland et al., 2006) and CCI model (Obata et al., 2003). 
Of interest, Obata et al., 2003 examined the relationship between axotomized neurons 
and the incidence of pain-related behavior by dividing rats into three groups according to 
the percentage of ATF-3 expression  (group 1 <12.5%, group 2 12.5-25%, group 3 
>25%). Mechanical and thermal hypersensitivity were observed in group 2 and 3 animals 
(ATF-3 expression >12.5%). Interestingly, no pain-related behaviour was observed in 
animals exhibiting ATF-3 expression <12.5%. The expression of GAP-43 may be related 
to the interruption of axonal transport as a consequence of nerve injury. The inhibition of 
axonal transport via capsaicin or vinblastine is enough to induce GAP-43 expression to 
similar levels observed following nerve crush injury (Woolf et al., 1990). The lack of 
correlation regarding NPY and galanin are supported by previous studies (Ma and Bisby, 
1997). In another study of a differing nature, Benoliel et al (2000) examined the 
expression of NPY in the trigeminal ganglia at 14 days post infraorbital CCI injury and 
indicated no correlation between expression and the degree of mechanical 
hypersensitivity in the vibrissal pads. Shi et al 1999 reported an inverse relationship 
between galanin expression and the degree of mechanical hypersensitivity across various 
models (PSNL, CSNT, and CCI.) i.e. low galanin expression → low PWT. Moreover, 
galanin expression was always found to be greater in the nerve injured animals which did 
not display mechanical hypersensitivity (<10% with PSNL, ~20% with CCI and ~35% 
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greater with total axotomy). This finding conflicts with both personal observations and 
that of other research groups and warrant further investigation. 
 
3.4.10 Conclusion 
 
To conclude, in this chapter I have characterized the temporal profile expressions of 
markers commonly dysregulated after nerve injury, namely, ATF-3, GAP-43, NPY, and 
galanin. In addition, I have correlated the expression profiles with the associated 
mechanical hypersensitivity. To summarize, in the acute stages of nerve injury, large 
diameter fibres were more proportionally affected (i.e. high percentage of cells 
immunoreactive for ATF-3 - an indicator of nerve damage), which is a novel finding. The 
neuropeptides NPY and galanin were robustly upregulated once neuropathic pain-like 
behaviours were established, both demonstrating a dynamic expression, with NPY 
particularly abundant in large diameter NF-200 immunoreactive cells. The upregulation 
of GAP-43 in injured ganglia provides evidence of nerve regeneration. There were no 
correlations between mechanical hypersensitivity and the markers investigated 
suggesting their expression is not critical towards the magnitude of neuropathic pain 
states.   
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Chapter 4 
 
4 Evaluation of DRG neurochemical markers in an animal model of 
antiretroviral drug d4T-induced peripheral toxic neuropathy 
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4.1 Introduction 
 
The introduction of highly active antiretroviral therapy (HAART) for the treatment of 
human immunodeficiency virus (HIV) infection/acquired immunodeﬁciency syndrome 
has resulted in improved patient clinical health and increased survival time (Beck et al., 
1999;Brinkman et al., 1998;Verma S et al., 2007).  The drugs belonging to the group 
nucleoside reverse transcriptase inhibitors (NRTIs) form an integral component of 
HAART, which acts to suppress HIV replication, therefore reducing the viral load and  
the deterioration of the immune system (Shafer and Vuitton, 1999). The development of 
peripheral neuropathies is a known consequence of HIV disease, however the prevalence 
has increased in association with the widespread use of NRTIs, particularly zalcitabine 
(ddC), stavudine (d4T) and didanosine (ddI) (13% in 1993 vrs 42% in 2006) (Smyth et 
al., 2007), and is now recognized as the disorder antiretroviral toxic neuropathy (ATN) 
(Bacellar et al., 1994). These treatments can cause a progressive ‘die back’ degeneration 
of small diameter unmylenated sensory neurons, that is associated with a reduced IENF 
density and significant pain in patients (Pardo et al., 2001). The degeneration of sensory 
nerve fibers is usually bilateral, symmetrical, and distal in nature affecting those with the 
longest axons - typically in the hands and feet. The symptoms experienced by patients 
include numbness, burning pain, and paraesthesiae, with motor dysfunction being 
relatively rare, but reduced or absent deep tendon reflexes can be observed (Verma et al., 
2004). The pain that results from antiretroviral therapies has a detrimental effect on the 
patient’s quality of life and is often a motivating factor for withdrawal of treatment 
(Pandya et al., 2005). The use of ddC, one of the most neurotoxic NTRIs, has been 
phased out of use in both developed and developing countries, and been replaced by 
other less toxic NRTIs such as zidovudine (AZT) or tenofovir (TDF). The use of d4T has 
also been indicated to be phased out of use by the WHO
1
, and although less toxic drugs 
are available, d4T is still widely used in resource limited settings due to its low cost and 
widespread availability (Cherry et al., 2012;Gilks et al., 2006;Makinson et al., 
2008;Renaud-Thery et al., 2007). There are currently 34 million people worldwide living 
with HIV, and much of the social-economic burdens of HIV-related sensory neuropathies 
are in Sub-Saharan Africa
1
. From the 34 million people worldwide living with HIV, 
approximately 6.6 million individuals are receiving antiretroviral therapy, and 5.5 million 
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of those are in Sub-Saharan Africa
1
, therefore this region are most at risk from 
developing painful neuropathies as a consequence of continued exposure to treatment.
 
Previous research has already indicated that the incidence of d4T-induced neuropathy is 
related to both the dose and length of use (Simpson and Tagliati, 1995). Although 
symptoms can improve upon cessation of treatment (Petersen et al., 1995), this 
improvement is often  preceded by a period of augmented symptoms that may last 
several weeks (Simpson and Tagliati, 1995), therefore treatment strategies remain 
challenging. Although the prevelance of HIV related sensory neuropathy has increased 
since 1993 (pre HAART era) amongst the use of d4T and other NRTIs such as ddI and 
ddC, the prevelance has remained unchanged from 2001 (44%) to 2006 (42%) despite the 
general decreased use of NRTIs (Smyth et al., 2007). There may be various factors 
involved to explain this outcome. This finding could be indicative of the direct 
neurotoxicity associated with HIV disease, or could indicate an inability of peripheral 
nerves to regenerate and recover from the effects of previous exposure to neurotoxic 
NRTIs, and therefore the neuropathic symptoms persist. 
 
d4T chemistry 
 
 
d4T is a synthetic pyrimidine nucleoside analogue and is a potent inhibitor of HIV 
replication in vitro in human cells (Guimaraes et al., 2010). When administered to a 
subject, d4T enters cells by non-facilitated diffusion where it is converted into its active 
triphosphate form. d4T competes for the binding site of HIV reverse transcriptase 
enzyme with the normal cellular triphosphates needed for DNA synthesis therefore 
mimicking their action. This disrupts HIV- reverse transcriptase activity, resulting in the 
termination of viral DNA replication. 
                                                                                                                                                                     
1
 World health organization: Progress report 2011: Global HIV/AIDS response 
(http://www.who.int/hiv/pub/progress_report2011/summary_en.pdf accessed  17/2/2012) 
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4.1.1 Effects of antiretroviral toxic neuropathy 
 
The exact pathogenesis of painful ATN to date remains unclear and is the topic of many 
investigations. The elucidation of specific mechanisms regarding ATN in human subjects 
is confounded by the concurrent viral (HIV) interaction with peripheral sensory neurons, 
and their supporting cells, which has also been identified to precipitate small fibre 
peripheral neuropathy in itself. The use of preclinical in vitro and in vivo studies has 
therefore provided a platform to which direct mechanisms can be investigated 
independently of HIV influence.  
 
Effects of NRTIs in vitro 
 
When primary DRG cultures are exposed to NRTIs they elicit a dose dependant toxicity 
which is characterized by neuronal cell death, decreased total number of neuritis per 
neuron,  and reduced neurite length (Cui et al., 1997;Keswani et al., 2003a). Reduced 
soma size has additionally been observed in feline DRG cultures (Zhu et al., 2007). The 
NRTI induced cell death is reported to involve both apoptotic and necrotic types of cell 
death. Evidence of necrotic cell death derives from the increased size of dead cells and 
the lack of TUNEL labelling in ddC treated DRG cultures, a common method for 
identifying apoptosis (Keswani et al., 2003a). Exposure of ddI to neonatal DRG cultures 
can induce a c-Jun N-terminal kinase depdendent apopotosis (Bodner et al., 2004). This 
NRTI toxicity is associated with a reduced rate of glycolosis and a decreased cellular 
content of mitochondrial DNA upon continuous exposure  (Chen and Cheng, 1989;Cui et 
al., 1997), which can be reversed following NRTI removal (Chen and Cheng, 1989). 
These results are suggestive of a mitochondrial toxicity mechanism which has become a 
recognised avenue of investigation. Antiretroviral drugs can alter mitochondrial DNA 
(mtDNA) content by inhibiting DNA polymerase γ; the enzyme responsible for the 
replication of mtDNA (Brinkman et al., 1999). Studies using various cell lines (e.g. T-
lymphoblastic cells, human myocytes, isolated rat mitochondria from brain, liver, and 
skeletal muscle) have demonstrated differing levels of potency regarding DNA 
polymerase inhibition with some minor discrepancies depending on the cell line used and 
NRTI concentration. The NRTI ddC, which is being phased out of use, demonstrates the 
most potency (Chen et al., 1991), followed by d4T and ddI which are still widely used 
(Kakuda, 2000). Other studies have reported ultrastructural abnormalities following 
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NRTI treatments in DRG culture such as loss of cristae in mitochondria, and the 
clustering of microtubules in neurons (Liu et al., 2008). NRTI toxicity has been 
associated with a reduced expression of mRNA for brain derived neurotrophic factor  
(BDNF) and its receptor, TrkB (Zhu et al., 2007). BDNF is an important modulator of 
peripheral neuronal function, released by neurons, providing support and encouraging 
growth and differentiation of new neurons and synapses (Pezet and McMahon, 2006). 
The sustained neuronal toxicity induced by NRTIs maybe a due to a lack of trophic 
support as a direct consequence of their inability to produce and respond to growth 
factors such as BDNF (Zhu et al., 2007). 
 
Effects of NRTIs in vivo  
 
In the earliest animal model of ATN, rabbits were exposed to chronic administration of 
oral ddC which resulted in reduced conduction velocities and amplititudes in the sural 
nerve compared to controls (Anderson et al., 1992).  In parallel to the observations made 
in vitro, these animals exhibited evidence of neuronal damage which included myelin 
splitting, intramyelinic oedema, demyelination, and axonal loss. Similar observations 
have been made regarding chronic exposures in rats (Schmued et al., 1996). This chronic 
exposure of ddC also elicits a reduction in intra-epidermal nerve fibre (IENF) density 
(Wallace et al., 2007b) which corresponds to the clinical situation of small fibre loss of 
distal axons and associated pain (Pardo et al., 2001;Polomano et al., 2001). Decreases in 
the conduction velocities (Chen and Levine, 2007) and morphological changes - 
including mitochondrial damage  (Van Steenwinckel et al., 2008), have been observed 
within a week of a single dose of ddC in rats. This indicates that acute exposures are 
sufficient to elicit a neuropathy, which reflects the clinical scenario. However it is to be 
noted that some reports indicate that this acute exposure is not associated with the  
induction of demyelination and axonal degeneration (Bhangoo et al., 2007;Van et al., 
2008) or decreases in paw IENF density in the paws that is evident upon chronic 
exposures (Siau et al., 2006).   
 
Despite an array of studies demonstrating in vivo models of ATN, other researchers have 
been unable to replicate the model, and have highlighted potential difficulties that may be 
related to species differences or varied drug treatment regimes. Zhu and colleagues 
(2007) failed to induce nerve fibre loss, electrophysiological changes, or reductions in 
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IENF density in cats administered oral ddI daily for 6 weeks. Furthermore, no evidence 
of neuropathy was reported in monkeys administered ddI on a daily basis for 1 year 
(Kaul et al., 1999) or rabbits for administered ddI for a 24 week period (Warner et al., 
1995). It is not clear why this is the case. Nonetheless it seems that rat models 
demonstrate more consistency regarding peripheral neuropathies upon exposure to 
NRTIs. While biochemical studies in animals have revealed some cellular effects of 
NRTIs that underlies ATN, including, most importantly, mitochondrial toxicity (Cherry 
and Wesselingh, 2003;Dalakas et al., 2001;Kakuda, 2000;Keilbaugh et al., 1997) the 
mechanisms underlying the pain experienced by these patients on these medications is 
yet to be fully elucidated. Several laboratories have now developed and reproduced 
models of ATN following injections with NRTIs (e.g. d4T, ddC, ddI) that develop a 
dose-dependent indices of pain-related behaviour (Bhangoo et al., 2007;Dorsey et al., 
2009;Joseph et al., 2004;Wallace et al., 2007b;Zheng et al., 2011a). These behaviours are 
also associated with reductions in IENF density (Wallace et al., 2007b).The nature of the 
pain related behaviours may be related to the expression of particular markers known to 
be dysregulated following traumatic nerve injury that may alter neuronal excitability 
(Lacroix-Fralish et al., 2011;Woolf and Salter, 2000;Zimmermann, 2001). These include 
markers of cell injury/stress e.g. activating transcription factor-3 (ATF-3), neuropeptides 
e.g. galanin and neuropeptide (NPY), Vgf, regenerating gene protein-2 (Reg-2), and 
vasoactive intestinal peptide (VIP). Further evidence for their involvement derives from 
the closely related model of gp120 and ddC combined toxicity, in which such proteins 
are upregulated (Maratou et al., 2009;Wallace et al., 2007b).  
 
Why d4T? 
 
Since the use of d4T is still prevalent in resource limited settings and has been associated 
with nerve damage and significant pain in humans, it is worth investigating the 
mechanisms associated with d4T use in order to reduce the clinical burden associated 
with HIV disease. Neurochemical marker dysregulation is a major consequence of nerve 
trauma and is associated with pain-related mechanical hypersensitivity. However, these 
neurochemical markers have not been comprehensively investigated in non-traumatic 
nerve injury models such as the d4T-induced neuropathy model where nerve damage and 
pain-related behaviours are also evident. 
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4.1.2 Aims of the study 
 
There are a number of aims in the following study: 
 
6) Characterize behavioural responses towards mechanical stimuli following  
treatment with d4T at acute and chronic time points 
7) Provide a temporal profile expression of ATF-3, NPY, galanin, and GAP-43 in 
the L5 DRG using immunohistochemical techniques and characterize the 
phenotype of those immunoreactive neurons via double labelling using markers 
for peripherin and NF-200.  
8) Perform a cell size analysis of investigative markers as a quality control for 
immunohistochemical data 
9) Provide a comparison with the effects of traumatic nerve injury as described in 
Chapter 3. 
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4.2 Results 
 
Animals were sacrificed at days 7, 21, and 43 post initial d4T injections, shortly after 
recording of mechanical behavioural responses, and immunohistochemistry for ATF-3, 
GAP-43, NPY, and galanin was performed in the left L5 DRG of d4T/saline treated 
animals. Double labelling with each investigative marker was conducted using antisera 
for peripherin and NF-200, as well as a cell size analysis. Following injections, animals 
exhibited no obvious signs of motor impairment; this was assessed by observing gait 
when animals were freely moving within the cage.  Phenotypic changes were only 
evident upon formal behavioural testing. A total of 28 animals were used in this study 
(Figure 4.1).  
 
 
Figure 4.1 A breakdown of the numbers of animals used in the study. Animals were 
divided into two groups: d4T groups (n=12) and saline groups (n=12) and further sub-
divided according the time of sacrifice (7, 22, and 43 days post injection). Naïve animals 
were used as additional controls 
 
 
 
Total animals used in 
study: (n=28) 
d4T study: (n=24) Naive group: (n=4) 
 
d4T group (n=12) 
 
Day 7       n=4 
Day 22     n=4 
Day 43     n=4 
 
Saline group (n=12) 
 
Day 7       n=4 
Day 22     n=4 
Day 43     n=4 
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4.2.1 d4T induces bilateral mechanical hypersensitivity 
 
At 7, 22, and 43 days post initial d4T injection, rats exhibited significant bilateral 
mechanical hypersensitivity in the mid-plantar region of the hind paws with respect to 
baseline values (Figure 4.2A-C). The PWTs in the left hind limb of animals at baseline 
and at day 7 post initial d4T injections were 47.5 ± 1.2 g and 32.7 ± 0.7 g respectively, 
representing a mean percentage decrease of 30.9 ± 3.1 (*p<0.01). This was similar to the 
right hind limb which was 45.1 ± 0.8 g and 31.0 ± 0.4 g at baseline and at day 7 post 
initial d4T injection respectively with a mean percentage decrease of 31.2 ± 2.0 
(*p<0.01). Behavioural mechanical hypersensitivity reached a peak in both hind limbs at 
22 days post initial d4T injection. The PWTs in the left hind limb of animals at baseline 
and at day 22 post initial d4T injections were 47.9 ± 1.1 g and 24.7 ± 0.5 g respectively, 
representing a mean percentage decrease of 48.3 ± 1.4 (*p<0.01). The PWTs in the right 
limb at baseline and at day 22 post initial d4T injections were 45.8 ± 1.6 g and 24.3 ± 1.6 
g respectively (mean percentage decrease from baseline of 46.7 ± 3.5, *p<0.01). 
Behavioural mechanical hypersensitivity at day 43 then reduced to values below that 
observed at day 7 and day 22 post d4T injection. The PWTs in the left hind limb at 
baseline and at day 43 post initial d4T injection were 46.9 ± 0.5 g and 38.5 ± 0.7 g 
respectively (mean percentage decrease from baseline of 17.9 ± 1.2, *p<0.05). Similarly, 
the reductions in the PWTs in the right hand limb were identical to that of the left with 
the baseline and day 43 values 45.1 ± 1.7 g and 37.8 ± 2.1 g respectively (mean 
percentage decrease from baseline of 16.0 ± 3.6 g, *p<0.01).  Significant hypersensitivity 
in saline treated animals was only observed at day 22 in the right hind limb (mean 
percentage decrease from baseline, 5.9 ± 1.8, *p<0.05). There were significant 
differences in the mean percentage decrease from baseline when comparing the left or 
right paws of d4T animals and their saline counterparts at all study groups (day 
7,**p<0.01; day 22, **p<0.01; and day 43, *p<0.05  post initial d4T injection, Figure 
4.3).    
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Figure 4.2 Mean paw withdrawal thresholds (PWT) to punctate mechanical stimuli 
measured using an electronic von Frey device at the various time point post d4T/saline 
injections in left and right hind limbs. Data presented as mean ± SEM.  **P<0.01 and 
*P<0.05 vs. respective baseline value using a Student’s paired t test. An unusual 
significant hypersensitivity in saline treated animals was observed at day 22 in the right 
hind limb. 
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Figure 4.3 Mean percentage change in PWTs from baseline at various time points post 
d4T/saline injection in (A) the left paw and (B) the right paw using an electronic von 
Frey device. **P<0.001 and *P<0.05 vs. respective baseline value using a Student’s 
paired t test.  
 
B 
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A 
  ** 
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4.2.2 Temporal profile expression of ATF-3 in left L5 DRG  
 
ATF-3 has been described as a marker of neuronal injury, and is not normally expressed 
or is present in low levels in uninjured animals (Tsujino et al., 2000). ATF-3 was not 
detected in the DRG of naïve animals (see Figure 4.4 and Table 3.2). Statistical analysis 
revealed that there were no significant differences in the temporal profile expression of 
ATF-3 in peripherin and NF-200 characterised cells (p>0.05, one way ANOVA). No 
significant differences were observed with sham DRG at respective time points (p>0.05, 
two way ANOVA). Following the administration of d4T to rats, the mean percentage 
ATF-3 immunoreactivity in peripherin and NF-200 characterised cells was <1% across 
all time points (Figure 4.4); a figure comparable to that of saline treated rats. Seven days 
following d4T administration, ATF-3 was expressed in few DRG cells (Figure 4.5) - 
ATF-3 immunoreactivity was 2.1. ± 1.2 % and 1.6 ± 0.6% in NF-200 and peripherin 
characterised cells respectively. At 22 days following d4T administration, ATF-3 was 
expressed in 1.7 ± 0.5 % and 0.1. ± 0.1 % of NF-200 and peripherin characterised cells 
respectively. Lastly, at 43 days post d4T administration, ATF-3 immunoreactivity was 
0.45 ± 0.45 % and 0.9 ± 0.5 % in NF-200 and peripherin characterised cells respectively. 
ATF-3 immunoreactivity was only observed in neuronal cells only, and the few cells that 
were ATF-3 immunoreactive were observed in large size cells (>900μm2) of which the 
immunoreactivity was nuclear. The cell size distribution analysis can be viewed across 
the various time points for ATF-3 immunoreactivity in Figure 4.6 for peripherin cells and 
Figure 4.7 for NF-200 cells. See Table 4.1 for mean cell size areas of ATF-3 
immunoreactive cells across time in peripherin/NF-200 cells. 
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Figure 4.4 Mean percentage of total peripherin and NF-200 immunoreactive cells 
expressing ATF-3 in d4T, saline, and naive animals (Left L5 DRG n=4 animals per 
group). Data presented as mean ± SEM.  
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Figure 4.5 Representative images of ATF-3 immunohistochemistry in L5 DRG of 
d4T/saline treated animals (day 7) in peripherin and NF-200 neuronal sub-populations, 
magnification x20.  
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Figure 4.6 Percentage cell size area distribution analysis of ATF-3 & peripherin 
immunoreactivity (ir) in the left L5 DRG at 7, 22, and 43 days post initial d4T/saline 
injections, and in naive animals, (n= total number of nucleated peripherin 
immunoreactive cells). 
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Figure 4.7 Percentage cell size area distribution analysis of ATF-3 & NF-200 
immunoreactivity (ir) in the left L5 DRG at 7, 22, and 43 days post initial d4T/saline 
injections and in naive animals, (n= total number of nucleated NF-200 immunoreactive 
cells). 
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4.2.3 Temporal profile expression of GAP-43 in left L5 DRG  
 
GAP-43 immunoreactivity in the L5 DRG of naïve animals only co-localised with 
peripherin immunoreactive cells (1.73 ± 1.73 %), and no GAP-43 immunoreactivity was 
observed in the NF-200 characterised population (see Figure 4.8 and Table 3.2). 
Following administration of d4T, a significant temporal pattern was observed in 
peripherin characterised cells but not in NF-200 cells (p<0.05, one way ANOVA). A 
significant temporal pattern was also observed in NF-200 cells of saline treated rats 
(p<0.05, one way ANOVA). There were no significant differences in GAP-43 
immunoreactivity in d4T treated animals with respect to saline controls (Figure 4.8). 
GAP-43 immunoreactivity in the left L5 DRG of d4T and saline treated rats was variable, 
but the temporal expression remained <6% in both peripherin and NF-200 characterised 
cells. Seven days following d4T administration, GAP-43 immunoreactivity was in 2.0 ± 
1.2 % and 1.6 ± 0.6 % of NF-200 and peripherin characterised cells respectively. At 22 
days following d4T administration, GAP-43 immunoreactivity was 1.1 ± 0.5 % and 0.1 ± 
0.1 % in NF-200 and peripherin characterised cells respectively. Lastly, at 43 days post 
d4T administration, GAP-43 immunoreactivity was observed in 0.45 ± 0.45 % and 0.9. ± 
0.5 % of NF-200 and peripherin characterised cells respectively. GAP-43 
immunoreactivity was present mainly in the cell soma, but immunoreactivity was also 
observed in axons (Figure 4.9). The cell size distribution analysis across the various time 
points can be viewed for GAP-43 immunoreactivity in Figure 4.10 for peripherin cells 
and Figure 4.11 for NF-200 cells. See Table 4.1 for mean cell size areas of GAP-43 
immunoreactive cells across time in peripherin/NF-200 cells. 
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Figure 4.8 Mean percentage of total peripherin and NF-200 immunoreactive cells 
expressing GAP-43 in d4T, saline, and naive animals (Left L5 DRG n=4 animals per 
group). Data presented as mean ± SEM.  
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Figure 4.9 Representative images of GAP-43 immunohistochemistry in L5 DRG of 
d4T/saline treated animals (day 7) in peripherin and NF-200 neuronal sub-populations, 
magnification x20. The arrowheads represent co-localisation of immunoreactive cells.  
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Figure 4.10 Percentage cell size area distribution analysis of GAP-43 & peripherin 
immunoreactivity (ir) in the left L5 DRG at 7, 22, and 43 days post initial d4T/saline 
injections and in naive animals, (n= total number of nucleated peripherin immunoreactive 
cells). 
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Figure 4.11 Percentage cell size area distribution analysis of GAP-43 & NF-200 
immunoreactivity (ir) in the left L5 DRG at 7, 22, and 43 days post initial d4T/saline 
injections and in naive animals, (n= total number of nucleated NF-200 immunoreactive 
cells). 
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4.2.4 Temporal profile expression of NPY in left L5 DRG  
 
NPY immunoreactivity in the L5 DRG of naïve animals only co-localised with NF-200 
immunoreactive cells (0.28 ± 0.28 %), and no NPY immunoreactivity was observed in 
the peripherin characterised population (see Figure 4.12 and Table 3.2). Following 
administration of d4T, no significant differences in the temporal profile expression of 
NPY were observed in both NF-200 and peripherin cells (p>0.05, one way ANOVA). No 
significant differences were observed compared with sham DRG at respective time points 
(p>0.05, two way ANOVA). NPY immunoreactivity remained low across all time points 
in both d4T and saline treated rats (<0.5%), a figure comparable to that observed in saline 
treated rats (<0.2%) and also naïve rats (Figure 4.12). Seven days following d4T 
administration, NPY immunoreactivity was present in 0.15 ± 0.15% of NF-200 
characterised cells, and no NPY immunoreactivity was observed in peripherin 
characterised cells (Figure 4.13). At 22 and 43 days following d4T injury, there were no 
NPY immunoreactive cells in both NF-200 and peripherin characterised cells. NPY 
immunoreactivity was cytoplasmic and was identified mainly in the cell soma however 
some immunoreactivity was observed in axons. The cell size distribution analysis across 
the various time points can be viewed for NPY immunoreactivity in Figure 4.14 for 
peripherin cells and Figure 4.15 for NF-200 cells. See Table 4.1 for mean cell size areas 
of NPY immunoreactive cells across time in peripherin/NF-200 cells. 
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NPY  
 
 
 
Figure 4.12 Mean percentage of total peripherin and NF-200 immunoreactive cells 
expressing NPY in d4T, saline, and naive animals (Left L5 DRG n=4 animals per group). 
Data presented as mean ± SEM.  
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Figure 4.13 Representative images of NPY immunohistochemistry in L5 DRG of d4T 
treated animals (day 7) in peripherin and NF-200 neuronal sub-populations, 
magnification x20.  
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Figure 4.14 Percentage cell size area distribution analysis of NPY & peripherin 
immunoreactivity (ir) in the left L5 DRG at 7, 22, and 43 days post initial d4T/saline 
injections and in naive animals, (n= total number of nucleated peripherin immunoreactive 
cells). 
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Figure 4.15 Percentage cell size area distribution analysis of NPY & NF-200 
immunoreactivity (ir) in the left L5 DRG at 7, 22, and 43 days post initial d4T/saline 
injections and in naive animals, (n= total number of nucleated NF-200 immunoreactive 
cells). 
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4.2.5 Temporal profile expression of galanin in left L5 DRG 
 
Galanin immunoreactivity in the L5 DRG of naïve animals was relatively low with 0.56 
± 0.56 % of galanin immunoreactivity in peripherin immunoreactive cells and no 
labelling present in NF-200 immunoreactive cells (see Figure 4.16 and Table 3.2). 
Following d4T administration, no significant differences was observed in the temporal 
profile expression of galanin in peripherin or NF-200 cells (p>0.05, one way ANOVA). 
No significant differences were observed with sham DRG at respective time points 
(p>0.05, two way ANOVA). The mean percentage galanin immunoreactivity in 
peripherin or NF-200 cells remained low (<2%) in all experimental time groups (Figure 
4.16). The few cells with galanin immunoreactivity exhibited granular appearance. Seven 
days following d4T administration, galanin immunoreactivity was in 0.94 ± 0.74% of 
peripherin characterised cells, and no galanin immunoreactivity was observed in NF-200 
characterised cells (Figure 4.17).  At 22 days following d4T administration, galanin 
immunoreactivity was present in 1.3 ± 0.8% of peripherin characterised cells, and no 
galanin immunoreactivity was observed in NF-200 characterised cells. Lastly, at 43 days 
post d4T administration, galanin immunoreactivity was present in 1.7 ± 0.3% of 
peripherin characterised cells, and no galanin immunoreactivity was observed in NF-200 
characterised cells. The cell size distribution analysis across the various time points can 
be viewed for galanin immunoreactivity in Figure 4.18 for peripherin cells and Figure 
4.19 for NF-200 cells. See Table 4.1 for mean cell size areas of galanin immunoreactive 
cells across time in peripherin/NF-200 cells. 
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Figure 4.16 Mean percentage of total peripherin and NF-200 immunoreactive cells 
expressing galanin in d4T, saline, and naive animals (Left L5 DRG n=3-4 animals per 
group). Data presented as mean ± SEM.  
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Figure 4.17 Representative images of galanin immunohistochemistry in L5 DRG of d4T 
treated animals (day 7) in peripherin and NF-200 neuronal sub-populations, 
magnification x20.  
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Figure 4.18 Percentage cell size area distribution analysis of galanin & peripherin 
immunoreactivity (ir) in the left L5 DRG at 7, 22, and 43 days post initial d4T/saline 
injections and in naive animals, (n= total number of nucleated peripherin 
immunoreactive cells). 
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Figure 4.19 Percentage cell size area distribution analysis of galanin & NF-200 
immunoreactivity (ir) in the left L5 DRG at 7, 22, and 43 days post initial d4T/saline 
injections and in naive animals, (n= total number of nucleated NF-200 immunoreactive 
cells). 
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4.2.6 Summary of cell size analysis 
 
 
Since few immunoreactive cells were observed regarding ATF-3, GAP-43, NPY, and 
galanin, the cell size distribution data remained inconclusive. Table 4.1 lists the cell size 
analysis data for the few immunoreactive cells observed regarding ATF-3, GAP-43, 
NPY, and galanin in peripherin and NF-200 cells.  
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 d4T/saline treated animals [ mean cell area μm2 ± standard error of mean ] 
Markers   Day 7 Day 22 Day 43 
ATF-3 
d4T 
Peripherin 
NF-200 
Saline 
Peripherin 
NF-200 
 
 
528.3  (1 of 1209) 
1376.9 ± 26.2 (1 of 323) 
 
n/a (0 of 1057) 
1276.4 ± 184.4 (3 of 281) 
 
 
n/a (0 of 947) 
1232.0 ± 74.6 (2 of 350) 
 
n/a (0 of 713) 
n/a (0 of 311) 
 
 
593.8 ± 220.8 (2 of 839) 
n/a (0 of 306) 
 
201.6 (1 of 824) 
n/a (0 of 359) 
GAP-43 
d4T 
Peripherin 
NF-200 
Saline 
Peripherin 
NF-200 
 
 
389.8  ± 35.4  (17 of 980) 
1038.0 ± 58.5 (10 of 363) 
 
400.7 ± 40.4 (21 of 766) 
1029.4 ± 102.4 (14 of 297) 
 
 
278  (1 of 821) 
1311.9 ± 204.2 (5 of 442) 
 
451.3 ± 53.9 (6 of 825) 
1014.9  ± 100.3 (3 of 317) 
 
 
477.0 ± 69.8 (7 of 784) 
2341.1 ± 661.4 (2 of 348) 
 
438.7  ± 53.4  (9 of  933) 
1011.7 ± 59.4 (15 of 320) 
NPY 
d4T 
Peripherin 
NF-200 
Saline 
Peripherin 
NF-200 
 
 
n/a (0 of 1057) 
840.8  (1 of 437) 
 
n/a (0 of 1057) 
n/a (0 of 260) 
 
 
n/a (0 of 899) 
n/a (0 of 353) 
 
n/a (0 of 554) 
n/a (0 of 393) 
 
 
373.0 (1 of 881) 
n/a (0 of 385) 
 
333.8 (1 of 802) 
n/a (0 of 279) 
Galanin 
d4T 
Peripherin 
NF-200 
Saline 
Peripherin 
NF-200 
 
 
306.5 ± 29.4 (7 of 748) 
1038.0 ± 58.5 (10 of 363) 
 
351.4 ±  20.0 (17 of 959) 
1029.4  ± 102.4 (14 of 297) 
 
 
361.5  ± 26.1 (17 of 1246) 
n/a  (0 of 416) 
 
345.6  ± 25.7 (5 of 1022) 
n/a  (0 of 305) 
 
 
346.7 ± 24.9 (14 of 863) 
n/a (0 of 384) 
 
327.8 ± 40 (11 of 814) 
1851.1 ± 923.5 (2 of 283) 
 
Table 4.1 Mean cell area (μm2) of ATF-3, GAP-43, NPY, and galanin immunoreactivity in NF-200 and peripherin characterised cell populations in left L5 DRG of 
d4t/saline injected animals at 7, 22, and 43 days post initial injection.  Data are presented as means ± SEM. The numbers of ATF-3, GAP-43, NPY, and galanin 
immunoreactivity cell profiles out of the total number of peripherin/NF-200 DRG immunoreactive cells are indicated in brackets (n/a = not applicable as no data 
was available).  
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4.3 Discussion 
 
This study was undertaken to investigate whether neurochemical markers known to be 
dysregulated in traumatic nerve injury exhibit similar expression patterns in a model of d4T 
induced peripheral neuropathy, and therefore reveal shared mechanisms. The mechanisms 
regarding ATN have not been fully elucidated and this toxicity presents a significant clinical 
problem. The results of the study demonstrated that those rats treated with d4T developed a 
robust bilateral hind paw mechanical hypersensitivity, during which, there was limited 
expression of ATF-3, NPY, galanin, and GAP-43 in both peripherin and NF-200 
characterised L5 DRG cells. The pattern of responses to nerve damage are different in nerve 
trauma compared to NRTI related injury where the responses are observed in the DRG (i.e. 
biochemical changes), however with d4T related injury, such responses occur at the 
peripheral and central terminals of axons where there is a ‘dying back’ and no such 
biochemical changes in DRG (Calvo et al., 2012a;Wallace et al., 2007b). This is an 
important finding which indicates that the expression of neurochemicals ATF-3, GAP-43, 
NPY, and galanin in the DRG are more associated with nerve trauma processes and not 
necessarily behavioural hypersensitivity. This is further supported by the lack of ATF-3, 
GAP-43, NPY, and galanin expression in the DRG of d4T treated rats, despite the 
development of hind paw mechanical hypersensitivity in these rats. 
  
Dosage 
 
One of the main consequences of NRTI treatment in those with HIV is the development of 
neuropathic pain. Animal studies have revealed dose-dependent effects regarding neuronal 
toxicity and development of pain-related behaviours following NRTI treatment. A dose of 2-
5 mg/kg has no effect on sensory thresholds (Ferrari and Levine, 2010). A slightly higher 
dose of 10mg/kg and 25mg/kg can produce behavioural mechanical hypersensitivity (Joseph 
et al., 2004). However this finding (the use of a slightly higher dose) disagrees with a study 
that has reported a decreasing but not signficiant trend in mechanical PWTs regarding the 
25mg/kg dose (Wallace et al., 2007b). Studies involving doses of 50mg/kg have 
unequivocally demonstrated robust behavioural effects indicating a neuropathic pain-like 
state and therefore this dose was chosen for all d4T experimental studies.  
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4.3.1 Development of ATN-associated mechanical hypersensitivity 
 
Upon the intravenous treatment of d4T (50mg/kg), rats demonstrated a bilateral decrease in 
PWTs that was evident at day 7 (~30%), peaking at day 22 (~47%) before reducing at day 43 
(~17%). This d4T induced hypersensitivity  is consistent with what is observed clinically 
(Dalakas, 2001;Reliquet et al., 2001) and in animal studies (Kamerman et al., 2012). 
However significant hypersensitivity in saline treated animals was observed at day 22 in the 
right hind limb. Although the percentage decrease from baseline was small (5.9 ± 1.8%), 
such a decrease is likely to be an anamaloie and not neceralliry a result of unintended nerve 
damage.  No overt motor deficits were observed in d4T injected animals, an observation 
supported by previous study in ddC treated rats following assessment with an accelerating 
rotor rod device (Joseph et al., 2004). The peak level of mechanical hypersensitivity in d4T 
treated animals was greater than what has previously been reported in rats. Wallace et al., 
2007b and Joseph et al., 2004, using ddC (50mg/kg), both reported a ~30% (day 21) and 20-
40% (day 14) decrease in PWTs from baseline respectively. Similar peak levels of 
mechanical hypersensitivity have been noted with ddI and ddC (20-40%) (Joseph et al., 
2004).  The early onset of mechanical hypersensitivity following exposure to d4T is 
comparable with previous studies using ddC (50mg/kg), which observed a ~30% decrease 
from baseline 5-8 days following initial injection (Joseph and Levine, 2004;Joseph and 
Levine, 2006). The long lasting nature of the d4T hypersensitivity is also comparable to a 
previous study where behavioural hypersensitivity was evident at 43 days post initial 
injection (Wallace et al., 2007b). It is to be noted that the treatment regimes have differed 
amongst the various studies. In the present study, animals were treated with two doses of 
d4T separated by 4 days, whereas Wallace et al., 2007b used a treatment regime consisting 
of 3 doses per week. Joseph et al., 2004 and Zheng et al., 2011b regime consisted of a single 
bolus dose (50mg/kg). Taken together, these results suggest that the acute administration of 
NRTIs can induce long lasting mechanical hypersensitivity which does not alter upon 
repeated doses. Indeed this is comparable to epidemiological data showing that even acute 
exposures to NRTIs can increase the risk of developing ATN (Cherry et al., 2009;Smyth et 
al., 2007).  The greater magnitude of behavioural hypersensitivity observed may reflect the 
differences between the methods used to analyze responses to mechanical stimuli. 
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Experiments by Wallace et al., 2007b used an electronic von Frey device to measure PWTs 
whereas experiments involving Joseph and colleagues had used an Analgesymeter which 
measures paw pressures according to the method of Randall-Selitto (Randall and Stelitto, 
1957). To describe briefly, a force is applied to the paw, which is placed on a small plinth 
under a cone-shaped pusher with a rounded tip, and represents a common method for 
assessing mechanically-related pain behaviours in rodents. A major drawback of the 
Analgesymeter however is the requirement of the animal to be restrained during testing 
which may engage stress-induced analgesia mechanisms that are known to affect 
behavioural outcome measures (Bardin et al., 2009). The nature of the experiments which 
involved the injection of pharmacological agents into the paw meant that it was not practical 
to use conventional von Frey techniques for nociceptive testing. This was not an issue in 
reports by Zheng et al., 2011b and Siau et al., 2006 (Bennett and colleagues) where 
mechanical hypersensitivity following ddC (50mg/kg) treatment was assessed via the 
response rate towards a 4g and 15g von Frey hair, indicating ‘allodynia’ and ‘hyperalgesia’ 
respectively. These animals demonstrated a ~30% and ~50% response rate towards the 4g 
and 15g von Frey respectively, suggestive of a neuropathic pain-like state. This behavioural 
analysis only ascertains the presence but not the degree of mechanical hypersensitivity. Such 
methods have been used to assess pain-like behaviours in ddC, d4T, and ddI models using 
10, 27.5, and 75.8 mN von Frey hairs, obtaining similar results (30-40% response rate) 
(Joseph et al., 2004). Although it is to be noted that hyperalgesia and allodynia are terms 
used to describe pain in humans and cannot be extrapolated to infer evoked or spontaneous 
pain in rats since there are no tools that can actually measure pain in rodents. Nonetheless 
these behavioural assessments only further reinforce the neuropathic nature of the model. 
Recently, a study has been described using a mouse model of d4T-induced peripherial 
neuropathy, where animals develop a robust mechanical hypersensitivity (>80% drop from 
baseline) which lasts for at least 28 days (Renn et al., 2011). I believe this high level of 
hypersensitivity, which somewhat contradicts presented results, may be explained by a 
fundamental difference between the species of animal chosen for study. Although it has been 
argued the degree of behavioural hypersensitivity following trauma nerve injury are similar 
in mice and rats (Rigaud et al., 2008), this may not necessarily be the case in NRTI induced 
neuropathies where the nature of the nerve damage differs. (RANDALL and Stelitto, 1957) 
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4.3.2 Temporal profile expressions of investigative markers 
 
Tsujino et al., 2000 first reported that the immediate early gene protein ATF-3 was a reliable 
and sensitive marker for injured neurons following traumatic nerve injury. ATF-3 now 
represents one of the most commonly used markers of DRG neuronal injury. The results of 
the study indicate that there is limited expression of ATF-3 within L5 DRG following d4T 
administration. The lack of ATF-3 expression would indicate that there is no apparent 
neuronal injury; however this may not necessarily be the case. This is because the treatment 
of NRTIs to rats has previously been shown to initiate a loss of IENF density which would 
suggest a toxicity of C-fibres and a degenerative process (Calvo et al., 2012a;Wallace et al., 
2007b). This toxicity may not be sufficient to induce ATF-3 expression in the DRG. Since 
there is an apparent toxicity to peripheral nerve fibres, investigations examined if there were 
evidence of axonal regeneration. There was no upregulation of the axonal regeneration 
marker GAP-43 (Schreyer and Skene, 1991) in the L5 DRG. This observation ties in with 
the lack of ATF-3 expression, a marker closely related to the regenerative process and the 
expression of GAP-43. Although the lack of GAP-43 does not rule out the possibility of a 
regenerative process since other growth associated proteins may be involved e.g. small 
proline rich protein 1A (SPRR1A), which is the case in trauma injury models (Seijffers et 
al., 2007;Starkey et al., 2009). The neuropeptides NPY and galanin which are upregulated in 
trauma models (Ma and Bisby, 1997;Ma and Bisby, 1998), did not exhibit any changes in 
their expression following treatment with d4T, even during peak mechanical 
hypersensitivity. The biochemical changes that occur in the DRG following peripheral nerve 
injury appear to be related to nerve trauma and not necessarily mechanical hypersensitivity 
since such reflex behaviours are apparent in the NRTI models where there is nerve damage 
but no such biochemical changes in the DRG. A similar argument can be made for the spinal 
microglial response that occurs following nerve trauma, which is not apparent in ddC treated 
animals (Blackbeard et al., 2012;Zheng et al., 2011a). 
 
A previous study conducted by Wallace et al., 2007b using the ddC model analyzed the 
expression of pathological markers of immune cells known to be expressed in the sciatic 
nerve/DRG following traumatic nerve injury. The study reported no sciatic nerve 
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macrophage infiltration or DRG expression of ATF-3 and the neuropeptides NPY & galanin 
(21 days following initial injection). However an increase in the expression of CCL2 and 
CD68 were reported. Recently, there has been increasing interest on the role of CCL2, which 
is involved in macrophage recruitment, but can also stimulate nociceptors, and therefore 
suggestive of a role in pain modulation (Sun et al., 2006;Zhang and De Koninck, 2006). 
Under naïve conditions, within the DRG, CCL2 is constitutively expressed in small-medium 
diameter neurons (Tanaka et al., 2004) of the peptidergic class (Dansereau et al., 2008). 
However, following nerve injury CCL2 is upregulated  in both damaged and undamaged 
primary sensory neurons (White et al., 2005b). The reported upregulation of CCL2 in ddC 
treated animals may be linked to the macrophage infiltration. CD68 (also known as ED-1) is 
protein that is expressed on the cell surface of macrophages and is commonly used to 
identify them in immunohistochemistry studies. The upregulation of CD68 in ddC treated 
animals indicates macrophage recruitment which is a likely consequence of the CCL2 
upregulation. Indeed this is the case following trauma nerve injury, where the release of 
CCL2 from the DRG (Morin et al., 2007) can initiate the recruitment of resident 
macrophages by acting on the CCR2 receptor expressed on macrophages (Perrin et al., 
2005). Taken together, the results from the current and previous studies indicate that other 
mechanisms are responsible for the development of pain like behaviour in ATN.   
 
4.3.3 Mechanisms regarding NRTI toxicity and associated pain behaviours 
 
There is a large body of evidence in both human and animal model studies implicating 
mitochondrial toxicity as a main mechanism regarding ATN. (Brinkman et al., 
1999;Fleischer et al., 2004;Lehmann et al., 2011;Zhu et al., 2007). Mitochondrial activity 
plays an important role in cells, providing energy in the form of adenosine triphosphate 
(ATP). Antiretroviral drugs can alter mtDNA content, or fidelity of DNA synthesis via 
inhibition of DNA polymerase γ by incorporation into newly synthesized strands or by 
causing chain termination thus leading to mitochondrial dysfunction (Lewis et al., 2003). It 
is likely that all downstream effects are a result of this primary toxicity. The NRTI-induced 
mitochondrial dysfunction is associated with apoptosis, and draws parallels with other drug 
induced neuropathies involving mitochondrial dysfunction (e.g. cancer chemotherapy 
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agents: vincristine, cisplatin, paxlitaxel), and metabolic diseases (e.g. diabetes), indicating 
possible shared mechanisms. Sustained exposure to antiretrovirals can result in oxidative 
stress (Opii et al., 2007) which may result in reduced ATP production, and an increased 
amount of reactive oxygen species (ROS) and nitric oxide in neurons. Mitochondria-
dependent apoptosis is known to be initiated by a number of factors that include ROS, 
ceramide, and nitric oxide (Kirkland et al., 2002), which results a release in cytochrome c 
and the eventual formation of a complex involving apoptotic protease activity factor-1 and 
caspase-9, leading to the activation of downstream caspases (Nomura, 2004). Inhibitors of 
caspase 1,2,8, and 9 have all been shown to attenuate mechanical behavioural 
hypersensitivity associated with ddC (and vincristine) treatment, thus demonstrating a link 
between apoptosis and neuropathic pain-like behaviour (Joseph and Levine, 2004). The 
increased ROS as well as activation of apoptotic pathways may also exacerbate pain 
behaviours by altering GABAergic transmission in the spinal cord, which can occur 
following peripheral nerve injury  (Yowtak et al., 2011). Indeed, the removal of ROS by 
scavengers (e.g. tempol) has been shown to reverse mechanical hypersensitivity in ddC 
treated animals (Zheng et al., 2011b), which further supports an important role of ROS 
systems in ATN related pain.  The increase in ROS might be explained by a decrease in 
endogenous superoxide dismutase-2 (SOD-2) that is additionally observed following ddC 
treatment. SOD-2 plays an important role in regulating ROS by binding to superoxide by 
products of the mitochondrial electron transport chain, converting them to hydrogen 
peroxide and oxygen. Failure of SOD-2 to remove the superoxide by products leads to an 
increase in mitochondrial ROS (Melov et al., 1998). The rise in ROS maybe countered by 
inhibitors of the mitochondrial electron transport chain complexes I, II, III, IV, and V, all of 
which have been shown to attenuated neuropathic pain-related behavior in rats (Joseph and 
Levine, 2004). Mitochondrial related apoptosis may also be activated via tumor necrosis 
factor (TNFα) (Micheau and Tschopp, 2003) and has been shown to be upregulated in DRG 
and spinal cord following NRTI treatment (Zheng et al., 2011c). TNFα has previously been 
described to contribute towards peripheral pain mechanisms (Joseph and Levine, 
2004;Schafers et al., 2003b;Schafers et al., 2003c). The acute administration of a soluble 
TNFR1 to scavenge TNFα can temporarily reduce mechanical hypersensitivity (effects 
lasting 1-4 hours) (Zheng et al., 2011c). The Mitochondria is an important regulator of 
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neuronal intracellular calcium concentrations (Svichar et al., 1997). Chronic exposure of ddC 
(7 μM)  to DRG cultures results in altered mitochondrial-related calcium homeostasis (Werth 
et al., 1994). These observations mirror experiments by Keswani et al., 2003a where ddC, 
ddI, and d4T (10 μM) treated cultures initiated a reduction in the mitochondrial membrane 
potential differential that was partially reversed by FK-506 - an inhibitor of calcineurin; a 
protein sensitive to intracellular calcium concentrations. This observation is suggestive of 
abnormal calcium buffering, further highlighted by Joseph et al., 2004, which demonstrated 
a reduction in ddC-induced mechanical hypersensitivity following administration of calcium 
buffers TMB-8 and Quin-2.  
 
Electrophysiological experiments have revealed that d4T treated mice (after 3 days) exhibit 
higher numbers of action potentials per second in WDR spinal neurons upon stimulation 
with brush, pressure, and noxious pinch (Renn et al., 2011). Alterations in the distribution of 
interspike intervals (ISIs) of C-fibres in ddC-treated rats during suprathreshold stimulus have 
been observed with increased percentages of ISIs between 0.1 and 0.3 seconds (Joseph et al., 
2004). Such changes in firing properties may transcend into exacerbated nociception or pain 
responses.  
 
The induction of pain-related behaviours in d4T treated animals may be in part related to an 
increase of BDNF growth factor in the superficial dorsal horn that is observed at 1, 3 and 7 
days post injection, (that returns to control levels by day 14) (Renn et al., 2011). BDNF is a 
known modulator of sensory transmission, acting on the trkB receptor, and plays a key role 
in central sensitization (Pezet and McMahon, 2006). The sequestering of BDNF by 
intrathecal treatment of trkB-Fc attenuates the d4T associated mechanical hypersensitivity 
(effect lasting 24 hours) (Renn et al., 2011).  
 
In summary, many potential mechanisms may contribute to NRTI-related neuropathic pain 
that may explain the behavioural observations in the current study. These include defects in 
mitochondrial function, production of ROS, and alterations in calcium homeostasis. The pre-
existing HIV infection in affected individuals may only serve to exacerbate the effects of 
NRTIs (Keswani et al., 2006;Wallace et al., 2007b). The possibility of genetic susceptibility 
  
208 
 
 
and environmental factors cannot be excluded, and has been proposed as factors that can 
influence the quality of the pain (Young et al., 2012) that maybe relevant in ATN. For 
instance, known polymorphisms in the gene encoding mitochondrial SOD-2 affect its 
activity (Pociot et al., 1993). Another example is alcohol abuse, a common incidence in 
acquired immunodeficiency syndrome (AIDS) patients (Welch, 2000) that can increase pain, 
and is associated with abnormal primary afferent function (Ferrari and Levine, 2010). 
 
4.3.4 Limitations and future studies 
 
The current study only examined mechanical behavioural hypersensitivity following d4T 
treatment and thermal nociception was not evaluated. There have been conflicting reports 
regarding the onset of thermal hypersensitivity in the ATN model. Joseph et al., 2004 
demonstrated thermal hypersensitivity in ddC-treated rats at 5 days post injection (~50% 
decrease from baseline). In contrast, Renn et al., 2011 observed a trend towards thermal 
hypersensitivity in d4T-treated mice over a 28 day period; however there were no significant 
difference in PWLs when compared to the saline controls. These findings are shared by 
Wallace et al., 2007 indicating that thermal hypersensitivity is not a significant consequence 
of NRTI treatment. This view is consistent with clinical data showing that patients with 
HIV-related pain do not usually present with thermal hypersensitivity (Martin et al., 2003). 
Nevertheless it would be worth perusing whether there is thermal hypersensitivity associated 
with d4T in rats, rather than in mice, which has been the common species of choice 
regarding ATN modeling. A possible drawback of the study is other tissues (e.g. sural & 
sciatic nerve, spinal cord, and paw skin) were not examined. Sural nerve biopsies from 
patients with ddC-neuropathy have shown severe axonal destruction, prominent in 
unmyelinated fibres (Lewis and Dalakas, 1995). This could be examined in d4T treated rats 
via immunohistochemical staining of β-amyloid precursor protein (β-APP) - an axonal injury 
marker that accumulates in the axon (Medana and Esiri, 2003). Moreover, the extent of any 
morphological damage observed can be correlated to the loss of small fibres observed in paw 
skin (Wallace et al., 2007b). The study could additionally be improved by investigating the 
expression profiles of other markers that have been implicated in ATN, particularly CCL2, 
which is upregulated in the DRG following ddC treatment (Wallace et al., 2007b). 
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Macrophage recruitment in the DRG of ddC treated animals (Wallace et al., 2007b) could be 
further investigated by characterizing CD-68 expression over time and could be correlated 
with the CCL2 expression. Since TNFα is found in the spinal cord of ddC treated animals 
(Zheng et al., 2011c), it would be interesting to investigate similar events in DRG, especially 
given the presence of macrophages, that can release TNFα (Holguin et al., 2004), thus 
altering the excitability of neurons (Schafers et al., 2003b).  
 
4.3.5 Conclusion 
 
In this chapter, I examined the effect of d4T induced nerve injury on the development of 
mechanical hypersensitivity and have characterized the temporal profile expressions of 
markers known to be dysregulated after nerve injury in the L5 DRG. Rats treated with d4T 
demonstrated mechanical hypersensitivity indicating a pain-like state but did not 
demonstrate any evidence of injury (ATF-3 expression) or nerve regeneration (GAP-43) in 
the DRG. Furthermore, there were no changes in the expression of the neuropeptides galanin 
and NPY. The results of this study therefore suggest that other mechanisms are responsible 
for ATN.  
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Chapter 5 
 
5 Evaluation of hind paw sensory behaviour and the DRG macrophage response 
following chronic administration of docosahexaenoic acid (DHA) in an animal 
model of TNT induced peripheral nerve trauma  
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5.1 Introduction 
 
5.1.1 PUFAs 
   
Poly unsaturated fatty acids (PUFAs) are fatty acids that contain more than one double bond 
in their chemical composition and are structural components and main constituents of cell 
membranes (Yaqoob and Calder, 2007). PUFAs are categorised according to the position of 
the first double bond from the n-terminal of the molecule (Shapiro, 2003). There are 
different types of PUFAs that includes the methylene-interrupted (i.e.  ω-3, ω-6, and ω-9 
fatty acids) and conjugated fatty acids (e.g. rumenic acid, calendic acid),  but the most 
frequently described fatty acids in the literature are the ω-3 fatty acids due to its associated 
health benefits and the ω-6 fatty acids due to its negatively associated health effects (Holub 
and Holub, 2004). High concentrations of the ω-6 PUFAs linoleic are (18:2n-6)2 are found in 
vegetable oils (e.g.  corn, sunflower and soybean), and is required for the production of 
arachidonic acid which is present in phospholipids of cell membranes. The activity of ω-6 
PUFAs such as arachidonic acid (AA) are considered to be proinflammatory whereas ω-3 
PUFAs such as eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) have anti-
inflammatory properties. The ω-3 PUFAs  EPA (20:5n-3), DHA (22-:6n-3), and α linolenic 
acid (ALA 18:3n-3), are all major constituents of fish oil and are essential components of the 
human diet that must be ingested since the body cannot synthesize them de novo, and are 
required for good health. For example, DHA is required for the normal function of nervous 
tissue, and modulates an array of biochemical and cellular processes including gene 
expression and neuronal growth and survival (Kitajka et al., 2004). High concentrations of 
DHA are found in the retina where it aids in photoreceptor biogenesis (Scott and Bazan, 
1989). 
 
The ω-3 PUFAs are likely to be beneficial in the prevention and management of various 
human inflammatory conditions including joint pain, irritable bowel syndrome (IBS), and 
                                                        
2 (x:an-6) x= number of carbon atoms, a= number of double bonds, n= position of first double bond from 
methyl end of fatty acid molecule 
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coronary artery disease (Goldberg and Katz, 2007). The the improved health outcomes 
regarding ω-3 PUFAs may be attributed to the neuroprotective and anti-inflammatory 
effects. Such properties have  been well documented especially in pre clinical studies, most 
notably in the stroke field (Bazan, 2005;Bazan, 2006;Bazan, 2007) and spinal cord injury 
(SCI) field (Huang et al., 2007;King et al., 2006;Ward et al., 2010).  
 
5.1.2 Anti-inflammatory and neuroprotective actions of ω-3 PUFAs 
 
Brain ischemia-reperfusion injury is often used as a model of stroke (Carmichael, 2005). 
Such injury in rats triggers the release of DHA from the membrane (Yoshida et al., 1984), 
which possibly acts to reduce inflammation since the exogenous administration of DHA to 
brain ischemia-reperfusion treated rats is associated with a reduced inflammatory response 
(Pan et al., 2009). Other ω-3 PUFAs such as ALA (i.v) administered either before or after a 
global ischemic insult have been shown to significantly reduce neuronal death (indicated by 
increased density of cresyl violet stained hippocampal sections) (Blondeau et al., 
2002;Lauritzen et al., 2000). The intravenous administration of mixed ω-3 PUFAs has been 
shown to inhibit age related apoptosis of cortical neurons in rats (Martin et al., 2002). The 
anti-inflammatory properties of DHA may be further enhanced by the production of 
metabolites such as resolvins and neuroprotectin D1 (NPD1) which have even greater anti-
inflammatory properties and these compounds are present in the resolving phase of 
inflammation (Serhan et al., 2008).  
 
Resolvins 
 
Resolvins were first identified in the exudates of mice that had been administered aspirin and 
DHA (Serhan et al., 2008), and have been subsequently shown to exhibit potent anti-
inflammatory and pro-resolution actions. DHA and EPA are metabolized by P450 
cytochrome enzymes in the liver, as well as lipoxygenase and cyclooxygenase-2 (COX-2) to 
form D and E series resolvins respectively (Figure 5.1) (Arnold et al., 2010). The 
intraplantar or intrathecal administration of resolvin D1 (or E1) in mice potently reverses the 
reduction in paw withdrawal thresholds (PWTs) induced by intraplantar injection of 
  
213 
 
 
formalin, carrageenan, or complete Freund's adjuvant, without affecting basal thresholds (Xu 
et al., 2010). This observation may be explained by the decreased production of the 
proinflammatory cytokines TNFα and IL-1β in the rat hind paw associated with resolvin D1 
administration (Hong et al., 2003;Lima-Garcia et al., 2011). Resolvin D1 has also been 
shown to inhibit neutrophil infiltration in a dose dependent fashion (at nanogram doses) in a 
mouse model of peritonitis (Sun et al., 2007). Resolvin D1 can initiate CCR5 expression in 
dying neutrophils (Ariel et al., 2006), and this receptor expression helps clear up the 
proinflammatory ligands of CCR5 (CCL3 and CCL5) from the inflammatory site.  
 
 
 
Figure 5.1 DHA is metabolised by 15-lipoxygenase action or acetylated COX-2 to form 
intermediate 17S- or 17R-H (p)DHA. Subsequent processing through epoxide intermediates 
leads to the formation of 17S-resolvins D1–D4 (15-lipoxygenase  pathway) and 17R-
Resolvins D1–D4 (aspirin-triggered acetylated COX-2 pathway) respectively. Image 
reproduced from Weylandt et al., 2012. (Weylandt et al., 2012)  
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Neuroprotectin D1 
 
The metabolism of DHA via lipoxygenase leads to the formation of NPD1 (see Figure 5.2) 
(Niemoller et al., 2009). NPD1 was first discovered in a human retinal pigment epithelial 
cell line following oxidative stress where it was associated with neuroprotection (Mukherjee 
et al., 2004). Research by Bazan and collagues have identified NPD1 as a compound that has 
both potent anti-inflammatory and neuroprotective properties (Bazan, 2005;Bazan, 
2009;Belayev et al., 2009). For example, NPD1 has been shown to inhibit T cell migration 
into the peritoneum in a model of zymosan A induced murine peritonitis (Ariel et al., 2005). 
Leucotriene B4 induced neutrophil migration in human microvascular endothelial cells has 
also been shown to be inhibited by NPD1 (Serhan et al., 2006). NPD1 has additionally been 
shown to inhibit apoptotic DNA damage, upregulate anti-apoptotic, and downregulate pro-
apoptotic proteins, as well as bind toxic peroxides (Bazan, 2006;Bazan, 2007;Mukherjee et 
al., 2004). Previous experiments in rats have shown that NPD1 is present in the hippocampus 
at least 1 hour following middle cerebral artery occlusion (MCA-O) injury (1 hour 
occlusion, 2 hour reperfusion) in mice, and is still present even at 25 hours post injury 
(Marcheselli et al., 2003). Following brain ischemia injury, DHA is released from the cell 
membrane (Yoshida et al., 1984) and is metabolized into NPD1 (Marcheselli et al., 2003). It 
is possible that a similar process occurs after peripheral nerve injury and the intravenous 
administration of DHA may lead to further production of NPD1 which can act to minimize 
inflammation, ensuring a suitable environment for neuronal survival. The mechanism behind 
the anti-inflammatory actions is thought to be the inhibition of NFκB and COX-2 
expression, which has been demonstrated in cultured human neural progenitor cells and in 
the hippocampus of MCA-O rats (Marcheselli et al., 2003).  
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Figure 5.2 An illustration of NPD1 biosynthesis: DHA is hydrolyzed by phospholipase A2 
(PLA2) where it undergoes lipoxygenation, followed by epoxidation, and then hydrolysis to 
generate NPD1.  Image reproduced from Serhan et al., 2004. (Serhan et al., 2004). 
 
Neuroprotection in SCI 
 
Traumatic injury of the spinal cord leads to apoptosis of both neuronal and glial cells and 
degeneration of ascending and descending tracts. The collective effects of the injury leads to 
the development of mechanical and thermal hypersensitivity in the hind paws (Bruce et al., 
2002;Christensen et al., 1996). The acute administration of DHA (i.v) following SCI (within 
30 minutes) has been associated with improved locomotion (from day 4 up to cessation of 
the study - 6 weeks) (Huang et al., 2007). Moreover, improvements in the level of oxidative 
stress, neuronal survival, and histological outcomes, including reduced inflammatory 
responsiveness, axonal injury, and cavity formation were observed. The acute administration 
of DHA (i.v.) also reduces axonal dysfunction, (indicated by a reduced accumulation of β-
amyloid precursor protein compared to saline controls) in the spinal dorsal columns (Ward et 
al., 2010). Histological outcomes were additionally improved with the combination of an 
acute DHA injection and an enriched DHA diet (Huang et al., 2007). Taken together, the 
results of these studies indicate that DHA is neuroprotective following nerve injury. Since ω-
3 PUFAs have been shown to be both anti-inflammatory and neuroprotective in a variety of 
nerve injury models (Bazan, 2007;Belayev et al., 2009;Gladman et al., 2012;Huang et al., 
2007;Ward et al., 2010), it raises the possibility that they could have therapeutic potential in 
peripheral neuropathic pain conditions. 
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5.1.3 ω-3 PUFAs in neuropathic pain 
 
Few studies have investigated the effects of ω-3 PUFAs on outcome measures of 
neuropathic pain in rodents. In a rat model of trigeminal neuralgia which involved chronic 
constriction of the infraorbital nerve, a diet enriched with linoleic acid was able to delay (for 
up to 2 weeks post nerve injury) the development of facial mechanical hypersensitivity 
associated with this type of nerve injury (Martin and Avendano, 2009). Although the injury 
induced mechanical hypersensitivity was not prevented, the delay in its development could 
be attributed to the neuroprotective effects of the ω-3 PUFAs. A previous study has indicated 
that the consumption of corn and soy fats (containing both ω-3 and ω-6 PUFAs) suppresses 
the level of hind paw mechanical and thermal hypersensitivity associated with partial sciatic 
nerve injury (Perez et al., 2004). However, a similar study within the same research group 
later concluded that ω-3 fatty acids may be associated with increased neuropathic ‘pain-like’ 
behaviours in sciatic nerve injured rats (Heller et al., 2006;Perez et al., 2005). Such 
observations may be explained by a compromised methodology that did not account 
specifically the composition of the various oils examined (i.e. canola, corn, hemp, soy, and 
sunflower oil), all of which differ in their ω-3 and ω-6 PUFA content. This consideration is 
important, given the proinflammatory effects of ω-6 PUFA (Serhan et al., 2008); although 
the actual ratio of ω-3 to ω-6 PUFAs is the crucial factor (Russo, 2009). EPA and DHA both 
compete with AA as a substrate for COX-2 and lipoxygenase. These enzymes are 
responsible for the formation of important biological mediators such as prostaglandins and 
protacyclins (Funk, 2001). If the concentration of ω-3 PUFAs increases in the membrane, 
this can lead to a reduction in synthesis of inflammatory eicosanoids, which has been 
demonstrated in glial cells in vitro (Petroni et al., 1994). Therefore it is possible that the 
effects of high ω-6 PUFAs could be overcome via a larger porportion/concentration of ω-3 
PUFAs present in vivo since they compete for the same enzymes (Shapiro, 2003).  
 
A recent transgenic study has demonstrated that mice expressing the fat-1 gene (encoding for 
ω-3 fatty acid desaturase) have increased endogenous ω-3 PUFAs (and a concomitant 
decrease in ω-6 PUFAs) that is associated with an accelerated improved outcome measures 
of sensory behavioural testing 7 days after sciatic nerve crush injury (Gladman et al., 2012). 
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The injury-induced expression of neuronal injury marker activating transcription factor-3 
(ATF-3) was also decreased in the DRG of fat-1 mice (Gladman et al., 2012). DRG cultures 
taken from fat-1 mice have demonstrated neuroprotection following mechanical strain or 
hypoxic injury (Gladman et al., 2012). In addition to the neuroprotection, DHA may 
encourage growth of neurons. Cultured DRG neurons when treated with DHA has been 
shown to increase neurite outgrowth, length of outgrowth, and the number of neurons with 
growth cones (Robson et al., 2010). In addition, the amplitude of the effects was comparable 
to that of nerve growth factor (NGF) and even greater in EPA treated cultures. In another 
study using cultured cortical neurons from rat pups, significant increases in the percentage of 
neurite outgrowth was associated with an increase in the level of growth associated protein-
43 (GAP-43) immunoreactivity upon treatment with DHA (Cao et al., 2005). Following 
peripheral nerve trauma there may be a loss of NGF from neurons and thus trophic support 
leading to a rise in neuropeptide expression (Averill et al., 2004;Verge et al., 1995). Since 
NGF is a well known regulatory factor of DRG neuropeptide expression and ATF-3, and can 
reduce their expression (Averill et al., 2004;Verge et al., 1995), their effects could be 
mimicked by DHA administration. Collectively this evidence suggests that DHA may reduce 
nerve damage (ATF-3 expression) associated with trauma injury and aid in the regenerative 
process that may have beneficial consequences in neuropathic pain.  
 
5.1.4 DHA regulation of the macrophage inflammatory response 
 
Data from in vitro experiments supports a dose dependent inhibition of 
IFNγ/lipopolysaccharide (LPS) stimulated macrophage activation when exposed to DHA 
(Ajmone-Cat et al., 2011;Dustin et al., 1990;Lu et al., 2010). This inhibition is associated 
with a reduction in NFκB activation, and the secretion of IL-1β, TNFα, and IL-6, all key 
cytokines involved in the inflammatory response (Mullen et al., 2010;Oliver et al., 2012). 
The reduction of proinflammatory cytokine release from stimulated macrophages has also 
been observed in animals administered DHA through diet supplementation – investigations 
by Lokesh et al., 1988 reported a reduction in the synthesis of leukotrienes (C4 and B4) and 
prostaglandins (E2 and F1α) following a diet containing 0.5% wt of EPA, DHA, and 
linolenic acid. A previous  in vivo study demonstrated a reduction in the release of  IL-6 
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from peritoneal macrophages in mice (Shi and Pestka, 2009).  Such anti-inflammatory 
properties have been demonstrated in Alzheimer disease patients treated with DHA 
(1700mg) –  these patients demonstrated a reduction in IL-1β, IL-6, and granulocyte colony-
stimulating factor from peripheral blood mononuclear cells (PBMCs) (Vedin et al., 2008). 
The mechanism by which DHA inhibits macrophage activation is thought to occur via the 
non-covalent binding to the peroxisome proliferator-activated receptors (PPARs) (Forman et 
al., 1995). PPARs are ligand activated transcription factors involved in the regulation of 
biological processes including lipid and glucose metabolism, and overall energy homeostasis 
(Stienstra et al., 2007). PPARs can form heterodimers with the retinoic-x-receptor (RXR) 
(Abdelrahman et al., 2005) which additionally binds DHA (de Urquiza et al., 
2000;Lengqvist et al., 2004), and may also be involved in regulating the inflammatory 
response (Chung et al., 2000). Of interest is the PPARγ isoform that is expressed in adipose 
tissue but also on monocytes/macrophages (Braissant et al., 1996). This isoform is involved 
in regulating the production of proinflammatory mediators (e.g. TNFα and IL-1β) (Jiang et 
al., 1998) by interfering with the binding of transcription factors including STAT, NF-κB, 
and activating protein-1 (AP-1) (Ricote et al., 1998). In addition, activated PPARγ can 
interact directly with NFκB, preventing its translocation to the nucleus (Vanden Berghe et 
al., 2003), or indirectly by stimulating the expression of the inhibitory protein IκBα, which 
reduces the effect of NF-κB, leading to suppression of NF-κB DNA-binding activity 
(Delerive et al., 2000).  
 
There is evidence to support that DHA is more potent than EPA. The pretreatment of LPS 
stimulated macrophages with 100 mM of EPA and DHA can significantly decrease TNFα, 
IL-1β, and IL-6 production compared to control cells, with a more profound effect observed 
in macrophages treated with DHA (Weldon et al., 2007). In a separate study also using LPS 
stimulated macrophages pretreated with EPA or DHA (50 μM for 5 days), there was an 
enhanced secretion of the anti-inflammatory cytokine IL-10 and reduced expression of the 
‘proinflammatory’ M1 macrophage phenotype (Oliver et al., 2012). In light of this evidence, 
and the accumulative evidence regarding neuroprotection in SCI, I hypothesized whether 
DHA could modulate the macrophage response following peripheral trauma nerve injury.  
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5.1.5 Aim of experiments 
 
 Investigate whether the administration of DHA (i.v.)3 at and every 3 days4 post TNT 
injury can reverse the development of mechanical hypersensitivity associated with 
such injury within a 4 week period.   
 
 Determine if DHA can modulate macrophage infiltration in the L5 DRG following 
TNT injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
3
 The intravenous route was taken because this route ensured maximum bioavailability and therefore maximum 
exposure of DHA to the injured tibial nerve.  
 
4
 The 3 day administration regime was deemed optimal since this was an appropriate time frame for the tail 
vein to recover while additionally reducing the stress on the rats, and ensuring the stability of plasma DHA 
levels. 
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5.2 Results  
 
DHA (500 nmol/kg) or saline (0.9%) was administered through the tail vein 30 minutes 
following TNT injury and every 3 days thereafter until day 28 when animals were culled. 
Figure 5.3 indicates the breakdown of the total number of animals used in the study and 
explanations of the relevant exclusions.   
 
 
 
 
 
 
 
Figure 5.3 Breakdown of the total number of animals used within the study. All animals 
(n=18) underwent TNT surgery and were divided into two groups: DHA treated (n=9) and 
saline treated groups (n=9). All animals were checked post mortem to identify transection of 
tibial nerve with aid of a dissecting microscope. A total of three animals were excluded from 
the study due to anaesthetic overdose (n=2) and inability to demonstrate ≥30% drop in 
baseline at any point within the 28 day behavioural testing period following TNT injury 
(n=1).  
 
 
Rats undergoing TNT 
surgery: (n=18) 
DHA treated group: (n=9) 
 
Saline treated group: 
(n=9) 
 
Final DHA treated group 
size: (n=8) 
 
Exclusions 
 
(n=1) Anaesthetic related 
death 
Final saline treated 
group size: (n=7) 
 
Exclusions 
 
(n=1) Anaesthetic related death 
 
(n=1) Mechanical 
hypersensitivity not evident 
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5.2.1 Effect of DHA on hind-paw mechanical sensory testing 
 
Behavioural sensory testing in the mid-plantar paw was conducted using an electronic von 
Frey device every 7 days post injury (Figure 5.4). Following TNT injury, there were no 
significant differences regarding ipsilateral mechanical hypersensitivity between DHA (n=8) 
and saline (n=7) treated animals over the 28 days (analyzed using a one way ANOVA and 
Tukey’s post hoc test). Saline and DHA treated animals exhibited baseline PWTs of 44.3 ± 
3.8 g and 44.9 ± 3.1 g respectively. No differences in PWTs were observed with respect to 
baseline 7 and 14 days post surgery in both groups. From at least 21 days following TNT 
injury, animals treated with DHA exhibited significant differences in mechanical 
hypersensitivity with respect to baseline values (p<0.05). The PWTs at 21 and 28 days post 
TNT injury in DHA animals were 28.3 ± 3.1 g (↓34.5 ± 6.8%) and 20.8 ± 1.5 g (↓51.1 ± 
4.2%) respectively. Saline treated TNT animals exhibited significant mechanical 
hypersensitivity 28 days following surgery with respect to baseline, 30 ± 0.1 s (↓43.6 ± 
8.1%) (p<0.05).  
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Figure 5.4 Mechanical behavioural responses using an electronic von Frey device over a 28 day 
period following TNT injury in DHA/saline treated rats. (A) Mean ipsilateral paw withdrawal 
latencies and (B) percentage change from baseline.*P<0.05 vs. baseline value using one way 
ANOVA followed by Dunnett’s test. A one way ANOVA followed by a Tukey’s test revealed no 
significant differences between DHA and saline treated animals on respective days.  
  A                  
 
         
  B                  
 
         
 * 
 * 
 * 
  * 
  * 
  * 
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5.2.2 Effect of DHA on hind-paw thermal sensory testing 
 
Behavioural sensory testing in the heel of the paw was conducted using a Hargreaves device 
every 7 days post injury. Following TNT injury, there were no significant differences 
regarding thermal paw withdrawal latencies between DHA and saline treated animals over 
the 28 day testing period (analyzed using a one way ANOVA and Tukey’s post hoc test) (see 
Figure 5.5). Saline and DHA treated animals exhibited baseline PWLs of 11.0 ± 1.0 s and 
8.2 ± 0.7 s respectively. At day one post TNT surgery saline and DHA treated animals 
exhibited PWLs of 13.2 ± 1.7 s and 10.9 ± 1.2 s respectively. At 7 days post TNT surgery 
saline and DHA treated animals exhibited PWLs of 9.7 ± 1.2 s and 7.8 ± 1.1 s respectively. 
At 14 days post TNT surgery saline and DHA treated animals exhibited PWLs of 7.7 ± 0.8 s 
and 6.6 ± 0.7 s respectively. At 21 days post TNT surgery saline and DHA treated animals 
exhibited PWLs of 10.2 ± 1.1 s and 7.3 ± 0.8 s respectively. At 28 days post TNT surgery 
saline and DHA treated animals exhibited PWLs of 8.9 ± 0.9 s and 7.0 ± 0.6 s respectively. 
There were no significant differences in post operative PWL values when compared to 
respective baseline in both DHA and saline treated TNT injured rats (analyzed using a one 
way ANOVA followed by Dunnett’s test post hoc test).   
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Figure 5.5 Thermal behavioural responses using a Hargreaves device over a 28 day period following 
TNT injury in DHA/saline treated rats. (A) Mean ipsilateral paw withdrawal latencies and (B) 
percentage change from baseline. A one way ANOVA with a Dunnett’s test revealed no significant 
differences between baseline and post injury PWLs. A one way ANOVA with a Tukey’s test 
revealed no significant differences between DHA and saline rats on respective days. 
  B                  
 
         
  A                  
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5.2.3 ED-1 labeling in the ipsilateral L5 DRG 
 
Macrophages can be identified immunohistochemically via the cell surface marker ED-1. 
The labeling pattern of ED-1was similar amongst DHA and saline treated rats 28 days post 
TNT injury (Figure 5.6A and B). In addition the macrophage morphology/labeling pattern 
was consistent with what is commonly observed after nerve trauma injury – a change into an 
amoeboid shape (Calvo and Bennett, 2012). There were no significant differences regarding 
the mean density of ED-1 immunoreactivity (per 250,000μm2) in the ipsilateral L5 DRG of 
rats treated with DHA or saline at 28 days post TNT injury. The mean density of ED-1 
immunoreactivity in DHA treated rats was 0.12 ± 0.03 μm2 compared to 0.15 ± 0.03 μm2 in 
saline controls (see Figure 5.6C).  
 
Figure 5.6 Representative images of ED-1 immunohistochemistry (macrophage marker) in 
TNT injured animals treated with (A) Saline and (B) DHA. Quantification of ED-1 was 
calculated via the mean percentage area per 250,000μm2 (C). Data presented as mean ± 
SEM. Magnification was at x20, and scale bar indicates 50μm. TNT Rats treated with DHA 
did not differ in the amount of ED-1 immunohistochemistry in the L5 DRG when compared 
to saline treated TNT rats indicating a lack of an effect on macrophage infilation in the DRG. 
  C                  
 
            
DH
A 
  B                    DHA   A                 Saline 
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5.3 Discussion 
 
5.3.1 Effect of DHA on pain related behaviours 
 
The aim of the study was to investigate whether repeated intravenous injections of DHA 
(500nmol/kg, every 3 days) could reverse mechanical related hypersensitivity associated 
with TNT injury. The results of the study suggest that the administration of DHA in TNT 
injured animals does not affect the development of mechanical hypersensitivity associated 
with such injury. These results contrast previous studies that have demonstrated efficacy in 
reducing ‘pain’ related behaviours following intravenous administration of DHA in SCI 
(dose used 250nmol/kg)  (Huang et al., 2007;King et al., 2006). The administration of DHA 
in the TNT model has provided a different result to that observed in SCI rats. In these 
previous studies, the effect of DHA was tested at a lower dose that the dose used in the 
current study. The lack of efficacy regarding DHA inability to reverse the TNT-associated 
hypersensitivity may perhaps be indicative of a sub optimal dosage regime. Although the 
dose used in the SCI studies (250 nmol/kg) demonstrated efficacy, it is possible that high 
dose used in the current study (500 nmol/kg) was detrimental to neurons in the DRG. As an 
exploratory study, only one dose of DHA was tested which was the 500nmol/kg dose. A 
previous study has demonstrated neuroprotective effects with a single bolus dose of 
intravenous DHA (500nmol/kg) administered 30 minutes after SCI (in mice) (Lim et al., 
2010). This treatment lead to a significant increase in neuronal and oligodendrocyte survival, 
as well as a marked reduction in the microglial response (Lim et al., 2010). In another study, 
the administration of linolenic acid 3 days before global ischemic insult (6 minutes duration) 
resulted in significant reductions in neuronal death 72 hours after insult using a similar high 
dose of 500nmol/kg (Blondeau et al., 2002). These observations, in conjunction with the 
robust nature of the TNT injury supported the use of the 500nmol/kg dose regime. It appears 
that there is a level of complexity regarding DHA mediated neuroprotection which may be 
influenced by the particular dose used and the timing of administration. In a previous study, 
the pre-treatment with DHA (500 nmol/kg, i.p.) at 1 hour and 3 days, or daily for 6 weeks 
before ischemia (90 minutes MCA-O), was accompanied by decreases in blood-brain barrier 
disruption, brain oedema,  inflammatory cell infiltration, IL-6 expression, and caspase-3 
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activity in rats (Pan et al., 2009). However results from another study has demonstrated that 
the acute post treatment with DHA (500 nmols per rat (0.16 mg) i.p., 1 hour after 
reperfusion) following 90 minutes of MCA-O is associated with exacerbated cerebral 
ischemia-reperfusion injury (Belayev et al., 2009). In a similar study, using the same model 
with a 2 hour MCA-O, rats demonstrated significant neuroprotection following the 
administration of DHA-albumin after injury (Belayev et al., 2005). The lower DHA–albumin 
dose used in this study (0.63 g/kg) was highly neuroprotective, whereas the larger DHA–
albumin dose (1.25 g/kg) was not. Such results indicate that high doses of DHA 
administered following trauma nerve injury could be accompanied by worsening outcomes 
of nerve damage (i.e. lowered PWTs), although it is to be noted that there were no 
significant differences in PWTs between DHA and saline treated rats on respective days in 
my study.  The reason for the DHA related exacerbated cerebral ischemia-reperfusion injury 
reported by Belayev et al., 2009 is not entirely clear. DHA has been shown to be susceptible 
to oxidative stress in vitro, which may be a contributing factor (Cho et al., 1987). At high 
concentrations, DHA may become a substrate for lipid peroxidation essentially converting 
into a free radical which has multiple negative effects including loss of membrane fluidity, 
reduced membrane potential, and membrane rupture leading to release of intracellular 
contents (Gutteridge, 1995). Furthermore, products of DHA such as  malondialdehyde and 4-
hydroxynonenal  may initiate further oxidative damage which is equally toxic that includes 
attacking amino acid side chains in proteins  (Requena et al., 2003) and the fragmentation of 
DNA (Wang et al., 2006). It is thought that the acute administration of DHA within one hour 
of injury is a critical window for the neuroprotective effects to be observed (Huang et al., 
2007). Dietary supplementation with DHA for 1 week, without an initial acute bolus has 
been shown to be ineffective for neuroprotection in a model of SCI (Huang et al., 2007). If 
the initial dose of DHA was not effective then it is likely that subsequent doses of DHA may 
not have been effective or a much longer time frame would have been required for the 
neuroprotective effects to be observed (i.e. effect on behavioural sensory testing). There is 
limited and weak evidence from a clinical case study report to suggested that ω-3 PUFAs are 
beneficial in peripheral neuropathic pain conditions when administered over a long period of 
time (months- years) (Ko et al., 2010), however this will need to be further investigated in a 
more robust fashion. 
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A second explanation for the lack of effect reported may be related to some fundamental 
properties of the TNT model which will be herein discussed. The TNT model was chosen 
because of its advantages over the more conventional nerve trauma models (e.g. SNT, CCI) 
due to its reproducibility and ease of surgical procedure. The nature of the injury restricts 
damage to one nerve region, so that the distribution of injured and uninjured (spared) 
populations can be standardized, therefore reducing nerve injury variability amongst 
animals. While the nerve damage is considered similar amongst animals, this uniformity 
may not translate into consistent PWTs upon mechanical sensory reflex testing. In addition, 
although the tibial and sural nerve territories of the plantar paw have been identified 
(Decosterd and Woolf, 2000), there might be possible overlap of innervation territories. This 
overlap in nerve territories could mean that upon testing of the midplantar paw, the probe-tip 
of the electronic von Frey device could be in contact with the more hypersensitive sural 
nerve region, in oppose to the intended tibial nerve region, resulting in either high or low 
PWTs. Such variability in the PWTs was not immediately obvious in the initial study 
(Chapter 3: Evaluation of DRG neurochemical markers in an animal model of tibial 
nerve transection induced peripheral nerve trauma injury). It was apparent that there 
were a number of inconsistent PWTs in TNT injured rats used in this particular study. Due to 
this variability, a Kolmogorov-Smirnov normality distribution test was conducted of all raw 
PWT’s in DHA/saline treated rats (Table 5.1): 
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 Baseline Day 1  Day7 Day 14 Day 21 Day 28 
DHA  
1       
2       
3       
4       
5       
6       
7       
8       
Saline 
 
1       
2       
3       
4       
5       
6       
7       
 
Table 5.1 Indication of normal distribution regarding PWTs in TNT rats treated with 
DHA/saline at baseline and at various time points post surgery following a Kolmogorov-
Smirnov normality test. Normality was calculated for each animal using raw data values – 10 
at baseline and 5 post surgery. 7.8% of data points failed to exhibit normal distribution; () 
passed (p>0.05); () failed (p<0.05). 
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The results of the normal distribution indicate that the majority of data points fitted a normal 
distribution (92.2%), and therefore I can conclude that the nature of the nerve injury was not 
likely to influence sensory reflex testing thresholds. Further discussion regarding the 
Kolmogorov-Smirnov normality distribution test is provided in the general discussion with 
comparisons to the TNT animals used in Chapter 3. The comparisons between the two sets 
of data are an important quality control step given that the same model was used for both 
studies.   
  
5.3.2 Macrophage infiltration in the ipsilateral L5 DRG 
 
The other aim of the study was to investigate whether DHA administration could modulate 
the macrophage response in the L5 DRG following TNT injury. Since DHA administration 
did not alter TNT induced mechanical hypersensitivity, key biochemical markers (i.e. ATF-
3, GAP-43, NPY, and galanin) were not evaluated.  Following traumatic peripheral nerve 
injury, Wallerian degeneration takes place; distal axons degenerate, Schwann cells 
differentiate, and macrophages become activated (Stoll et al., 1989). Activated macrophages 
will aid in the clearance of debris via phagocytosis at the site of injury and their presence 
normally contributes towards the healing and repair of injured tissue, returning it to a normal 
physiological state (Perry et al., 1987;Scholz and Woolf, 2007). However, macrophages also 
co-ordinate an immune response releasing proinflammatory mediators such as cytokines, and 
interleukins (Scholz and Woolf, 2007). The infiltration of macrophages into the DRG is 
associated with the development of behavioural paw mechanical  hypersensitivity (Coyle, 
1998;Liu et al., 2000b). The ED-1 antibody identifies CD68; a marker present on the surface 
of macrophages, and can be used to label macrophages in nerve tissue (Coyle, 1998;Hu and 
McLachlan, 2003;Scholz and Woolf, 2007). Analysis of ED-1 immunoreactivity was 
conducted using similar methodology to a previous report (Wallace et al., 2007b). To 
mention briefly, the mean percentage area of ED-1 immunoreactivity per 250,000μm2 
(500µm x 500µm) was calculated per animal using comparable levels of DRG representing 
the beginning, mid, and end sections of the DRG (3 DRG sections; 2 images per DRG), and 
a mean was determined for the respective groups. Quantitative analysis of ED-1 labeling in 
the ipsilateral L5 DRG of TNT rats (28 days post injury), treated with saline or DHA 
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(500nmol/kg, administered every 3 days post injury) revealed no differences in the 
expression levels between the two groups; a result consistent with the lack of behavioural 
effect observed (i.e. no reversal of paw mechanical hypersensitivity). The nature of the ED-1 
staining pattern was consistent with literature reports depicting activated macrophages (Hu 
and McLachlan, 2003). No studies to date have examined the effects of DHA on 
macrophage infiltration into the DRG following peripheral nerve injury. Nonetheless, these 
findings contrast previous studies that propose a modulatory role for DHA on macrophages 
in experimental nerve injured animal models including stroke and SCI models. SCI initiates 
the recruitment of neutrophils, macrophages, and microglial cells at the injury site (Dusart 
and Schwab, 1994). The acute administration of DHA (250nmol/kg) within 30 minutes 
of SCI injury in rats has been shown to reduce ED-1 immunolabeling in the spinal cord at 6 
weeks post injury (Huang et al., 2007). Similarly, in a rat model of acute ischemic stroke 
injury, intravenous DHA has been shown to attenuate ED-1 immunoreactivity in the brain 
and was associated with a reduced infarct size at 4 and 5 hours post injury (Belayev et al., 
2011), thus indicating DHA has short and long term anti-inflammatory effects. However the 
results of the current study parallel a previous investigation that has demonstrated no 
significant differences in the density of ED1-positive macrophages  at the lesion site 
following administration of DHA (250nmol/kg) 7 days after SCI in rats (King et al., 2006).  
The results of my study also adds to existing knowledge from in vitro experiments that 
demonstrates an inhibition of  macrophage activity (IFNγ/LPS activated) when exposed to 
DHA (Ajmone-Cat et al., 2011;Dustin et al., 1990;Lu et al., 2010). There are no obvious 
explanations for this discrepancy, but it appears that there are multiple and complex factors 
that can determine the effects of DHA on macrophages in vivo. Such factors are likely to 
include the nature of nerve trauma injury, the timing of DHA administration (either before or 
after injury), and the production of potent metabolites.  
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5.3.3 Mechanisms of DHA mediated analgesia 
 
There are numerous proposed mechanisms that may explain the neuroprotective and anti-
inflammatory of ω-3 PUFAs. A growing and widely supported mechanism is the regulation 
of macrophages and inflammation (Yaqoob and Calder, 2007). DHA can bind to PPARγ 
which can regulate the transcription of anti-inflammatory cytokines such as  TNFα and IL-
1β (Jiang et al., 1998). Experiments in rodents have shown that the intraplantar or intrathecal 
administration of both TNFα and IL-1β cytokines are associated with mechanical paw 
hypersensitivity in rodents (Cunha et al., 1992;Safieh-Garabedian et al., 1995;Youn et al., 
2008). The reduction of TNFα and IL-1β release from macrophages in response to DHA in 
peripheral nerve injury may reduce the sensitization of neurons that otherwise would lead to 
an increase in neuronal excitability and perhaps the development of pain (McMahon et al., 
2005). Studies involving chronic ω-3 PUFAs supplementation suggest that after such 
intervention, the ω-3 fatty acid content (i.e. arachidonic acid content) of the cell membrane is 
likely to decrease, in parallel with an increasing DHA content. Since DHA competes with 
arachidonic acid for the action site of lipooxygenase, a higher membrane content of DHA 
may ‘out compete’ arachidonic acid, therefore reducing the production or effects of 
prostanoids and proinflammatory cytokines. Prostanoids have been shown to facilitate the 
release of neuropeptides from nerve terminals such as substance P (SP) and calcitonin gene 
related peptide (CGRP) (Martin et al., 1987), both of which participate in nociceptive 
signalling (Benemei et al., 2009;Snijdelaar et al., 2000). Furthermore, the EP1 prostanoid 
receptor, has been shown to increase in sensory neurons after injury which may additionally 
sensitise neurons (Durrenberger et al., 2006). DHA can further modulate the inflammatory 
responses via the production of metabolites such as NPD1 and resolvin D1 both of which 
exhibits significant anti-inflammatory and neuroprotective properties (Bazan, 2009;Hong et 
al., 2003;Marcheselli et al., 2010;Mukherjee et al., 2004;Serhan et al., 2008), and could have 
therapeutic potential. For example, the intrathecal or intraplantar resolvin D1 has been 
shown to reduce mechanical hypersensitivity in various models of inflammatory ‘pain’ (Xu 
et al., 2010).  Inflammation is also associated with the production of reactive oxygen species 
(ROS) such as super oxide (Wang et al., 2004). ROS have been implicated in degenerative 
disease processes such as Alzheimer's disease and Parkinson's disease (Uttara et al., 2009). 
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Evidence from pre clinical studies have shown that the systemic injection of ROS scavenger 
phenyl-N-tert-butylnitrone (PBN) in rats relieves spinal nerve ligation (SNL)-induced 
mechanical hypersensitivity in a dose-dependent manner (Kim et al., 2004). Such 
observations support a role of ROS in nerve trauma and perhaps neuropathic pain. The ω-3 
PUFAs have been shown to reduce oxidative stress following neurological injury, thus 
limiting the potential for mitochondrial damage or apoptosis initiated by ROS (Dyall and 
Michael-Titus, 2008). Previous in vitro experiments demonstrate that the exposure of 
cultured hippocampical cells to DHA leads to an increase in antioxidant enzyme activity, 
including glutathione peroxidase and glutathione reductase (Wang et al., 2003b). Such 
effects on antioxidant processes have been observed in vivo – investigations by Songour et 
al., 2003 have shown that rats consuming an ω-3 PUFA diet (0.4 g/kg/day) for 30 days 
exhibit significantly less nitric oxide and SOD activity compared to respective control rats, 
in the hypothalamus. The effect of DHA on antioxidant enzyme activity could restrict the 
potential damage to DRG neurons caused by nerve trauma injury induced ROS, thus 
allowing the continuation of nerve regeneration and the likelihood of a quicker recovery. 
(Songur et al., 2004). 
It has been suggested that ω-3 PUFAs can bind and block both the voltage gated soduim ion 
channels (VGSCs) and voltage gated calcium ion channels (VGCCs) (Shapiro, 2003). 
Previous in vitro data has shown DHA can exert a dose-dependent suppression of voltage-
activated sodium currents in rat ventricular cardiac myocytes (Xiao et al., 1995). DHA has 
also been shown to prevent toxin-induced fibrillation of cultured neonatal rat cardiac 
myocytes via blockade of L-type VGCCs  (Leaf, 2001). Other in vitro data also supports the 
blockade of T-type VGCCs (Danthi et al., 2005). The interaction of ω-3 PUFAs with VGSCs 
is of interest because following peripheral nerve trauma there are complex changes in the 
type of VGSCs expressed as well as changes in channel function and number expressed in 
the DRG (Wood et al., 2004). These changes are thought to contribute to increased 
hyperexcitability and ectopic activity in neurons which may contribute towards neuropathic 
pain pathophysiology (Lai et al., 2004). It is possible that DHA may reduce the excitation of 
neurons following peripheral nerve trauma via blockade of VGSC’s and VGCC’s.  
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The neuroprotective effects of ω-3 PUFAs may also be attributed to their activation of a 
subset of K
+
 channels that contain two pore-forming domains; namely, TREK-1 and 
TRAAK (Lesage and Lazdunski, 2000). These channels are abundant in the brain, 
particularly the hippocampus where they are located pre and postsynaptically (Lauritzen et 
al., 2000). The activation of these cannels by ω-3 PUFAs might reduce the resting potential 
as well as in the firing properties of neurons (Lauritzen et al., 2000). The activation of 
TREK-1 prevents the excessive release of excitotoxic glutamate thus acting as a break on 
neuronal excitability (Blondeau et al., 2002) – such actions may also reduce 
hyperexcitability of damaged peripheral sensory neurons in the DRG. More research is 
needed to identify the potency of such actions since specific TREK-1 and TRAAK blockers 
have not yet been discovered (Lauritzen et al., 2000). 
 
5.3.4 Limitations and future studies 
 
A major limitation to the study is serum phospholipids levels before and at time points post 
injury was not measured and therefore the mean blood serum DHA levels were not 
determined. Additionally, the production of DHA metabolites (e.g. NPD1 and resolvins D1) 
was not measured and their likely effects cannot be ascertained. The blood serum levels of 
DHA and its metabolites could have been measured by taking routine blood samples at 
various time points post injury, and conducting a lipid analysis using high performance 
liquid chromatography (Marcheselli et al., 2003). Lipid analysis techniques has been used 
previously to quantify ω-3 PUFA content in the blood serum of rats with traumatic brain 
injury following dietary fish oil supplementation (Mills et al., 2011). Such data would also 
indicate whether the dosage regime was robust to ensure DHA serum levels remained at a 
dose deemed to be effective. The use of single dose regime to evaluate the effects of DHA is 
another limitation of the study. The explorative nature of the study allowed for the 
examination of a single dose regime, however a dose dependent study (using lower doses 
e.g. 250nmol/kg and 100nmol/kg) would strengthen the data and allow comparisons with 
other studies of nerve trauma injury that have used such doses. Furthermore, the use of a 
dose-response is essential in pharmacological studies in order to analyse the safety profile 
and identify the therapeutic window, and within the current study, to define an optimum 
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dose that would maximize the degree of neuroprotection. A more robust approach could 
have been the oral administration of DHA via powered diet which would have allowed a 
sustained delivery of ω-3 PUFAs without the unnecessary stress of regular tail vein 
injections. Dietary DHA enrichment via powdered diet has been beneficial in other models 
of traumatic nerve injury such as SCI (although with an initial acute bolus of DHA following 
injury) (Huang et al., 2007;King et al., 2006;Mills et al., 2011). A future experiment could 
involve analyzing the effect of pre injury administration of DHA and would focus on the 
likelihood of pre-emptive strategies. A recent study have shown that the pretreatment of 
DHA (250nmol/kg, ~82 μg/kg) 7 days and 1 hour before SCI results in axonal preservation 
and increased white matter sparing compared to the vehicle injections 7 days after nerve 
injury (Figueroa et al., 2012), such a treatment regime is worth exploring for  peripheral 
nerve injury. The administration of other ω-3 PUFAs such as EPA could have been tested 
since they also have neuroprotective and anti-inflammatory properties similar to DHA, and 
can be metabolized to form E series resolvins which have enhanced anti-inflammatory 
properties (Serhan et al., 2008). The phenotype of microglia in the spinal cord could have 
been examined since their activation has been recognized as a key contributor towards 
neuropathic pain mechanisms (Coull et al., 2005). Macrophages/microglia continuously alter 
the expression of surface markers in response to local stimuli and can be characterised 
accordingly as  either ‘activated’ proinflammatory (M1) or ‘alternative’ immunomodulatory 
or anti-inflammatory (M2) cells (Kigerl et al., 2009;Shapiro et al., 2011). Further 
investigations could have examined the phenotype of the macrophages present in the DRG 
or spinal cord in DHA treated animals via double labeling experiments using surface 
receptors associated with M1 macrophages (CD86, CD16, and CD32) or  M2 macrophages 
(CD206 and argenase-1) (Kigerl et al., 2009). It would be interesting to discover if DHA 
initiates a switch to the M2 phenotype which typically promotes tissue repair/remodeling 
(Shapiro et al., 2011). 
 
It is possible that the TNT model could have been an inappropriate choice for this study due 
to an insufficient macrophage response that is attributed to the limited surgery of TNT, and 
therefore inflammation and macrophages could play less of a role in paw related mechanical 
hypersensitivity compared to other trauma nerve injury models. This could be investigated 
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by using the more robust nerve damage SNT model as a control group and comparing the 
ED-1 immunoreactivity. The activation state of spinal microglia could have been assessed 
via double labeling experiments using MAPKs such as p38 or ERK, both of which are both 
upregulated in the spinal cord after peripheral and spinal nerve injury (Calvo et al., 2012b;Ji 
and Suter, 2007) and are thought to be reflective of an M1 phenotype (Jin et al., 2003;Tsuda 
et al., 2004). DHA has been shown to impair p38 MAPK signaling in cultured macrophages 
(Ajmone-Cat et al., 2011); therefore investigations could reveal similar findings in vivo.  
 
This study could have considered the use of a naive group for the ED-1 
immunohistochemistry as an additional control to make a comparison to baseline levels. 
Additionally a negative control could have been conducted to assert the validity of the ED-1 
immunohistochemistry.   
 
5.3.5 Conclusions 
 
To conclude, in this chapter I have examined the effects of DHA on the development of 
mechanical hypersensitivity following TNT injury. There were no differences in mechanical 
or thermal behavioural hypersensitivity between DHA and saline treated animals following 
TNT injury over 28 days. Additionally, no differences were observed regarding macrophage 
infiltration in the injured L5 DRG between DHA and saline treated TNT animals. I have 
raised some concerns regarding the dose of DHA used in the study and the inconsistencies in 
the behaviour that may have may have contributed to the reported outcomes.  
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6 General discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
238 
 
 
General discussion 
 
Peripheral nerve injury results in biochemical changes and neuroinflammation within the DRG 
(Lacroix-Fralish et al., 2011;Woolf and Salter, 2000;Zimmermann, 2001). In this thesis, I 
attempted characterize such changes using immunohistochemical techniques and therefore 
further our understanding of neuropathic pain mechanisms.  
 
Research aims:  
 
(1) To provide temporal profile expressions of commonly dysregulated neurochemical 
markers (i.e. ATF-3, GAP-43, NPY, and galanin) in traumatic and non-traumatic nerve 
injury using the TNT and d4T induced models of peripheral nerve injury respectively.  
(2) To compare and contrast these changes in both models. 
(3) Characterize, compare, and contrast evoked sensory parameters (limb withdrawal 
responses) in both models. 
(4) Investigate whether DHA (ω-3 PUFA) can reverse mechanical and thermal 
hypersensitivity associated with TNT injury and alter the expression of neurochemical 
markers in the DRG. Since no behavioural changes were observed upon sensory testing 
in DHA treated animals, investigations focused on the potential of DHA to modulate the 
DRG macrophage response. 
 
Research hypothesis: 
 
Peripheral nerve damage initiates neurochemical changes in the dorsal root ganglion, and the 
development pain-like behaviours, which can be modulated via the administration of ω-3 
polyunsaturated fatty acids. 
 
Forwarding remarks 
 
This thesis has demonstrated completely different expression patterns of neurochemical markers 
in the DRG following TNT injury and d4T induced nerve damage in rats which highlights the 
mechanistic difference between nerve trauma and antiretroviral associated neuropathic pain. 
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6.1 Summary of the DRG neurochemical response to TNT injury and d4T induced 
nerve damage 
 
The majority of neuropathic pain studies focus on the use of trauma nerve models, which is 
not wholly representative of the clinical situation that includes other aetiologies relating to 
diabetes, herpes zoster, and HIV.  Therefore my experiments addressed this issue by 
investigating mechanisms of nerve trauma and NRTI related neuropathy using the TNT and 
d4T model respectively ( 
Table 6.1).  
 
 TNT d4T 
ATF-3  Greater proportion of ATF-3 expression in NF-200 
immunoreactive cells (71.1 ± 7.2 % [also the peak]) 
compared to peripherin immunoreactive cells (11.9. ± 
5.6 % ) 1 day after injury 
 Expression downregulated in NF-200 cells 1 day post 
injury 
 Expression levels remained consistent at all other time 
points in peripherin (peak; 25.4. ± 8.3 %)  and NF-200 
immunoreactive cells 
 Low expression across 
all time points (<0.1%) 
in peripherin and NF-
200 immunoreactive 
cells. No significant 
temporal trends were 
observed.  
NPY  Distinct expression patterns in small vrs. Large cells 
 Expression observed at 7, 14, 28, and 43 days post 
surgery, mainly in NF-200 cells (peak; 51.7 ± 8.3 %) 
 An increasing temporal trend was observed in 
peripherin immunoreactive cells but expressions 
remained low (<6.5%) 
 Low expression across 
all time points (<0.5%) 
in peripherin and NF-
200 immunoreactive 
cells. No significant 
temporal trends were 
observed. 
GAP-43  Expression observed at all time points and temporal 
profile expressions were similar in peripherin and NF-
200 immunoreactive cells 
 Peak observed day 14 in both peripherin (15.7 ± 1.7 %) 
and NF-200 (15.8 ± 4.8 %) immunoreactive cells 
 Low expression across 
all time points (<2%) in 
peripherin and NF-200 
immunoreactive cells 
No significant temporal 
trends were observed. 
Galanin  Expression observed at all time points and temporal 
profile expressions were similar in peripherin and NF-
200 immunoreactive cells 
 Low expression 1 day post injury (<2%) in peripherin 
and NF-200 immunoreactive cells 
 Peak observed day 14 in both peripherin (19.3 ± 4.8 %) 
and NF-200 (25.8 ± 4.2 %) immunoreactive cells 
 Low expression across 
all time points (<2%) in 
peripherin and NF-200 
immunoreactive cells 
time point. No 
significant temporal 
trends were observed. 
 
Table 6.1 Summary of DRG neurochemical marker expression in the TNT and d4T models 
of peripheral nerve damage  
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6.2 DRG neurochemical response to peripheral nerve trauma  
 
Results outlined in Chapter 3 demonstrate that TNT injury results in a robust upregulation 
of axonal injury marker ATF-3, nerve regeneration maker GAP-43, and the neuropeptides 
NPY & galanin. Evidence from the literature parallels with the observation of ATF-3 
expression in the DRG following peripheral nerve damage at various time points post injury 
(Averill et al., 2004;Averill et al., 2002;Djouhri et al., 2006;Fukuoka et al., 2012;Obata et 
al., 2003;Peters et al., 2005;Shortland et al., 2006;Tsujino et al., 2000;Wright et al., 2004). 
Of particular interest is the novel finding of disproportionate upregulation of ATF-3 in large 
DRG cells one day post TNT injury (acute stage of nerve trauma) compared to small DRG 
cells. Such observations parallel with previous studies that have demonstrated microscopic 
damage and degeneration in large myelinated fibres with less severe changes evident in 
smaller unmyelinated fibres (Basbaum et al., 1991;Munger et al., 1992), although the 
proportion of ATF-3 immunoreactive DRG cells after this time remains consistent in both 
small and large sized cells. The function of ATF-3 is not clear, however its presence is 
linked to cell stress and cancer (Thompson et al., 2009), and in neurons has been associated 
with regeneration of peripheral sensory neurons  (Hunt et al., 2004;Saito and Dahlin, 2008). 
The over expression of ATF-3 in cancer cell lines has been found to be associated with 
increased proliferation and increased transition of the G1 (growth phase) to the S-phase 
(DNA synthesis) of the cell cycle (Pelzer et al., 2006). Another study has found ATF-3 to be 
protective against apoptosis in a HeLa cells (Wolfgang et al., 1997). In light of this evidence, 
it is likely that ATF-3 expression may be protective against neuronal cell death following 
nerve damage. Such neuroprotection (or reduced cell death) has been demonstrated in 
superior nerve ganglion neurons in which ATF-3 has been overexpressed via a viral vector 
(Nakagomi et al., 2003).  
 
The upregulation of GAP-43 has been associated with nerve renegration (Woolf et al., 
1990). Pervious studies have identified GAP-43 in the DRG following peripheral nerve 
injury (Nahin et al., 1994;Schreyer and Skene, 1991;Schreyer and Skene, 1993;Woolf et al., 
1990). Following TNT injury, GAP-43 was upregulated in both peripherin and NF-200 cells, 
with both populations exhibiting similar but not significant temporal profiles. This 
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observation indicates nerve regeneration processes occurring after TNT injury. Although 
nerve regeneration has been recognized as a likely role for GAP-43, it has been proposed 
that GAP-43 may be involved in neuronal remodeling (Benowitz and Routtenberg, 
1997;Neve et al., 1987). GAP-43 could also be important in the maintenance and structure of 
the soma, and axonal fibres including their synaptic terminals. The regenerative process may 
represent an important event that enables primary sensory neurons to recover and regain 
normal physiology. However, it could be that those damaged neurons that have ‘regenerated’ 
could maintain abnormal physiology that could perpetuate neuropathic pain processes e.g. 
ectopic activity.  
 
The upregulation of galanin is a known consequence of peripheral nerve trauma and has 
been observed at various time points post injury, mainly in small diameter DRG neurons 
(Averill et al., 2002;Fukuoka et al., 1998;Hokfelt et al., 1987;Hokfelt et al., 1994;Holmes et 
al., 2003;Ma and Bisby, 1997;Shi et al., 1999;Shortland et al., 2006;Villar et al., 1989). This 
thesis has examined the temporal nature of galanin expression in the L5 DRG after nerve 
trauma injury and has identified a similar dynamic expression profile that occurs in both 
peripherin/NF-200 cells (peak at 14 days in both peripherin/NF-200 cells). The percentage 
expression observed in both populations was lower than that observed in aformentioned 
studies and is likely explained via the use of arguably more robust models of peripheral 
nerve trauma (i.e. SNT, CCI, and complete sciatic nerve transection (CSNT)). The idea that 
the degree of nerve damage influences expression of galanin is supported by a previous 
study using the single ligature nerve constriction model where animals were grouped 
according to the degree of ligation to represent light (10-30%), medium (40-80%) and stong 
ligature (90%). After light liguature, a modest upregulation of galanin was observed, mainly 
in small-sized neurons. However, following medium or strong ligatures, there was a larger 
increase in the number of galanin immunoreactive neurons, involving also medium and large 
sized cells (Coronel et al., 2008). 
 
The results in this thesis agrees with the observations of others that have observed the 
upregulation of NPY following peripheral nerve trauma, mainly in large sized neurons (Ma 
and Bisby, 1997;Ohara et al., 1994;Wakisaka et al., 1991;Wakisaka et al., 1992). The 
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temporal profile indicates a robust downgreulation after 28 days in large sized cells.  In 
addition to this, the results demonstrate that small sized cells also upregulate NPY, but to a 
much lesser extent compared to large dimater cells.  
 
The release of neuropeptides that are associated with antinociception such as NPY (Hua et 
al., 1991;Intondi et al., 2008) or galanin (Hua et al., 2004) may reflect the nervous system 
attempts to restore normal nociceptive processing following nerve trauma. Their 
downreguation after peripheral nerve trauma suggests a partial recovery from nerve injury 
and is associated with the downgreulation of ATF-3.  
 
In order to determine if there were a relationship between the temporal expression of 
investigative markers in both cell populations (peripherin and NF-200) and the degree of 
behavioural mechanical hypersensitivity, a Pearson’s correlation co-efficient was calculated. 
Although there was a noticeable trend towards an association in both peripherin and NF-200 
cells with regards to GAP-43, NPY, and galanin immunoreactivity and also with ATF-3 
expression in peripherin characterized cells. The likelihood of a significant association could 
have been investigated through the use of increased experimental group sizes. No 
correlations were observed and this suggests that these markers may be indicators of nerve 
injury and less likely to be markers of neuropathic pain. The lack of correlation between 
mechanical hypersensitivity and expression of neurochemical markers ATF-3 and GAP-43 
parallels with that of previous findings  (Jaken et al., 2011;Shortland et al., 2006). 
 
A proposed mechanism for nerve trauma injury is the loss of target derived trophic support 
(e.g. NGF, BDNF, NT-3) leading to a dysregulation of neuropeptide expression, and 
associated ‘pain’ (Ohara et al., 1995). Previous work have demonstrated that the intrathecal 
administration of NGF via an osmotic pump to sciatic nerve injured rats can partially or fully 
prevent the upregulation of NPY, galanin, and ATF-3 in the DRG (Averill et al., 
2004;Fitzgerald et al., 1985) and additionally prevent the development of pain-related 
behaviours (Wang et al., 2003a). Since sensory neurons depend on the presence of NGF for 
viability (Molliver et al., 1997), the concept of NGF treatment reliving neuropathic pain 
seems a plausible hypothesis. However, evidence from animal studies suggests NGF induces 
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hypersensitivity through the activation of trkA receptors (McMahon et al., 1995), which 
correlates with clinical observations regarding pain at site of injection, or widespread pain 
upon systemic administration (Svensson et al., 2003). This contradiction likely reflects 
differences in dose surrounding the affected nerve, and the dynamic responses to nerve 
injury. Further evidence regarding the role of NGF in pain derives from humans that have 
mutations in NGF/trkA signaling, in which they consequently demonstrate congenital 
analgesia (Indo et al., 2001). Various clinical trials have now provided support towards anti-
NGF therapies that include the sequestration of NGF via antisera or soluble receptors (Lane 
et al., 2010;Pezet and McMahon, 2006). However concerns regarding safety (i.e. 
autoimmune reactions) will need to be addressed since side effects/worsening of condition 
have been observed in osteoarthritis patients leading to temporary suspension of the clinical 
trial (Wood, 2010).  
 
6.3 DRG neurochemical response to antiretroviral induced nerve damage 
 
This study revealed that d4T treated animals do not exhibit altered expressions of axonal 
injury marker ATF-3, nerve regeneration maker GAP-43, and the neuropeptides NPY & 
galanin. Such observations corroborate with a previous study examining such markers 
following administration of a similar antiretroviral ddC in rats (Wallace et al., 2007b). The 
lack of altered expression of all investigated markers in d4T treated rats suggests that there is 
no alteration in trophic support in NRTI neuropathy models or it could be that any putative 
alterations are compensated by other, perhaps unknown trophic factors. However the effects 
of neurotrophins may still play a role in NRTI related neuropathy. In a recent study, the 
systemic administration of d4T in mice (at similar doses used in the thesis) induced 
mechanical, but not thermal hypersensitivity that was associated with an increase in neuronal 
activity and BDNF expression in the spinal dorsal horn (Renn et al., 2011). Exogenous 
intrathecal BDNF exacerbated these observations, and the pretreatment with intrathecal 
trkB-Fc or a tyrosine kinase inhibitor reduced the d4T-induced mechanical hypersensitivity. 
BDNF, like NGF is a known modulator of sensory transmission, acting on the trkB receptor, 
and plays a key role in central sensitization (Pezet and McMahon, 2006). It is possible that 
the presence of BDNF in the cord, in d4T animals is enough to precipitate the changes in 
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sensory behaviour without necessarily inducing the changes in neuropeptide expression that 
is observed in peripheral nerve trauma injury.  
 
6.4 Comparison and contrast between nerve trauma and antiretroviral associated 
neuropathy 
 
This thesis has revealed that there are distinct differences in the neurochemical responses to 
nerve damage in the DRG in two different types of nerve damage that are both associated 
with neuropathic pain. This is an important finding that is only beginning to transcend 
throughout the neuropathic pain field. In both animal models and patients, there are critical 
differences between the responses to different types of nerve damage that are associated with 
neuropathic pain. Both the d4T and TNT models fit the definition for nerve damage (Jensen 
et al., 2011). Although neurochemical changes were not apparent in the DRG of d4T treated 
rats, evidence from previous studies have demonstrated a clear neurotoxicity that manifests 
in the retraction of C-fibres from the paw skin that is analogous to the ‘die back’ 
phenomenon that occurs in ATN patients (Calvo et al., 2012a;Wallace et al., 2007b). In 
contrast to the d4T model, TNT injured rats demonstrated an apparent DRG neurochemical 
response that manifested in the expression of axonal injury marker ATF-3, neuropeptides 
NPY & galanin, and axonal regeneration marker GAP-43; all findings consistent with 
literature reports. This result suggests that these markers are possibly markers of nerve injury 
and not to be interpreted as generic markers for neuropathic pain since evidence for nerve 
damage is apparent in d4T treated rats, as aforementioned (retraction of C-fibres from paw 
skin). Such distinct responses to nerve damage between these two models are also observed 
at gene level within the DRG (Maratou et al., 2009) and with regards to spinal microglia 
infiltration which is only evident following nerve trauma (Blackbeard et al., 2012;Zheng et 
al., 2011a). My research also supports the argument that there different mechanisms for 
neuropathic pain, and that the use of a diverse range of animal models that reflect different 
clinical antilogies can play an important role in understanding these mechanisms. Evidence 
from clinical studies have indicated that various mechanisms may be at play and that 
neuropathic pain patients can be grouped according to their symptoms and sensory profiles 
using quantitative sensory testing (QST) (Baron et al., 2009;Maier et al., 2010).  
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Much of the evidence regarding NRTI associated pain relates to mitochondrial toxicity; a 
feature that may not be relevant in nerve trauma associated pain. The neuropathic changes in 
NRTI treated animals originate from mitochondrial dysfunction, leading to oxidative stress, 
apoptosis of neurons, altered calcium homeostasis, and axonal degeneration (Joseph and 
Levine, 2004;Opii et al., 2007;Wallace et al., 2007b). Although this thesis has revealed 
potentially differing mechamisms between d4T and nerve trauma associated nerve damage, 
some of the end processes are similar. For example, activated caspase-3 (the critical 
executioner of cell death) is induced in the L5 DRG following L5 spinal nerve crush injury 
(Sekiguchi et al., 2009) and is associated with mechanical hypersensitivity. Inhibitors of both 
activator (1,2,8, and 9) and effector (3) caspases have all been shown to attenuate 
mechanical behavioural hypersensitivity associated with the ddC induced neuropathy model 
(Joseph and Levine, 2004). Another example of similar process between trauma and NRTI 
nerve damage is retraction of C-fibres in paw skin. Immunostaining of skin biopsies using 
neuronal marker protein gene product 9.5 (PGP 9.5, a ubiquitincarboxyl hydrolase), can be 
used to quantify the IENF density in rats (Smith et al., 2005) and in humans (McCarthy et 
al., 1995). A reduced IENF density is observed in ddC treated rats (Wallace et al., 2007b) 
but also in nerve trauma models (Hsieh et al., 2009) and chemotherapy associated 
neuropathies (Zheng et al., 2011a) – a phenomenon that may be relevant to neuropathic pain 
mechanisms.  
Inflammation may be more relevant in trauma related pain. After traumatic nerve injury, 
microglia become activated, and there is an increase in the total number infiltrating the 
spinal cord (Blackbeard et al., 2007). Activated microglia can release BDNF that can modify 
chloride currents and alter neuronal excitability in the cord of nerve trauma rats (Coull et al., 
2005). This microglial infiltration/activation response is not observed in the ddC 
antiretroviral model (Blackbeard et al., 2012;Zheng et al., 2011a), and the administration of 
minocyclin (a microglia inhibitor) has no effect on the associated mechanical 
hypersensitivity (Wallace et al., 2007b). Moreover, there is no macrophage infiltration in the 
sciatic nerve and collectively, the evidence suggests that inflammation is not a mitigating 
factor for ATN neuropathy. However, contradictory to this is the presence of CCL2 (a 
macrophage chemoattractant) in the DRG of ddC treated rats, which does not entirely rule 
out the possibility that inflammation may have some role to play, and could be investigated. 
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6.5 Evaluation of ω-3 PUFAs role in nerve damage 
 
Data from this thesis has only proven part of the hypothesis. The administration of DHA to 
TNT injured rats did not alter outcomes of behavioural sensory testing or the infiltration of 
ED-1 immunoreactive cells in the DRG, a result that contradicts the recognized 
neuroprotective and anti-inflammatory properties of this compound.  
 
The intake of  ω-3 PUFAs (e.g. DHA or EPA) in the diet can improve joint pain and reduce 
the risk of cardiovascular disease (Goldberg and Katz, 2007). Evidence from preclinical 
studies suggests ω-3 PUFA supplementation in the diet can reduce both the histological 
outcomes and sensory behavioural outcome measures associated with SCI (Huang et al., 
2007). I sought to examine the effect of DHA (administered every 3 days following nerve 
injury) at a dose comparable to previous studies in which an effect was observed (Lim et al., 
2010). Data from earlier experiments (Chapter 3) revealed no correlations between TNT 
associated mechanical hypersensitivity and the temporal expression profiles of investigative 
markers (i.e. ATF-3, Gap-43, NPY, and galanin). There were also no observed differences in 
the development of mechanical hypersensitivity between DHA and saline treated rats 
following TNT injury. Therefore histological analysis in the DRGs of DHA/saline treated 
rats did not focus on the expression profiles of neurochemical makers associated with nerve 
trauma, but rather the potential modulation of the macrophage response. Following 
peripheral nerve injury, macrophages infiltrate the DRG, where they are likely to release an 
array of cytokines (e.g. TNFα and IL-1β) that can promote inflammation which can sensitize 
neurons and exacerbate outcome measures of sensory behavioural responses. Consequently, 
I sought to investigate whether DHA administered to TNT injured rats could decrease the 
macrophage response in the ipsilateral DRG compared to saline treated rats. The results 
demonstrated no differences in the percentage area of ED-1 immunoreactivity (macrophage 
marker), a finding consistent with the lack of behavioural change observed. This result may 
be reflective of a sub optimal dosage regime that could have been detrimental to the DRG 
neurons. Although the dose used in a previous SCI study (250 nmol/kg i.v.) demonstrated 
efficacy (Huang et al., 2007), it is possible that at higher doses, there is the possibility of 
tipping the balance between the detrimental effects of lipid peroxidation that can occur with 
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ω-3  PUFAs (Gutteridge, 1995) and the benefits of neuroprotection. A previous identical 
study using the dose used in the current study (500 nmol/kg) identified neuroprotection at 
this dose (Lim et al., 2010). The nature of this balance will need to be understood to fully 
realize the potential of DHA as a neuroprotective agent. Since inconsistent and large 
standard deviation values were observed in some animals regarding PWTs (especially during 
the early stages of nerve injury) a Kolmogorov-Smirnov normality distribution test was 
conducted of all DHA/saline treated rats. Results of this analysis revealed a small percentage 
of data points that reflect an abnormal distribution (see Table 6.2). A normality distribution 
test was also conducted for all data points regarding TNT/sham animals (data acquired in 
Chapter 3), in order to demonstrate validity of earlier results (see Table 6.3). Analysis 
revealed few rats exhibiting abnormal distribution of PWT values, a result comparable to 
that of TNT rats treated with DHA/Saline and therefore I can conclude that the majority 
(>90%) of data sets exhibits normal distribution.  
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 Baseline Day 1  Day7 Day 14 Day 21 Day 28 
DHA  
1       
2       
3       
4       
5       
6       
7       
8       
Saline 
 
1       
2       
3       
4       
5       
6       
7       
 
 
Table 6.2 Indication of normal distribution regarding PWTs in TNT rats treated with 
DHA/saline at baseline and at various time points post surgery following a kolmogorov-
Smirnov normality test. Normality was calculated for each animal using raw data values – 10 
at baseline and 5 post surgery. 7.8% of data points failed to exhibit normal distribution; () 
passed (p>0.05); () failed (p<0.05). 
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 BL 
1 
Day 
1 
BL 
7 
Day 
7 
BL 
14 
Day 
14 
BL 
28 
Day 
28 
BL 
43 
Day 
43 
TNT  
1           
2           
3           
4 
N/A N/A N/A N/A N/A N/A     
Sham 
 
1           
2           
3           
4 
   N/A N/A      
 
Table 6.3 Indication of normal distribution regarding mechanical PWTs in TNT/sham 
operated rats at baseline (BL) and at the various time points post surgery following a 
kolmogorov-Smirnov normality test. Normality was calculated for each animal using raw 
data values – 10 at baseline and 5 post surgery. 6.9% of data points failed to exhibit normal 
distribution; () passed (p>0.05); () failed (p<0.05). 
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6.6 Study limitations and further studies 
 
6.6.1 Assessment of mechanical hypersensitivity 
 
The use of the electronic von Frey device offers many advantages and was originally used to 
overcome some of the issues surrounding the use the graded von Frey monofilaments  which 
are mechanically unstable and difficult to standardize (Moller et al., 1998). The size of the 
electronic von Frey probe tip is consistent and therefore limits the response bias upon 
application. Graded von Frey filaments alter performance in response to varying humidity 
and temperature, in a way that the electronic device is not, and this could have a bearing on 
withdrawal responses (Andrews, 1993). The electronic von Frey device also allows 
continuous measurements of PWTs as opposed to incremental measurements of the graded 
von Frey filaments.  The electronic von Frey setup is computerized, and there is the 
advantage of a real time display of withdrawal responses. Copies of the traces can be 
obtained and referred to for future reference. The results of the graded von Frey test is 
commonly converted from Newton’s to grams and the scale is log rhythmic, and therefore its 
use is attached with an inheritable degree of error. Finally, the electronic von Frey has been 
shown to have a high interobserver reliability, both between PWT’s obtained and between 
rates of application used (Moller et al., 1998). Despite the advantages of the electronic von 
Frey, some essential prerequisites must be understood. Firstly, the probe tip of the electronic 
von Frey device must be held perpendicular to the hind paw skin surface to ensure an 
appropriate delivery of the presenting stimulus. Secondly, the rate of application needs to 
remain constant every time, anything contrary may change the nature of the force applied. If 
the application is too fast, the animal may lift its paw abruptly before there is a chance to 
measure the withdrawal threshold. Too slow an application, and a withdrawal response may 
not be obtained since the force applied was not enough to reach threshold. Lastly, the region 
of the paw stimulated must remain consistent since different regions of the paw may react 
differently when presented with the same stimulus. The electronic von Frey device allows 
standardization of testing, detailed documentation of each experiment, and provides an 
objective and accurate method for measuring PWTs to mechanical stimuli and was suitable 
for experiments detailed in this thesis. 
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Examination of PWTs in TNT animals were conducted in the mid-plantar region of the paw 
which is innervated by the tibial nerve. Other studies using the TNT model have examined 
the lateral part of the paw which receives sural nerve innervations  and is reported to be the 
hypersensitive part of the paw in the acute stages of nerve injury (Lee et al., 2000;Unal-
Cevik and Oaklander, 2011). The sural nerve is one of the branches of the sciatic nerve that 
conveys mainly sensory information whereas the tibial transmits both sensory and motor 
information. Following chronic exposure to ddC  in humans, there is a disproportionate 
degree of injury to the sural nerve in particularly (Lewis and Dalakas, 1995). Alternatively 
the lateral part of the paw could be examined in TNT injured animals and subsequently 
compared to the PWT responses in d4T injured animals.  
 
Increases in PWTs 
 
An increase was observed in the ipsilateral PWTs of sham operated animals across time that 
at 43 days post injury. An increase was also observed in contralateral paw of TNT operated 
animals at day 28 post injury. While somewhat unusual, this might be explained by an 
increase in weight over time, thus leading to larger PWTs. This may not be a frequent 
occurance in most peripheral nerve injury animal models studies since most studies rarely 
examine time points beyond 14-21 days, and therefore such increases in PWTs are generally 
not observed.   This phenomenon could be further examined and accounted for by measuring 
the PWTs in a naïve control group of standard adult weight (200-250g) to normalise post 
surgery PWTs of all experimental animals. 
 
6.6.2 Assessment of thermal hypersensitivity 
 
The Hargreaves device was used to assess reflex withdrawal responses to noxious thermal 
stimuli (Hargreaves et al., 1988). This device has advantages over other assays such as the 
hot plate test. Firstly, the Hargreaves device has an automated reflex withdrawal detector 
that is sensitive to the nearest 0.1 second. Secondly, the intensity of the stimulus can be 
altered; additionally there is a cut-off limit of 21.4 seconds if the animal is still in contact 
with the stimulus to prevent any potential cutaneous injury. Lastly, the heat beam can be 
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focused to different parts of the paw allowing for testing in different regions of the paw. 
There are however some disadvantages, some of which are not directly related to the 
function of the device. There is the potential for the animal to acclimatise to the device 
which can also be interpreted as ‘habitual learning’. The animal may also urinate and/or 
defecate on the Plexi glass surface of the chamber which if not cleaned up can interfere with 
testing. Finally, the Hargreaves device may be vulnerable to experimental bias in which the 
experimenter switches the part of the paw that is being stimulated, therefore the proper use 
of the device is dependent on the integrity of the user. One of the main facets of nerve 
trauma models is the altered posture of the paw so that it is dorsi-flexed. This abnormal 
placement of the paw means that upon testing the heat stimulus may not be in full contact 
with the mid-plantar region of the paw, which can lead to an inaccurate PWL reading. As a 
result, the presentation of the thermal stimulus to the heel of the paw which was found to be 
more often than not in contact with the glass surface of the testing chamber. Thermal 
hypersensitivity (i.e. drop in PWL’s) was evident in TNT animals at 28 days post surgery, 
however such hypersensitivity has not been observed in some neuropathic pain models 
where the nature of the injury is similar (Decosterd and Woolf, 2000).  
 
The current study only examined mechanical behavioural hypersensitivity following d4T 
treatment and thermal nociception was not evaluated. There have been conflicting reports 
regarding the onset of thermal hypersensitivity in the NRTI peripheral neuropathy model. 
Joseph et al., 2004 demonstrated thermal hypersensitivity in ddC-treated rats at 5 days post 
injection (~50% decrease from baseline). In contrast, Renn et al., 2011 observed a trend 
towards hypersensitivity in d4T-treated mice over a 28 day period; however there were no 
significant differences in PWLs when compared to the saline controls. These findings are 
shared by Wallace et al., 2007 indicating that thermal hypersensitivity is not a significant 
consequence of NRTI treatment. This view is consistent with clinical data showing that 
patients with HIV-related pain do not usually present with thermal hypersensitivity (Martin 
et al., 2003). Nevertheless it would be worth perusing whether there is thermal 
hypersensitivity associated with d4T in rats, rather than in mice, since this has been the 
common species of choice regarding ATN modeling.  
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Decosterd and Woolf, 2000, using the SNI and sciatic nerve crush injury models revealed no 
changes in PWL in response to a radiant heat stimulus (using a Hargreaves device). However 
the duration of withdrawal in response to the heat stimulus increased significantly 14 days 
post injury. Perhaps it would have been more appropriate to measure the duration of 
response when assessing thermal behavioural responses in TNT injured rats. The 
measurement of PWLs represents the most widely used outcome measure in pain studies, but 
this is not a feature typical in neuropathic pain patients (Koltzenburg, 1998). In fact, in 
certain neuropathic states such as PHN, there is a paradoxical phenomenon of thermal 
sensory loss in areas where extreme pain is experienced  (Rowbotham and Fields, 1996). 
 
6.6.3 Oversimplification of DRG cellular phenotype markers 
 
It is widely acknowledged that small sized DRG cells are the unmyelinated C-fibre 
population which encode nociceptive information and the larger sized DRG cells are the 
myelinated Aβ fibre population which encode non-noxious stimuli (Snider and McMahon, 
1998). The size of a DRG cell correlates with both its physiological and electrophysiological 
properties. Large diameter DRG cells have fast conduction velocities whereas the smaller C-
fibres have slow conduction velocities (Lawson and Waddell, 1991). Various markers can be 
used to identify different subpopulations of sensory neurons (see Figure 1.5, Chapter 1).  
However the notion that there are distinct populations of sensory neurons in the DRG is 
somewhat oversimplified. For instance, there is ~10% crossover between the small diameter 
IB4 and CGRP cell populations (see Figure 1.5, Chapter 1). Furthermore, crossover is 
evident between the large myelinated NF-200 and the CGRP population and also the 
peripherin population (<8%) (Quick et al., 2012). In this thesis, immunohistochemical 
analysis did not account for potential cross over between peripherin and NF-200 
immunoreactive neurons which could have been identified via specific double labeling 
control experiments. However it is to be noted that the cell size distribution analysis of 
peripherin and NF-200 immunoreactive neurons provided an important safeguard, and would 
have revealed any potential inconsistencies in the cell size. Another limitation of the study 
was the analysis of investigative markers did not account for the possibility of such labeling 
not occurring in either the peripherin (small) or NF-200 (large) populations examined.  
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Another limitation of the study, which was not previously considered, was the possibility of 
changes in the expression of peripherin and NF-200 in the DRG after nerve injury which 
could potentially have affected the reported percentage temporal profiles of ATF-3, GAP-43, 
NPY, and galanin. There is evidence to suggest that the mRNA for NF-200 is decreased after 
nerve crush injury within the first 4 weeks and only start to recover after this time (Wong 
and Oblinger, 1990). Another study using insitu hybridization has revealed that the mRNA 
for peripherin (type III) in small sized neurons is not significantly different from that 
observed in normal uninjured rats 2 weeks after axotomy. At this time medium and large 
sized DRG increased their mRNA for peripherin (type III) (Oblinger et al., 1989). This 
evidence suggests that there is a possibility that the protein levels of peripherin and NF-200 
may not been consistent throughout the study, but the extent to which the results are affected 
is yet to be determined. This aspect of the study could be further investigated my counting 
the total number nucleated peripherin and NF-200 cells in the L5 DRG across the various 
study time points to correct for any potential variability.  
 
6.6.4 Co-localization of investigative markers 
 
The study could be further extended by completing double labeling experiments between 
ATF-3 and other investigative markers (i.e. NPY, galanin, GAP-43) in the DRG - this will 
identify if those neurons exhibiting evidence of regeneration or altered neuropeptide 
expression are axotomized (injured) or intact neurons. Previous experiments using different 
trauma models have shown NPY co-localises with other neuropeptides that have been 
associated with nerve injury such as vasoactive intestinal peptide (VIP) & galanin (Ma and 
Bisby, 1998), reg-2 (Averill et al., 2002), and ATF-3 (Shortland et al., 2006). It would also 
be of interest if the sciatic nerve could be examined for GAP-43 expression which will 
indicate nerve regeneration occurring in the tibial nerve. 
 
6.6.5 Characterization of other pathological/dysregulated proteins  
 
In recent years, a number of other neuropeptides have been associated with the response to 
nerve injury. Reg-2 (also known as PAP1) is a macrophage chemoattractant that has been 
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reported to exhibit proregenerative properties in motor and sensory neurons after peripheral 
nerve injury by stimulating Schwann cell growth (Livesey et al., 1997;Namikawa et al., 
2006). Reg-2 is not normally expressed in the adult rat nervous system (Livesey et al., 1997). 
However 24 hours after peripheral nerve injury, reg-2 is upregulated, predominately in small 
diameter cell neurons, with expression switching to larger cells (within 5 days); an 
observation suggestive of differing regeneration mechanisms/factors in various DRG 
subpopulations (Averill et al., 2002). The upregulation of reg-2 mRNA has been additionally 
observed in microarray experiments involving the DRG 14 days following SNL (Maratou et 
al., 2009). 
 
Of interest is VGF, a neuropeptide that is associated with the regulation of metabolism 
(Hahm et al., 1999) and synaptic plasticity (Alder et al., 2003), but its role in neuropathic 
pain is unknown. The upregulation of  VGF mRNA in the L5 DRG of SNL rats 14 days after 
injury is suggestive of an associative role in nerve damage (Maratou et al., 2009), and 
perhaps neuropathic pain, and could have been further investigated. VGF, like other 
neuropeptides, maintains low expression levels in normal conditions, but peripheral nerve 
injury results in increased VGF expression in both small and large diameter L4/5 DRG 
neurons following SNI (Moss et al., 2008). VGF gene transcription is driven by the 
neurotrophic factors NGF and BDNF, which are released by macrophages, mast cells, and 
Schwann cells following peripheral nerve injury, and could have been additionally 
investigated.  
 
VIP - another neuropeptide that is upregulated in nerve injury (Ma and Bisby, 1998) 
(predominately in small diameter neurons) could be investigated. The intrathecal 
administration of VIP decreases reaction time of the tail flick test, and reveals a potentially 
excitatory role in nociception and perhaps neuropathic pain (Cridland and Henry, 1988). 
Lastly, immunohistochemical analysis for caspase-3 in the DRG (an indicator of apoptotic 
processes) would particularly be of interest especially in the acute stages of nerve trauma, 
given the high level of ATF-3 expression present at this stage following nerve trauma. 
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One way to identify potential mechanisms regarding neuropathic pain, and specifically 
NRTI related neuropathy, is to conduct a gene microarray of the DRG. Such studies have 
been performed using peripheral nerve trauma animals (Costigan et al., 2002;Maratou et al., 
2009;Valder et al., 2003;Wang et al., 2002) but not in NRTI treated animals. A similar 
approach has been used to describe dysregulated genes involving the combined ddC + gp120 
model (Maratou et al., 2009), but such data is complicated by the toxic effects of the gp120. 
A gene microarray and proteomic study could identify dysregulated proteins in the DRG of 
trauma and NRTI treated animals, and comparisons could be made between the two model 
types. The advantage of proteomics is that further information regarding protein isoforms, 
modifications, and the interactions between them can be obtained (Tyers and Mann, 2003); 
this can provide targets for conventional immunohistochemistry studies.   
 
6.6.6 Analysis of other nervous tissue 
 
A possible drawback of the study is other tissues (e.g. L4 DRGs, contralateral L5 DRGs, 
sural & sciatic nerve, spinal cord, and paw skin) were not examined. Based on observations 
from the Fluorogold tract tracing study, it would appear that the majority of damage 
following TNT injury occurs in the L4 DRG, and therefore it would have been of interest to 
examine the expression of biochemical markers here to make comparisons with the L5 DRG. 
Evidence from previous studies using trauma models indicate either no or minimal changes 
in expression of neuropeptides in contralateral DRGs (Ma and Bisby, 1997), however this 
has not been confirmed in the TNT model. Since d4T injury is bilateral, any altered 
expression of investigative makers in the opposing DRG would have been expected to be 
identical. Neuropeptide expression has been observed in the graclias tract of the spinal cord 
of trauma animals, and it is likely that in this context NPY is transported from the DRG into 
the spinal cord where it can exert its anti nociceptive effects. Neuropeptide immunoreactivity 
could have been examined in the spinal cord. 
 
Sural nerve biopsies from patients with ddC-neuropathy have shown severe axonal 
destruction, prominent in unmyelinated fibres (Lewis and Dalakas, 1995). This could be 
examined in d4T treated rats via immunohistochemical staining of β-amyloid precursor 
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protein (β-APP) - an axonal injury marker that accumulates in the axon (Medana and Esiri, 
2003). Moreover, the extent of any morphological damage observed can be correlated to the 
loss of small fibres observed in paw skin (Wallace et al., 2007b). The study could 
additionally be improved by investigating the expression profiles of other markers that have 
been implicated in NRTI associated neuropathy, particularly CCL2, which is upregulated in 
the DRG following ddC treatment (Wallace et al., 2007b). Macrophage recruitment in the 
DRG of ddC treated animals (Wallace et al., 2007b) could be further investigated by 
characterizing CD-68 expression over time and could be correlated with the CCL2 
expression. Since TNFα is found in the spinal cord of ddC treated animals (Zheng et al., 
2011c), it would be interesting to investigate similar events in DRG, especially given the 
presence of macrophages, that are capable of releasing TNFα (Holguin et al., 2004), thus 
altering the excitability of neurons (Schafers et al., 2003b).  
 
6.6.7 Additional immunohistochemistry control experiments for ED-1 in saline/DHA 
treated rats  
 
This study could have considered the use of a naive group for the ED-1 
immunohistochemistry as an additional control to make a comparison to baseline levels 
since both saline and DHA treated rats underwent TNT surgery. Additionally a negative 
control could have been conducted to assert the validity of the ED-1 immunohistochemistry.   
 
6.6.8 Measuring co-morbidities of pain  
 
Patients suffering from neuropathic pain often experience co-morbidities such as sleep 
disturbances, physical inactivity,  stress, anxiety and depression (Daniel et al., 2008;Meyer-
Rosberg et al., 2001;Nicholson and Verma, 2004). Other co-morbidities can be associated 
with particular chronic pain syndromes such as complex regional pain syndrome (CRPS) 
such as asthma, osteoporosis, and asthma (de Mos et al., 2008). To extend the current study, 
more outcome measures of ‘neuropathic pain’ behaviour could have been included to 
address these co-morbidities. For example, the open field or elevated plus maze could 
measure anxiety-like behaviours in TNT injured or d4T treated rats. These assays are 
  
258 
 
 
ethologically valid, and utilizes the conflict between the rats desire to explore new 
environments and their natural aversion to exposed well-lit areas. Such anxiety-like 
behaviours have been demonstrated in peripheral nerve trauma and ddC-treated rats (Hasnie 
et al., 2007;Roeska et al., 2008;Seminowicz et al., 2009;Wallace et al., 2007c;Wallace et al., 
2007b). Other researchers have focused on assessing depressive-like behaviours, using 
assays such as the FST or the tail suspension test which additionally could be used in a 
future study (Cryan et al., 2005;Cryan and Holmes, 2005).  
 
6.7 Conclusion 
 
The past 20 years has seen a number of advances in technology and neuropathic pain 
research that has furthered our understanding and led to the identification of potential targets 
for drug development. For instance, gene microarrys have allowed the analysis of global 
gene expression in the DRG following nerve injury.  
 
In this thesis I have: 
 
1. Demonstrated that there are distinct differences in the neurochemical responses to 
nerve damage in the DRG in two different types of nerve damage that are both 
associated with neuropathic pain; TNT nerve trauma and d4T associated neuropathy. 
This may have implications for neuropathic pain research in terms of how potential 
mechanisms are interpreted since the expression of a given marker after nerve 
damage may not always be necessarily indicative of behavioural hypersensitivity or 
neuropathic pain. 
 
2. Shown no significant changes in the expression of ATF-3, GAP-43, NPY and galanin 
in the L5 DRG following d4T administration in rats. 
 
3. Demonstrated that in the acute stages of nerve trauma damage (one day post TNT 
injury), large diameter fibres are more proportionally affected, which is indicated by 
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a greater percentage of ATF-3 expression in NF-200 immunoreactive neurons 
compared to peripherin immunoreactive neurons in the ipsilateral L5 DRG.  
 
4. Shown dynamic expression patterns of ATF-3, NPY, galanin, and GAP-43 following 
TNT injury. While the expression of these markers generally peaked at post operative 
day 14 (with exception of ATF-3), this did not correspond with the peak of 
mechanical hypersensitivity which was observed 28 days post TNT injury.  
 
5. Demonstrated no correlations between TNT associated mechanical hypersensitivity 
and the expression of ATF-3, NPY, GAP-43, and galanin, suggesting that their 
expression is not critical towards the magnitude of neuropathic pain states. This 
further supports the argument that these markers are markers of nerve trauma and not 
neuropathic pain.  
 
6. Raised concerns regarding the dose of DHA used to achieve neuroprotection 
following peripheral trauma nerve injury since the dose used in the study may have 
been sub-optimal which possibly explains the lack of effect. Further research is 
warranted to understand the mechanisms of the neuroprotection, with the first step 
being an appropriate dose response of DHA to peripheral trauma nerve injury. 
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